HBB-modifying compositions and methods

A gene modifying system with a template RNA and polypeptide corrects the Glu6Val mutation in the HBB gene, addressing integration inefficiencies and treating sickle cell disease by substituting nucleotides in the HBB gene.

WO2026241109A2PCT designated stage Publication Date: 2026-11-19TESSERA THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027507
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-12
Filing Date
2026-05-11
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current methods for integrating longer sequences into a genome are inefficient and lack site specificity, and there is a need for effective treatments for sickle cell disease by modifying the HBB gene.

Method used

A gene modifying system comprising a template RNA and a gene modifying polypeptide, which includes a gRNA spacer, gRNA scaffold, heterologous object sequence, and primer binding site, is used to introduce a point mutation in the HBB gene, utilizing a reverse transcriptase domain to polymerize a sequence complementary to the heterologous object sequence.

Benefits of technology

The system effectively modifies the HBB gene, potentially treating and preventing sickle cell disease by substituting nucleotides to correct the Glu6Val mutation, demonstrating high efficacy in human cells and hematopoietic stem cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000166_0001
    Figure IMGF000166_0001
  • Figure IMGF000166_0002
    Figure IMGF000166_0002
  • Figure IMGF000166_0003
    Figure IMGF000166_0003
Patent Text Reader
Need to check novelty before this filing date? Find Prior Art

Description

Attorney Docket No.: 2017469-0062HBB-MODIFYING COMPOSITIONS AND METHODSCROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to and benefit of U. S. Provisional Patent Application No.63 / 804,574, filed May 12, 2025, the contents of which are hereby incorporated herein by reference in their entirety.BACKGROUND

[0002] Integration of a nucleic acid of interest into a genome occurs at low frequency and with little site specificity, in the absence of a specialized protein to promote the insertion event. Some existing approaches, like CRISPR / Cas9, are more suited for small edits that rely on host repair pathways, and are less effective at integrating longer sequences. Other existing approaches, like Cre / loxP, require a first step of inserting a loxP site into the genome and then a second step of inserting a sequence of interest into the loxP site. There is a need in the art for improved compositions (e.g., proteins and nucleic acids) and methods for inserting, altering, or deleting sequences of interest in a genome.

[0003] Sickle cell anemia, a common form of sickle cell disease, is caused by a particular mutation in the HBB gene. This mutation results in the production of an abnormal version of beta-globin called hemoglobin S or HbS. In this condition, hemoglobin S replaces both beta-globin subunits in hemoglobin. The mutation changes a single amino acid in beta-globin. Specifically, the amino acid glutamic acid is replaced with the amino acid valine at amino acid position 6 in beta-globin, written as Glu6Val or E6V. Replacing glutamic acid with valine causes the abnormal hemoglobin S subunits to stick together and form long, rigid molecules that bend red blood cells into a sickle or crescent shape. Mutations in the HBB gene can also cause other abnormalities in beta-globin, leading to other types of sickle cell disease. In these other types of sickle cell disease, just one beta-globin subunit is replaced with hemoglobin S. The other beta-globin subunit is replaced with a different abnormal variant, such as hemoglobin C or hemoglobin E.

[0004] There is currently no universal cure for sickle cell disease. The available options for treating sickle cell disease are limited to a bone marrow or stem cell transplant. Accordingly, there is a need for new and more effective treatments for sickle cell disease by modifying the HBB gene.SUMMARY

[0005] This disclosure relates to novel compositions, systems, and methods for modifying a genome at one or more locations in a host cell, tissue, or subject, in vivo or in vitro. In particular, the presentPage 1 of 28713508126v1Attorney Docket No.: 2017469-0062disclosure features compositions, systems, and methods for modifying (e.g., inserting, altering, mutating, substituting, and / or deleting) one or more sequences of interest in a host genome. For example, the disclosure provides gene modifying systems that are capable of modifying the HBB gene and methods of treating and / or preventing sickle cell disease (SCD) by administering a gene modifying system to introduce a point mutation in the HBB gene to treat and / or prevent SCD.

[0006] In some embodiments, the present disclosure provides a template RNA comprising from 5’ to 3’: (i) a gRNA spacer, (ii) a gRNA scaffold comprising a nucleotide sequence at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any one gRNA scaffold sequence listed in TABLE 16, (iii) a heterologous object sequence, and (iv) a primer binding site (PBS) sequence.

[0007] In some embodiments, a gRNA spacer is at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% complementary to a first portion of an HBB gene. In some embodiments, a gRNA spacer comprises a polynucleotide sequence at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%. or 100% identical to a polynucleotide sequence according to SEQ ID NO: 22010 or SEQ ID NO: 22012.

[0008] In some embodiments, a heterologous object sequence is 10 to 25 nucleotides in length. In some embodiments, a heterologous object sequence comprises a polynucleotide sequence at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%. at least 97%, at least 98%, at least 99%, or 100% identical to a polynucleotide sequence according to any heterologous object sequence listed in TABLE 17.

[0009] In some embodiments, a PBS sequence is 8 to 14 nucleotides in length. In some embodiments, a PBS sequence comprises a polynucleotide sequence at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to a polynucleotide sequence according to any PBS sequence listed in TABLE 18 In some embodiments, a PBS sequence comprises one or more phosphorothioate linkages.

[0010] In some embodiments, a template RNA comprises a polynucleotide sequence at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to a polynucleotide sequence according to any one of the template RNA sequences listed in TABLE 19, TABLE 27, TABLE 28, or TABLE 29

[0011] The present disclosure additionally provides a gene modifying system comprising: (i) a template RNA as described herein; and (ii) an mRNA encoding a gene modifying polypeptide.Page 2 of 28713508126v1Attorney Docket No.: 2017469-0062

[0012] In some embodiments, a gene modifying system comprises (i) a template RNA comprising a polynucleotide sequence at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to a polynucleotide sequence according to any one of the template RNA sequences listed in TABLE 19. TABLE 27, TABLE 28, or TABLE 29; and (ii) an mRNA encoding a gene modifying polypeptide.

[0013] In some embodiments, a gene modifying system further comprises a second strand-targeting gRNA. In some embodiments, a second strand-targeting gRNA comprises a gRNA spacer and a gRNA scaffold. In some embodiments, a gRNA spacer of a second strand-targeting gRNA comprises a polynucleotide sequence at least 75%, at least 80%, at least 85%, at least 90%, at least 91%. at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%. at least 99%, or 100% identical to a polynucleotide sequence according to SEQ ID NO: 22014. In some embodiments, a gRNA spacer of a second strand-targeting gRNA comprises one or more phosphorothioate linkages.

[0014] In some embodiments, a gene modifying polypeptide comprises: (i) an endonuclease and / or DNA-binding domain; (ii) a peptide linker; and (iii) a reverse transcriptase (RT) domain. In some embodiments, a gene modifying polypeptide comprises an amino acid sequence at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to an amino acid sequence according to any one of SEQ ID NO: 22006 to SEQ ID NO: 22009.

[0015] In some embodiments, the present disclosure provides a lipid nanoparticle (LNP) formulation comprising a gene modifying system described herein. In some embodiments, an LNP formulation comprises: (i) one or more ionic lipids: (ii) one or more conjugated lipids; and (iii) one or more sterols.

[0016] The present disclosure also provides a method of modifying a target HBB locus in a cell, the method comprising contacting the cell with a gene modifying sy stem described herein, thereby modifying the target HBB locus. In some embodiments, modifying the target HBB locus comprises substituting an adenine in the sixth codon of an HBB gene for a guanine. In some embodiments, modifying the target HBB locus comprises substituting a nucleotide in a codon encoding a valine residue in HbS to a different nucleotide resulting in a codon encoding a glutamic acid residue. In some embodiments, a cell is a human or non-human primate cell. In some embodiments, a cell is a hematopoietic stem and progenitor cell (HSPC) or long-term hematopoietic stem cell (LT-HSC).

[0017] In some embodiments, the present disclosure additionally provides a method for treating or preventing sickle cell disease in a subject, the method comprising administering to the subject a gene modifying system or an LNP formulation as described herein.Page 3 of 28713508126v1Attorney Docket No.: 2017469-0062BRIEF DESCRIPTION OF THE DRAWINGS

[0018] FIG. 1 depicts a gene modifying system as described herein. The left hand diagram shows a gene modifying polypeptide, which comprises a Cas nickase domain and a reverse transcriptase domain (RT domain) which are linked by a linker. Hie right hand diagram shows a template RNA which comprises, from 5‘ to 3?, a gRNA spacer, a gRNA scaffold, a heterologous object sequence, and a primer binding site sequence (PBS sequence). The heterologous object sequence can comprise a mutation region that comprises one or more sequence differences relative to the target site. The heterologous object sequence can also comprise a pre-edit homology region and a post-edit homology region, which flank the mutation region. Without wishing to be bound by theory, it is thought that the gRNA spacer of the template RNA binds to the second strand of a target site in the genome, and the gRNA scaffold of the template RNA binds to the gene modifying polypeptide, e.g., localizing the gene modifying polypeptide to the target site in the genome. It is thought that the Cas domain of the gene modifying polypeptide nicks the target site (e.g., the first strand of the target site), e.g., allowing the PBS sequence to bind to a sequence adjacent to the site to be altered on the first strand of the target site. It is thought that the RT domain of the gene modifying polypeptide uses the first strand of the target site that is bound to the complementary sequence comprising the PBS sequence of the template RNA as a primer and the heterologous object sequence of the template RNA as a template to, e.g.. polymerize a sequence complementary to the heterologous object sequence. Without wishing to be bound by theory', it is thought that reverse transcription can then proceed through the pre-edit homology region, then through the mutation region, and then through the post-edit homology region, thereby producing a DNA strand comprising a mutation specified by the heterologous object sequence.

[0019] FIG. 2A is a diagram depicting a gRNA scaffold comprising a Repeat and Anti-Repeat (RAR), Tetraloop (TL), Linker, Stem Loop 2 (SL2) and / or Stem Loop 3 (SL3) regions.

[0020] FIG. 2B is a bar graph showing mean percent rewriting of the HBB gene to introduce tire Makassar point mutation in primary human CD34+ cells following nucleofection with gene modifying systems comprising various template RNAs comprising gRNA scaffold mutations in the RAR, tetraloop region (TL). linker, stem loop 2 (SL2) and / or stem loop 3 (SL3) regions and combinations thereof.

[0021] FIG. 3A is a diagram depicting gRNA scaffolds of exemplary7template RNA constructs RNACS30159 (SEQ ID NO: 22243), RNACS24772 (SEQ ID NO: 22244), and RNACS24770 (SEQ ID NO: 22248).

[0022] FIG. 3B is a bar graph showing mean percent rewriting of the HBB gene to introduce the Makassar point mutation in HSPCs and LT-HSCs obtained from humanized NBSGW mice following administration of LNPs comprising the gene modifying systems comprising exemplary template RNAsPage 4 of 28713508126v1Attorney Docket No.: 2017469-0062(RNACS22744; SEQ ID NO: 22219), RNACS24770 (SEQ ID NO: 22248), RNACS24772 (SEQ ID NO: 22244), or RNACS30159 (SEQ ID NO: 22243).

[0023] FIG. 4A is a diagram depicting gRNA scaffolds of exemplary template RNA constructs RNACS31736 (SEQ ID NO: 27155), RNACS31758 (SEQ ID NO: 27159), RNACS31739 (SEQ ID NO: 27157), RNACS31761 (SEQ ID NO: 27161), RNACS31738 (SEQ ID NO: 27156), and RNACS31760 (SEQ ID NO: 27160).

[0024] FIG. 4B is a bar graph showing mean percent rewriting of the HBB gene codon encoding valine at position 6 of SCD HBB (i.e., HbS) to glutamic acid (e.g., wildtype sequence) in primary' human CD34+ cells obtained from a SCD donor following nucleofection with gene modifying systems comprising RNACS26536 (SEQ ID NO: 27154), RNACS31736 (SEQ ID NO: 27155), RNACS31738 (SEQ ID NO: 27156), RNACS31739 (SEQ ID NO: 27157), RNACS27504 (SEQ ID NO: 27158). RNACS31758 (SEQ ID NO: 27159), RNACS31760 (SEQ ID NO: 27160), or RNACS31761 (SEQ ID NO: 27161).DETAILED DESCRIPTION

[0025] The present disclosure relates to methods for treating sickle cell disease (SCD) and compositions for targeting, editing, modifying or manipulating a DNA sequence (e.g.. inserting a heterologous object sequence into a target site of a mammalian genome) at one or more locations in a DNA sequence in a cell, tissue or subject, e.g., in vivo or in vitro. A heterologous object DNA sequence may include, e.g., a substitution.

[0026] More specifically, the present disclosure provides methods for treating SCD using reverse transcriptase-based systems for altering a genomic DNA sequence of interest, e.g., by inserting, deleting, or substituting one or more nucleotides into / from the sequence of interest. The present disclosure provides, in part, methods for treating SCD using a gene modifying system comprising a gene modifying polypeptide and a template nucleic acid (e.g., template RNA). In some embodiments, a gene modifying system can be used to introduce an alteration into a target site in a genome. In some embodiments, a gene modifying polypeptide comprises a writing domain (e g., a reverse transcriptase domain), a DNA-binding domain, and an endonuclease domain (e.g., nickase domain). In some embodiments, a template nucleic acid (e.g., template RNA) comprises a gRNA spacer sequence that binds a target site in the genome, a gRNA scaffold sequence that binds the gene modifying polypeptide, a heterologous object sequence, and a PBS sequence. Without wishing to be bound by any, it is thought that a template nucleic acid (e.g., template RNA) binds to a DNA strand at a target site in a host genome, and binds to a gene modifying polypeptide (e.g., localizing the gene modifying polypeptide to the target site in the genome). It is thought that an endonuclease (e.g.. nickase) of a gene modifying polypeptide component cuts the target site (e.g., a first strand of the target site), e.g., allowing a PBS sequence to bind to a sequence adjacent to the cut sitePage 5 of 28713508126v1Attorney Docket No.: 2017469-0062to be altered on the first strand of the target site. It is thought that a writing domain (e.g., reverse transcriptase domain) of a gene modifying polypeptide uses a first strand of the target site that is bound to a complementary sequence of a PBS sequence of a template nucleic acid (e.g., template RNA) as a primer and a heterologous object sequence of the template nucleic acid (e.g.., template RNA) as a template to, e.g., polymerize a sequence complementary to the heterologous object sequence. Without wishing to be bound by any theory, it is thought that selection of an appropriate heterologous object sequence can result in substitution, deletion, and / or insertion of one or more nucleotides at a target site.I. Definitions

[0027] The term ‘‘about,” when used herein in reference to a value, refers to a value that is similar, in context to the referenced value. In general, those skilled in the art, familiar with the context, will appreciate the relevant degree of variance encompassed by ‘’about” in that context. For example, in some embodiments, the term “about” may encompass a range of values that are within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less of the referred value.

[0028] An “amino acid,” as used herein in its broadest sense, refers to a compound and / or substance that can be, is, or has been incorporated into a polypeptide chain, e.g., through formation of one or more peptide bonds. In some embodiments, an amino acid has the general structure H2N-C(H)I-COOH. In some embodiments, an amino acid is a naturally-occurring amino acid. In some embodiments, an amino acid is a non-natural amino acid; in some embodiments, an amino acid is a D-amino acid; in some embodiments, an amino acid is an L-amino acid. “Standard amino acid” refers to any of the twenty standard L-amino acids commonly found in naturally occurring peptides. “Nonstandard amino acid” refers to any amino acid, other than the standard amino acids, regardless of whether it is prepared synthetically or obtained from a natural source. In some embodiments, an amino acid, including a carboxy- and / or amino-terminal amino acid in a polypeptide, can contain a structural modification as compared with the general structure above. For example, in some embodiments, an amino acid may be modified by methylation, amidation, acetylation, pegylation, glycosylation, phosphorylation, and / or substitution (e.g., of the amino group, the carboxylic acid group, one or more protons, and / or the hydroxyl group) as compared with the general structure. In some embodiments, such modification may, for example, alter the circulating half-life of a polypeptide containing the modified amino acid as compared with one containing an otherwise identical unmodified amino acid. In some embodiments, such modification does not significantly alter a relevant activity of a polypeptide containing the modified amino acid, as compared with one containing an otherwise identical unmodified amino acid. As will bePage 6 of 28713508126v1Attorney Docket No.: 2017469-0062clear from context, in some embodiments, the term ‘'amino acid’’ may be used to refer to a free amino acid; in some embodiments it may be used to refer to an amino acid residue of a polypeptide.

[0029] As used herein, the term “comparable” refers to two or more agents, entities, situations, sets of conditions, etc., that may not be identical to one another but that are sufficiently similar to pennit comparison there betw een so that one skilled in the art will appreciate that conclusions may reasonably be drawn based on differences or similarities observed. In some embodiments, comparable sets of conditions, circumstances, individuals, or populations are characterized by a plurality of substantially identical features and one or a small number of varied features. Those of ordinary skill in the art will understand, in context, what degree of identity is required in any given circumstance for two or more such agents, entities, situations, sets of conditions, etc. to be considered comparable. For example, those of ordinary skill in the art will appreciate that sets of circumstances, individuals, or populations are comparable to one another when characterized by a sufficient number and type of substantially identical features to warrant a reasonable conclusion that differences in results obtained or phenomena observed under or with different sets of circumstances, individuals, or populations are caused by or indicative of the variation in those features that are varied.

[0030] As used herein, the term “corresponding to” refers to a relationship between two or more entities. For example, the term “corresponding to” may be used to designate the position / identity of a structural element in a compound or composition relative to another compound or composition (e.g., to an appropriate reference compound or composition). For example, in some embodiments, a monomeric residue in a polymer (e.g., an amino acid residue in a polypeptide or a nucleic acid residue in a polynucleotide) may be identified as “corresponding to” a residue in an appropriate reference polymer. For example, those of ordinary skill will appreciate that, for purposes of simplicity, residues in a polypeptide are often designated using a canonical numbering system based on a reference related polypeptide, so that an amino acid “corresponding to” a residue at position 190, for example, need not actually be the 190th amino acid in a particular amino acid chain but rather corresponds to the residue found at 190 in the reference polypeptide; those of ordinary skill in the art readily appreciate how to identify “corresponding” amino acids. For example, those skilled in the art will be aware of various sequence alignment strategies, including software programs such as, for example, BLAST, CS-BLAST. CUSASW++, DIAMOND, FASTA, GGSEARCH / GLSEARCH, Genoogle, HMMER, HHpred / HHsearch, IDF, Infernal, KLAST, USEARCH, parasail, PSI-BLAST, PSI-Search, ScalaBLAST, Sequilab, SAM, SSEARCH, SWAPHI, SWAPHI-LS, SWIMM, or SWIPE that can be utilized, for example, to identify “corresponding” residues in polypeptides and / or nucleic acids in accordance with tire present disclosure. Those of skill in the art will also appreciate that, in some instances, the term “corresponding to” may be used to describe an event or entity that shares a relevant similarity withPage 7 of 28713508126v1Attorney Docket No.: 2017469-0062another event or entity (e.g., an appropriate reference event or entity). To give but one example, a gene or protein in one organism may be described as “corresponding to” a gene or protein from another organism in order to indicate, in some embodiments, that it plays an analogous role or performs an analogous function and / or that it shows a particular degree of sequence identity or homology, or shares a particular characteristic sequence element.

[0031] In the context of an amino acid sequence (peptide or polypeptide) “derived from” a designated amino acid sequence (peptide or polypeptide), refers to a structural analogue of a designated amino acid sequence. In some embodiments, an amino acid sequence which is derived from a particular amino acid sequence has an amino acid sequence that is identical, essentially identical or homologous to that particular sequence or a fragment thereof. Amino acid sequences derived from a particular amino acid sequence may be variants of that particular sequence or a fragment thereof. Similarly, in the context of a nucleotide sequence (e.g., DNA or RNA) “derived from” a designated polynucleotide sequence, refers to a structural analogue of a designated polynucleotide sequence. In some embodiments, a polynucleotide sequence which is derived from a particular polynucleotide sequence has a sequence that is identical, essentially identical or homologous to that particular sequence or a fragment thereof. Polynucleotide sequences derived from a particular polynucleotide sequence may be variants of that particular sequence or a fragment thereof.

[0032] The term “detecting” is used broadly herein to include appropriate means of determining the presence or absence of an entity of interest or any form of measurement of an entity of interest in a sample. Thus, “detecting” may include determining, measuring, assessing, or assaying the presence or absence, level, amount, and / or location of an entity of interest. Quantitative and qualitative determinations, measurements or assessments are included, including semi-quantitative. Such determinations, measurements or assessments may be relative, for example when an entity of interest is being detected relative to a control reference, or absolute. As such, the term “quantifying” when used in the context of quantifying an entity of interest can refer to absolute or to relative quantification. Absolute quantification may be accomplished by correlating a detected level of an entity of interest to known control standards (e.g., through generation of a standard curve). Alternatively, relative quantification can be accomplished by comparison of detected levels or amounts between two or more different entities of interest to provide a relative quantification of each of the two or more different entities of interest, i.e., relative to each other.

[0033] As used herein, the term “encode” or “encoding” refers to sequence information of a first molecule that guides production of a second molecule having a defined sequence of nucleotides (e.g., a polyribonucleotide) or a defined sequence of amino acids. For example, a DNA molecule can encode an RNA molecule (e.g., by a transcription process that includes a DNA-dependent RNA polymerasePage 8 of 28713508126v1Attorney Docket No.: 2017469-0062enzyme). An RNA molecule can encode a polypeptide (e.g., by a translation process). Thus, a gene, a cDNA, or an RNA molecule encodes a polypeptide if transcription and translation of RNA corresponding to that gene produces the polypeptide in a cell or other biological system. In some embodiments, a coding region of a polyribonucleotide encoding a target antigen refers to a coding strand, the nucleotide sequence of which is identical to the polyribonucleotide sequence of such a target antigen. In some embodiments, a coding region of a polyribonucleotide encoding a target antigen refers to a non-coding strand of such a target antigen, which may be used as a template for transcription of a gene or cDNA.

[0034] Tire term “engineered” refers to the aspect of having been manipulated by the hand of man. For example, a polynucleotide is considered to be “engineered” when tw o or more sequences that arc not linked together in that order in nature are manipulated by the hand of man to be directly linked to one another in the engineered polynucleotide and / or when a particular residue in a polynucleotide is non-naturally occurring and / or is caused through action of the hand of man to be linked with an entity or moiety with which it is not linked in nature.

[0035] As used herein, the term “expression” of a nucleic acid sequence refers to the generation of a gene product from the nucleic acid sequence. In some embodiments, a gene product can be a transcript, e.g., a polyribonucleotide as provided herein. In some embodiments, a gene product can be a polypeptide. In some embodiments, expression of a nucleic acid sequence involves one or more of the following: (1) production of an RNA template from a DNA sequence (e.g., by transcription); (2) processing of an RNA transcript (e.g., by splicing, editing, etc.); (3) translation of an RNA into a polypeptide or protein; and / or (4) post-translational modification of a polypeptide or protein.

[0036] A “gRNA spacer,” as used herein, refers to a portion of a nucleic acid that has complementarity to a target nucleic acid and can, together with a gRNA scaffold, target a Cas protein to a target nucleic acid.

[0037] A “gRNA scaffold,” as used herein, refers to a portion of a nucleic acid that can bind a Cas protein and can, together with a gRNA spacer, target the Cas protein to a target nucleic acid. In some embodiments, a gRNA scaffold comprises a crRNA sequence, a tetraloop, and / or a tracrRNA sequence.

[0038] A “variant gRNA scaffold,” as used herein, refers to gRNA scaffold having a non-naturally occurring sequence. In some embodiments, a variant gRNA scaffold sequence comprises one or more substitutions relative to a closest naturally occurring sequence. In some embodiments, a variant gRNA scaffold sequence comprises one or more insertions relative to a closest naturally occurring sequence. In some embodiments, a variant gRNA scaffold sequence comprises one or more deletions relative to a closest naturally occurring sequence.

[0039] A “gene modifying polypeptide,” as used herein, refers to a polypeptide comprising a retroviral reverse transcriptase, or a polypeptide comprising an amino acid sequence having at least 75%, 80%, Page 9 of 28713508126v1Attorney Docket No.: 2017469-006285%, 90%, 95%, 96%, 97%, 98%, or 99% amino acid sequence identity to a retroviral reverse transcriptase, which is capable of integrating a nucleic acid sequence (e.g., a sequence provided on a template nucleic acid) into a target DNA molecule (e.g., in a mammalian host cell, such as a genomic DNA molecule in a host cell). In some embodiments, a gene modifying polypeptide is capable of integrating a sequence substantially without relying on host machinery. In some embodiments, a gene modifying polypeptide integrates a sequence into a random position in a genome. In other embodiments, a gene modifying polypeptide integrates a sequence into a specific target site. In some embodiments, a gene modifying polypeptide includes one or more domains that, collectively, facilitate 1) binding to a template nucleic acid, 2) binding to a target DNA molecule, and 3) integration of at least a portion of the template nucleic acid into the target DNA. Gene modifying polypeptides include both naturally occurring polypeptides as well as engineered variants, e.g., having one or more amino acid substitutions as compared to the naturally occurring sequence. Gene modifying polypeptides also include heterologous constructs, e.g., where one or more domains of a gene modifying polypeptide are heterologous to each other, whether through a heterologous fusion (or other conjugation) of otherw ise wild-type domains, or fusions of modified domains, e.g., by way of replacement or fusion of a heterologous sub-domain or other substituted domain. Exemplary gene modifying polypeptides, and systems comprising them and methods of using them, that can be used in the methods provided herein are described, e.g.. inPCT / US2021 / 020948, which is incorporated herein by reference with respect to gene modifying polypeptides that comprise a retroviral reverse transcriptase domain. In some embodiments, a gene modifying polypeptide integrates a sequence into a gene. In some embodiments, a gene modifying polypeptide integrates a sequence into a sequence outside of a gene. A “gene modifying system,” as used herein, refers to a system comprising a gene modifying polypeptide and a template nucleic acid.

[0040] The term “domain” as used herein refers to a structure of a biomolecule that contributes to a specified function of the biomolecule. A domain may comprise a contiguous region (e.g., a contiguous sequence) or distinct, non-contiguous regions (e.g., non-contiguous sequences) of a biomolecule.Examples of protein domains include, but are not limited to, an endonuclease domain, a DNA binding domain, a reverse transcription domain; an example of a domain of a nucleic acid is a regulatory domain, such as a transcription factor binding domain. In some embodiments, a domain (e.g., a Cas domain) can comprise two or more smaller domains (e.g., a DNA binding domain and an endonuclease domain).

[0041] As used herein, the term “exogenous”, when used with reference to a biomolecule (such as a nucleic acid sequence or polypeptide) means that the biomolecule was introduced into a host genome, cell, or organism by the hand of man. For example, a nucleic acid that is added into an existing genome, cell, tissue, or subject using recombinant DNA techniques or other methods is exogenous to the existing nucleic acid sequence, cell, tissue or subject.Page 10 of 28713508126vAttorney Docket No.: 2017469-0062

[0042] The terms “first strand” and “second strand,” as used herein to describe individual DNA strands of target DNA, distinguish the two DNA strands based upon which strand a reverse transcriptase domain initiates polymerization, c.g., based upon where target-primed synthesis initiates. A first strand refers to a strand of target DNA upon which a reverse transcriptase domain initiates polymerization, e.g., where target-primed synthesis initiates. A second strand refers to the other strand of the target DNA. First and second strand designations do not describe the target site DNA strands in other respects; for example, in some embodiments first and second strands are nicked by a polypeptide described herein, but the designations ‘first’ and ‘second’ strand have no bearing on the order in which such nicks occur.

[0043] The term “heterologous,” as used herein to describe a first element in reference to a second element means that the first element and second element do not exist in nature disposed as described. For example, a heterologous polypeptide, nucleic acid molecule, construct or sequence refers to (a) a polypeptide, nucleic acid molecule or portion of a polypeptide or nucleic acid molecule sequence that is not native to a cell in which it is expressed, (b) a polypeptide or nucleic acid molecule or portion of a polypeptide or nucleic acid molecule that has been altered or mutated relative to its native state, or (c) a polypeptide or nucleic acid molecule with an altered expression as compared to the native expression levels under similar conditions. For example, a heterologous regulatory sequence (e.g., promoter, enhancer) may be used to regulate expression of a gene or a nucleic acid molecule in a way that is different than the gene or a nucleic acid molecule is normally expressed in nature. In another example, a heterologous domain of a polypeptide or nucleic acid sequence (e.g., a DNA binding domain of a polypeptide or nucleic acid encoding a DNA binding domain of a polypeptide) may be disposed relative to other domains or may be a different sequence or from a different source, relative to other domains or portions of a polypeptide or its encoding nucleic acid. In some embodiments, a heterologous nucleic acid molecule may exist in a native host cell genome, but may have an altered expression level or have a different sequence or both. In other embodiments, heterologous nucleic acid molecules may not be endogenous to a host cell or host genome but instead may have been introduced into a host cell by transformation (c.g., transfection, electroporation), wherein the added molecule may integrate into the host genome or can exist as extra-chromosomal genetic material either transiently (e.g., mRNA) or semi-stably for more than one generation (e.g., episomal viral vector, plasmid or other self-replicating vector).

[0044] As used herein, the term “homology” or “homolog” refers to the overall relatedness between polynucleotide molecules (e.g., DNA molecules and / or RNA molecules) and / or between polypeptide molecules. In some embodiments, polynucleotide molecules (e.g., DNA molecules and / or RNA molecules) and / or polypeptide molecules are considered to be “homologous” to one another if their sequences are at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%. at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, atPage 11 of 28713508126v1Attorney Docket No.: 2017469-0062least 85%, at least 90%, at least 95%, or at least 99% identical. In some embodiments, polynucleotide molecules (e.g., DNA molecules and / or RNA molecules) and / or polypeptide molecules are considered to be “homologous” to one another if their sequences are at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% similar (e.g., containing residues with related chemical properties at corresponding positions). For example, as is well known by those of ordinary skill in the art, certain amino acids are typically classified as similar to one another as “hydrophobic” or “hydrophilic” amino acids, and / or as having “polar” or “non-polar” side chains.Substitution of one amino acid for another of the same type may often be considered a “homologous” substitution.

[0045] As used herein, the term “identity” refers to the overall relatedness between polynucleotide molecules (e.g., DNA molecules and / or RNA molecules) and / or between polypeptide molecules. In some embodiments, polynucleotide molecules (e.g., DNA molecules and / or RNA molecules) and / or polypeptide molecules are considered to be “substantially identical” to one another if their sequences are at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical. Calculation of the percent identity of two nucleic acid or polypeptide sequences, for example, can be performed by aligning the two sequences for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second sequence for optimal alignment and non-identical sequences can be disregarded for comparison purposes). In some embodiments, the length of a sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%. at least 95%, at least 96%, at least 97%, at least 98%, at least 99%. or substantially 100% of the length of a reference sequence. The nucleotides at corresponding positions are then compared. When a position in the first sequence is occupied by the same residue (e.g., nucleotide or amino acid) as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which needs to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. For example, the percent identity between two nucleotide sequences can be determined using the algorithm of Meyers and Miller, 1989, which has been incorporated into the ALIGN program (version 2.0). In some embodiments, nucleic acid sequence comparisons made with the ALIGN program use a PAM120 weight residue table, a gap length penalty ofPage 12 of 28713508126v1Attorney Docket No.: 2017469-006212 and a gap penalty of 4. The percent identity between two nucleotide sequences can, alternatively, be determined using the GAP program in the GCG software package using an NWSgapdna. CMP matrix.

[0046] As used herein, the terms “increased,” “induced,” “reduced,” or grammatically comparable comparative temis, indicate values that are relative to a comparable reference measurement. For example, in some embodiments, an assessed value achieved with a provided composition or system (e.g., gene modifying system) may be “increased” relative to that obtained with a comparable reference composition or system. Alternatively or additionally, in some embodiments, an assessed value achieved in a subject may be “increased” relative to that obtained in the same subject under different conditions (c.g., prior to or after an event; or presence or absence of an event such as administration of a composition or system (e g., a gene modifying system) as described herein, or in a different, comparable subject (e.g., in a comparable subject that differs from the subject of interest in prior exposure to a condition, e.g., absence of administration of a composition or system (e.g., a gene modifying system) as described herein ). In some embodiments, comparative terms refer to statistically relevant differences (e.g., that are of a prevalence and / or magnitude sufficient to achieve statistical relevance). Those skilled in the art will be aware, or will readily be able to determine, in a given context, a degree and / or prevalence of difference that is required or sufficient to achieve such statistical significance. In some embodiments, the term “reduced” or equivalent terms refers to a reduction in the level of an assessed value by at least 5%, at least 10%, at least 20%, at least 50%, at least 75% or higher, as compared to a comparable reference. In some embodiments, the term “reduced” or equivalent terms refers to a complete or essentially complete inhibition, i.e., a reduction to zero or essentially to zero. In some embodiments, the term “increased” or “induced” refers to an increase in the level of an assessed value by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 80%, at least 100%. at least 200%, at least 500%, or higher, as compared to a comparable reference.

[0047] As used herein with reference to a polynucleotide or polyribonucleotide, “in order” refers to the order of features from 5' to 3' along the polynucleotide or polyribonucleotide. As used herein with reference to a polypeptide, “in order” refers to the order of features moving from the N-terminal-most of the features to the C-terminal-most of the features along the polypeptide. “In order” does not mean that no additional features can be present among the listed features. For example, if Features A, B, and C of a polynucleotide are described herein as being “in order, Feature A, Feature B, and Feature C,” this description does not exclude, e g., Feature D being located between Features A and B.

[0048] As used herein, “insertion” of a sequence into a target site refers to the net addition of DNA sequence at the target site, e g., where there are new nucleotides in the heterologous object sequence with no cognate positions in the unedited target site. In some embodiments, a nucleotide alignment of a primerPage 13 of 28713508126v1Attorney Docket No.: 2017469-0062binding site (PBS) sequence and heterologous object sequence to a target nucleic acid sequence results in an alignment gap in a target nucleic acid sequence.

[0049] As used herein, “introduction,” “installment,” or grammatically comparable comparative terms, when used in the context of a modification at a target site refers to a heterologous insertion, deletion, substitution, or mutation at the target site.

[0050] As used herein, a “deletion” generated by a heterologous object sequence in a target site refers to the net deletion of DNA sequence at the target site, e.g., where there are nucleotides in the unedited target site with no cognate positions in the heterologous object sequence. In some embodiments, a nucleotide alignment of a PBS sequence and heterologous object sequence to the target nucleic acid sequence would result in an alignment gap in the molecule comprising the PBS sequence and heterologous object sequence.

[0051] As used herein, “substitution” or “mutation” of one or more nucleotides in a target site refers to the replacement of one or more nucleotides with one or more different nucleotides resulting in no net addition or deletion of the number of nucleotides at the target site. In the context of an amino acid sequence, “substitution” or “mutation” of one or more amino acids in a target site refers to the replacement of one or more amino acids with one or more different amino acids resulting in no net addition or deletion of the number of amino acids at the target site.

[0052] As used herein, the terms “lipid” and “lipid-like material” are broadly defined as molecules which comprise one or more hydrophobic moieties or groups and optionally also one or more hydrophilic moieties or groups. Molecules comprising hydrophobic moieties and hydrophilic moieties are also typically denoted as amphiphiles.

[0053] As used herein, the term “lipid nanoparticle” or “LNP” refers to a nanoparticle comprising at least one lipid. In some embodiments, a lipid nanoparticle comprises at least one cationic amino lipid. In some embodiments, a lipid nanoparticlc comprises at least one cationic amino lipid, at least one helper lipid, and at least one polymer-conjugated lipid (e.g., PEG-conjugated lipid). In various embodiments, a lipid nanoparticle can have an average size (e.g., Z-average) of about 100 nm to 1000 nm. or about 200 nm to 900 nm, or about 200 nm to 800 nm, or about 250 nm to about 700 nm. In some embodiments, lipid nanoparticles can have a particle size (e.g., Z-average) of about 30 nm to about 200 nm, or about 30 nm to about 150 nm, about 40 nm to about 150 nm, about 50 nm to about 150 nm, about 60 nm to about 130 nm, about 70 nm to about 110 nm, about 70 nm to about 100 nm, about 80 nm to about 100 nm, about 90 nm to about 100 nm, about 70 to about 90 nm, about 80 nm to about 90 nm, or about 70 nm to about 80 nm. In some embodiments, an average size of lipid nanoparticles is determined by measuring the average particle diameter. In some embodiments, lipid nanoparticles may comprise one or more andPage 14 of 28713508126v1Attorney Docket No.: 2017469-0062RNA molecules, e.g., one or more polyribonucleotides as provided herein. RNA lipid nanoparticles may be prepared by mixing lipids with RNA molecules described herein.

[0054] As used herein, the term “polypeptide” refers to a polymeric chain of amino acids. In some embodiments, a polypeptide has an amino acid sequence that occurs in nature. In some embodiments, a polypeptide has an amino acid sequence that does not occur in nature. In some embodiments, a polypeptide has an amino acid sequence that is engineered in that it is designed and / or produced through action of the hand of man. In some embodiments, a polypeptide may comprise or consist of natural amino acids, non-natural amino acids, or both. In some embodiments, a polypeptide may comprise or consist of only natural amino acids or only non-natural amino acids. In some embodiments, a polypeptide may comprise D-amino acids, L-amino acids, or both. In some embodiments, a polypeptide may comprise only D-amino acids. In some embodiments, a polypeptide may comprise only L-amino acids. In some embodiments, a polypeptide may include one or more pendant groups or other modifications, e g., modifying or attached to one or more amino acid side chains, at the polypeptide’s N-terminus, at the polypeptide’s C-terminus, or any combination thereof. In some embodiments, such pendant groups or modifications comprise acetylation, amidation, lipidation, methylation, pegylation, etc., including combinations thereof. In some embodiments, a polypeptide may be cyclic, and / or may comprise a cyclic portion. In some embodiments, a polypeptide is not cyclic and / or does not comprise any cyclic portion. In some embodiments, a polypeptide is linear. In some embodiments, a polypeptide may be or comprise a stapled polypeptide. In some embodiments, the term “polypeptide” may be appended to a name of a reference polypeptide, activity, or structure; in such instances it is used herein to refer to polypeptides that share the relevant activity or structure and thus can be considered to be members of the same class or family of polypeptides. For each such class, the present specification provides and / or those skilled in the art will be aware of exemplary polypeptides within the class whose amino acid sequences and / or functions are known; in some embodiments, such exemplary polypeptides are reference polypeptides for the polypeptide class or family. In some embodiments, a member of a polypeptide class or family shows significant sequence homology or identity with, shares a common sequence motif (e.g., a characteristic sequence element) with, and / or shares a common activity (in some embodiments at a comparable level or within a designated range) with a reference polypeptide of the class; in some embodiments with all polypeptides within the class). For example, in some embodiments, a member polypeptide shows an overall degree of sequence homology or identity with a reference polypeptide that is at least about 30-40%, and is often greater than about 50%, greater than about 60%, greater than about 70%, greater than about 80%, greater than about 90%, greater than about 91%, greater than about 92%, greater than about 93%, greater than about 94%, greater than about 95%, greater than about 96%, greater than about 97%, greater than about 98%, or greater than about 99% or more and / or includes at least one region (e.g., aPage 15 of 28713508126v1Attorney Docket No.: 2017469-0062conserved region that may in some embodiments be or comprise a characteristic sequence element) that shows very high sequence identity, often greater than 90% or even greater than 95%, greater than 96%, greater than 97%, greater than 98%, or greater than 99%. Such a conserved region usually encompasses at least 3-4 and often up to 35 or more amino acids; in some embodiments, a conserved region encompasses at least one stretch of at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8. at least 9, at least 10, at least 11. at least 12, at least 13, at least 14, at least 15. at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35 or more contiguous amino acids. In some embodiments, a relevant polypeptide may comprise or consist of a fragment of a parent polypeptide.

[0055] As used herein, the terms “prevent” or “prevention” when used in connection with the occurrence of a disease, disorder, and / or condition, refers to reducing the risk of developing the disease, disorder and / or condition and / or to delaying onset of one or more characteristics or symptoms of the disease, disorder or condition. Prevention may be considered complete when onset of a disease, disorder or condition has been delayed for a predefined period of time.

[0056] The term “mutation region,” as used herein, refers to a region in a template RNA having one or more sequence difference relative to a corresponding sequence in a target nucleic acid. A sequence difference may comprise, for example, a substitution, insertion, frameshift, or deletion.

[0057] Tire term “mutated,” when used in the context of nucleic acid sequences, refers to nucleotides in a nucleic acid sequence that are inserted, deleted, or changed compared to a reference (e.g., native or wildtype) nucleic acid sequence. A single alteration may be made at a locus (a point mutation), or multiple nucleotides may be inserted, deleted, or changed at a single locus. In addition, one or more alterations may be made at any number of loci within a nucleic acid sequence. A nucleic acid sequence may be mutated by any method known in the art.

[0058] ‘‘Nucleic acid molecule” refers to both RNA and DNA molecules including, without limitation, complementary DNA (“cDNA”), genomic DNA (“gDNA”). and messenger RNA (“rnRNA”). and also includes synthetic nucleic acid molecules, such as those that are chemically synthesized or recombinantly produced, such as RNA templates, as described herein. A nucleic acid molecule can be double-stranded or single-stranded, circular, or linear. If single-stranded, a nucleic acid molecule can be a sense strand or an antisense strand. Unless otherwise indicated, and as an example for all sequences described herein under the general fomiat “SEQ ID NO:,” or “nucleic acid comprising SEQ ID NO: X” refers to a nucleic acid, at least a portion which has either (i) the sequence of SEQ ID NO: X, or (ii) a sequence complimentary to SEQ ID NO: X. The choice between the two is dictated by the context in which SEQ ID NO: X is used. For instance, if a nucleic acid is used as a probe, the choice between the two is dictatedPage 16 of 28713508126v1Attorney Docket No.: 2017469-0062by the requirement that the probe be complementary to the desired target. Nucleic acid sequences of the present disclosure may be modified chemically or biochemically or may contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those of skill in the art. Such modifications include, for example, labels, methylation, substitution of one or more naturally occurring nucleotides with an analog, inter-nucleotide modifications such as uncharged linkages (for example, methyl phosphonates, phosphotriesters, phosphoramidates. carbamates, etc.), charged linkages (for example, phosphorothioates. phosphorodithioates, etc.), pendant moieties, (for example, polypeptides), intercalators (for example, acridine, psoralen, etc.), chelators, alkylators, and modified linkages (for example, alpha anomeric nucleic acids, etc.). Also included are chemically modified bases (see, for example, TABLE 21), backbones (see, for example, TABLE 22), and modified caps (see, for example, TABLE 23). Also included are synthetic molecules that mimic polynucleotides in their ability to bind to a designated sequence via hydrogen bonding and other chemical interactions. Such molecules are known in the art and include, for example, those in which peptide linkages substitute for phosphate linkages in the backbone of a molecule, e.g., peptide nucleic acids (PNAs). Other modifications can include, for example, analogs in which the ribose ring contains a bridging moiety or other structure such as modifications found in “locked” nucleic acids (LNAs). In various embodiments, the nucleic acids are in operative association with additional genetic elements, such as tissue-specific expression-control sequence(s) (e.g., tissue-specific promoters and tissue-specific microRNA recognition sequences), as well as additional elements, such as inverted repeats (e.g., inverted terminal repeats, such as elements from or derived from viruses, e.g., AAV ITRs) and tandem repeats, inverted repeats / direct repeats, homology regions (segments with various degrees of homology to a target DNA), untranslated regions (UTRs) (5', 3', or both 5' and 3' UTRs), and various combinations of the foregoing. The nucleic acid elements of the systems provided by the present disclosure can be provided in a variety of topologies, including single -stranded, double-stranded, circular, linear, linear with open ends, linear with closed ends, and particular versions of these, such as doggy bone DNA (dbDNA), closed-ended DNA (ceDNA). In some embodiments, a nucleic acid comprises one or more, or all, non-natural residues. In some embodiments, a non-natural residue comprises a nucleoside analog (e.g., 2-aminoadenosine, 2 -thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5-methylcytidine. C-5 propynyl -cytidine, C-5 propynyl -uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5 -iodouridine. C5 -propynyl -uridine. C5 -propynyl -cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, 6-0-methylguanine, 2-thiocytidine. methylated bases, intercalated bases, and combinations thereof). In some embodiments, a non-natural residue comprises one or more modified sugars (e.g., 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose) as compared to those in natural residues. In some embodiments, a nucleic acid has a nucleotide sequence that encodes a functional gene product such as an RNA orPage 17 of 28713508126v1Attorney Docket No.: 2017469-0062polypeptide. In some embodiments, a nucleic acid has a nucleotide sequence that comprises one or more introns. In some embodiments, a nucleic acid may be prepared by isolation from a natural source, enzymatic synthesis (e.g., by polymerization based on a complementary template, e.g., in vivo or in vitro), reproduction in a recombinant cell or system, or chemical synthesis. In some embodiments, a nucleic acid is at least 3. at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20. at least 25, at least 30, at least 35, at least 40. at least 45, at least 50, at least 55. at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at least 95, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 225, at least 250, at least 275, at least 300, at least 325, at least 350, at least 375, at least 400, at least 425, at least 450, at least 475, at least 500, at least 600, at least 700, at least 800, at least 900, at least 1000, at least 1500, at least 2000, at least 2500, at least 3000. at least 3500. at least 4000. at least 4500, at least 5000, at least 5500, at least 6000, at least 6500, at least 7000, at least 7500, at least 8000, at least 8500, at least 9000, at least 9500, at least 10,000, at least 10,500, at least 11,000, at least 11,500, at least 12,000, at least 12,500, at least 13,000, at least 13,500, at least 14,000, at least 14,500, at least 15,000, at least 15,500, at least 16,000, at least 16,500, at least 17,000, at least 17,500, at least 18,000, at least 18,500, at least 19,000, at least 19,500, or at least 20,000 or more residues or nucleotides long.

[0059] The term "‘chemically modified nucleotide,” as used herein, refers to a nucleotide comprising one or more structural differences relative to the canonical ribonucleotides (i.e., adenine, cytosine, deoxyadenosine, de oxy cytidine, deoxyguanosine, deoxythymidine, guanine, thymine, uracil). A chemically modified nucleotide may have (relative to a canonical nucleotide) a chemically modified nucleobase, a chemically modified sugar, a chemically modified phosphodiester linkage, or a combination thereof. In some embodiments, a chemically modified nucleotide is a 2'-O-methyl nucleotide, e.g., 2'-O-methyl-Adenosine, 2'-O-methyl-Cytidine. 2'-O-methyl-Guanosine, or 2'-O-methyl-Uridine. No particular process of making is implied; for instance, a chemically modified nucleotide can be produced directly by chemical synthesis, or by covalently modifying a canonical nucleotide.

[0060] Tire term “chemical modification,” as used herein, refers to a structural difference of a chemically modified nucleotide relative to canonical ribonucleotides (i.e., G, U. C, and A). A chemical modification may comprise a modification resulting in a chemically modified nucleobase, a chemically modified sugar, a chemically modified phosphodiester linkage, or a combination thereof. In some embodiments, a chemical modification is 2’-O-methylation or 2’-fluoro modification. No particular process of making is implied; for instance, a chemical modification can be produced directly by chemical synthesis, or by covalently modifying a canonical nucleotide.

[0061] As used herein, the terms “ribonucleic acid,” “RNA,” or “polyribonucleotide” refers to a polymer of ribonucleotides. In some embodiments, an RNA is single stranded. In some embodiments, an RNA is Page 18 of 28713508126v1Attorney Docket No.: 2017469-0062double stranded. In some embodiments, an RNA comprises both single and double stranded portions. In some embodiments, an RNA can comprise a backbone structure as described in the definition of “Nucleic acid / Polynucleotide” above. An RNA can be a regulatory RNA (e.g., siRNA, microRNA, etc.), or a messenger RNA (mRNA). In some embodiments, an RNA is an mRNA. In some embodiments, where an RNA is a mRNA, an RNA typically comprises at its 3' end a poly(A) region. In some embodiments, where an RNA is a mRNA, an RNA typically comprises at its 5' end an art-recognized cap structure, e.g., for recognizing and attachment of a mRNA to a ribosome to initiate translation. In some embodiments, an RNA is a synthetic RNA. Synthetic RNAs include RNAs that are synthesized in vitro (e.g., by enzymatic synthesis methods and / or by chemical synthesis methods).

[0062] As used herein, the tenn “ribonucleotide” encompasses unmodified ribonucleotides and modified ribonucleotides. For example, unmodified ribonucleotides include the purine bases adenine (A) and guanine (G), and the pyrimidine bases cytosine (C) and uracil (U). Modified ribonucleotides may include one or more modifications including, but not limited to, for example, (a) end modifications, e.g., 5' end modifications (e.g., phosphorylation, dephosphorylation, conjugation, inverted linkages, etc.), 3' end modifications (e.g., conjugation, inverted linkages, etc.), (b) base modifications, e.g., replacement with modified bases, stabilizing bases, destabilizing bases, bases that base pair with an expanded repertoire of partners, or conjugated bases, (c) sugar modifications (e.g., at the 2' position or 4' position) or replacement of the sugar, and (d) intemucleoside linkage modifications, including modification or replacement of the phosphodiester linkages. The term “ribonucleotide” also encompasses ribonucleotide triphosphates including modified and non-modified ribonucleotide triphosphates.

[0063] As used herein, the tenn “position” with respect to a polynucleotide sequence refers to tire nucleotide of the polynucleotide sequence that aligns with a corresponding nucleotide of a reference sequence. Alignments of nucleic acid or polypeptide sequences can be performed by using a routine sequence analysis tool such as Basic Local Alignment Search Tool (BLAST), for instance NIH megablast using default parameters.

[0064] As used herein, a “gene expression unit” is a nucleic acid sequence comprising at least one regulatory nucleic acid sequence operably linked to at least one effector sequence. A first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter or enhancer is operably linked to a coding sequence if the promoter or enhancer affects the transcription or expression of the coding sequence. Operably linked DNA sequences may be contiguous or noncontiguous. Where necessary to join two protein-coding regions, operably linked sequences may be in the same reading frame.Page 19 of 28713508126v1Attorney Docket No.: 2017469-0062

[0065] The terms “host cell” or “host genome,” as used herein, refer to a cell and / or its genome into which protein and / or genetic material has been introduced. It should be understood that such terms are intended to refer not only to the particular subject cell and / or genome, but to the progeny of such a cell and / or the genome of the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term “host cell” as used herein. A host cell or host genome may be an isolated cell or cell line grown in culture, or genomic material isolated from such a cell or cell line, or may be a host cell or host genome which comprises living tissue or an organism. In some embodiments, a host cell may be an animal cell. In certain instances, a host cell may be a mammalian cell, a human cell, a non-human primate (e.g., rhesus or cynomolgus macaque) cell, avian cell, reptilian cell, bovine cell, horse cell, canine cell, feline cell, pig cell, goat cell, sheep cell, chicken cell, or turkey cell.

[0066] The term “heterologous object sequence,” as used herein, refers to a polynucleotide sequence that a gene modifying polypeptide can use as a template for reverse transcription to write a desired sequence into a target nucleic acid.

[0067] The term “primer binding site sequence” or “PBS sequence.” as used herein, refers to a portion of a template RNA capable of binding to a region in a target nucleic acid sequence. In some embodiments, a PBS sequence is a nucleic acid sequence comprising at least 3, at least 4, at least 5, at least 6, at least 7, or at least 8 bases with 100% identity to a region in a target nucleic acid sequence. In some embodiments, a PBS sequence comprises at least 5, at least 6, at least 7, or at least 8 bases with 100% identity to a region in a target nucleic acid sequence. Without wishing to be bound by any theory, in some embodiments, when a template RNA comprises a PBS sequence and a heterologous object sequence, the PBS sequence binds to a region in a target nucleic acid sequence, allowing a reverse transcriptase domain to use that region as a primer for reverse transcription, and to use the heterologous object sequence as a template for reverse transcription.

[0068] As used herein, the term “reference” describes a standard or control relative to which a comparison is performed. For example, in some embodiments, an agent, animal, individual, population, sample, sequence or value of interest is compared with a reference or control agent, animal, individual, population, sample, sequence or value. In some embodiments, a reference or control is tested and / or determined substantially simultaneously with the testing or determination of interest. In some embodiments, a reference or control is a historical reference or control, optionally embodied in a tangible medium. Typically, as would be understood by those skilled in the art, a reference or control is determined or characterized under comparable conditions or circumstances to those under assessment.Page 20 of 28713508126v1Attorney Docket No.: 2017469-0062Those skilled in the art will appreciate when sufficient similarities are present to justify reliance on and / or comparison to a particular possible reference or control.

[0069] Tire term “second strand targeting gRNA,” as used herein, refers to a polyribonucleotide designed to bind to an opposite DNA strand of a target sequence and promote the introduction of a second nick.

[0070] As used herein, a “stem-loop sequence” refers to a nucleic acid sequence (e.g., RNA sequence) with sufficient self-complementarity to form a stem-loop, e.g., having a stem comprising at least two (e.g., 3, 4, 5, 6, 7, 8, 9, or 10) base pairs, and a loop with at least three (e.g., four) base pairs. The stem may comprise mismatches or bulges.

[0071] As used herein, the term “subject” refers to an organism to be administered with a composition described herein, e.g., for experimental, diagnostic, prophylactic, and / or therapeutic purposes. Typical subjects include animals (e.g., mammals such as non-human primates, mice, rats, rabbits, domestic pets, etc.) and humans. In some embodiments, a subject is a human subject. In some embodiments, a subject is suffering from a disease, disorder, or condition (e.g., sickle cell disease). In some embodiments, a subject is susceptible to a disease, disorder, or condition (e.g., sickle cell disease). In some embodiments, a subject displays one or more symptoms or characteristics of a disease, disorder, or condition (e.g., sickle cell disease). In some embodiments, a subject displays one or more non-specific symptoms of a disease, disorder, or condition (e.g., sickle cell disease) infection). In some embodiments, a subject does not display any symptom or characteristic of a disease, disorder, or condition (e.g., sickle cell disease). In some embodiments, a subject is someone with one or more features characteristic of susceptibility to or risk of a disease, disorder, or condition (e.g., sickle cell disease). In some embodiments, a subject is a patient. In some embodiments, a subject is an individual to whom diagnosis and / or therapy is and / or has been administered.

[0072] An individual who is “suffering from” a disease, disorder, and / or condition (e.g., sickle cell disease) has been diagnosed with and / or displays one or more symptoms of a disease, disorder, and / or condition.

[0073] An individual who is “susceptible to” a disease, disorder, and / or condition (e.g.. sickle cell disease) is one who has a higher risk of developing the disease, disorder, and / or condition (e.g., sickle cell disease) than does a member of the general public. In some embodiments, an individual who is susceptible to a disease, disorder and / or condition (e.g., sickle cell disease) may not have been diagnosed with the disease, disorder, and / or condition (e.g., sickle cell disease). In some embodiments, an individual who is susceptible to a disease, disorder, and / or condition (e.g., sickle cell disease) may exhibit symptoms of tire disease, disorder, and / or condition (e.g., sickle cell disease). In some embodiments, an individual who is susceptible to a disease, disorder, and / or condition may not exhibit symptoms of the disease, disorder, and / or condition (e.g., sickle cell disease). In some embodiments, an individual who is Page 21 of 28713508126v1Attorney Docket No.: 2017469-0062susceptible to a disease, disorder, and / or condition (e.g., sickle cell disease) will develop the disease, disorder, and / or condition (e.g., sickle cell disease). In some embodiments, an individual who is susceptible to a disease, disorder, and / or condition (e.g., sickle cell disease) will not develop the disease, disorder, and / or condition (e.g., sickle cell disease).

[0074] The term "therapy" refers to an administration or delivery of an agent or intervention that has a therapeutic effect and / or elicits a desired biological and / or pharmacological effect (e.g., has been demonstrated to be statistically likely to have such effect when administered to a relevant population). In some embodiments, a therapeutic agent or therapy is any substance that can be used to alleviate, ameliorate, relieve, inhibit, prevent, delay onset of, reduce severity of, and / or reduce incidence of one or more symptoms or features of a disease, disorder, and / or condition (e.g., sickle cell disease).

[0075] As used herein, the term "treat." "treatment." or treating” refers to any method used to partially or completely alleviate, ameliorate, relieve, inhibit, prevent, delay onset of, reduce severity of, and / or reduce incidence of one or more symptoms or features of a disease, disorder, and / or condition (e.g., sickle cell disease). Treatment may be administered to a subject who does not exhibit signs of a disease, disorder, and / or condition (e.g., sickle cell disease). In some embodiments, treatment may be administered to a subject who exhibits only early signs of the disease, disorder, and / or condition (e.g.. sickle cell disease), for example for the purpose of decreasing the risk of developing pathology associated with the disease, disorder, and / or condition. In some embodiments, treatment may be administered to a subject at a later-stage of disease, disorder, and / or condition (e.g., sickle cell disease).

[0076] The term “Makassar variant,” as used herein, refers to the non-pathogenic point mutation in codon 6 of exon 1 in the HBB gene that naturally occurs in the human population, whereby the wild-type codon encoding glutamic acid (GCA) is mutated to an alanine codon (GCG) (i.e.. an A to G substitution).II. Gene modifying systems

[0077] In some embodiments, a gene modifying system described herein comprises: (A) a gene modifying polypeptide or a polynucleotide (e.g., mRNA) encoding tire gene modifying polypeptide, wherein the gene modifying polypeptide comprises (i) a reverse transcriptase (RT) domain and (ii) an endonuclease domain that contains DNA binding functionality or an endonuclease domain and a separate DNA binding domain; and (B) a template RNA. In some embodiments, a gene modifying polypeptide of the present disclosure acts as a substantially autonomous protein machine capable of integrating a template nucleic acid sequence into a target DNA molecule (e.g., in a mammalian host cell, such as a genomic DNA molecule in tire mammalian host cell), substantially without relying on host machinery.

[0078] In some embodiments, a gene modifying polypeptide comprises a DNA-binding domain, a reverse transcriptase domain, and an endonuclease domain. In some embodiments, the DNA-bindingPage 22 of 28713508126v1Attorney Docket No.: 2017469-0062function may involve an RNA component that directs the protein to a DNA sequence, e.g., a gRNA spacer. In other embodiments, a gene modifying polypeptide may comprise a reverse transcriptase domain and an endonuclease domain. A template RNA of a gene modifying system is typically heterologous to the gene modifying polypeptide element and provides an object sequence to be inserted (reverse transcribed) into the host genome. In some embodiments, a gene modifying polypeptide is capable of target-primed reverse transcription. In some embodiments, A gene modifying polypeptide is capable of second-strand synthesis.

[0079] In some embodiments, a gene modifying system is combined with a second polypeptide. In some embodiments, a second polypeptide may comprise an endonuclease domain. In some embodiments, a second polypeptide may comprise a polymerase domain, e.g., a reverse transcriptase domain. In some embodiments, a second polypeptide may comprise a DNA-dependent DNA polymerase domain. In some embodiments, a second polypeptide aids in completion of a genomic modification, e.g., by contributing to second-strand synthesis or DNA repair resolution.

[0080] A functional gene modifying polypeptide can be made up of unrelated DNA binding, reverse transcription, and endonuclease domains. Without being bound by any particular theory, this modular structure allows combining of functional domains, e.g., dCas9 (DNA binding), MMLV reverse transcriptase (reverse transcription), FokI (endonuclease). In some embodiments, multiple functional domains may arise from a single protein, e.g., Cas9 or Cas9 nickase (DNA binding, endonuclease).

[0081] In some embodiments, a gene modifying polypeptide includes one or more domains that, collectively, facilitate 1) binding a template nucleic acid, 2) binding a target DNA molecule, and 3) integration of at least a portion of the template nucleic acid into the target DNA. In some embodiments, a gene modifying polypeptide is an engineered polypeptide that comprises one or more amino acid substitutions to a corresponding naturally occurring sequence. In some embodiments, a gene modifying polypeptide comprises two or more domains that are heterologous relative to each other, e.g., through a heterologous fusion (or other conjugate) of otherw ise wild-type domains, or as fusions of modified domains, e.g., by way of replacement or fusion of a heterologous sub-domain or other substituted domain. For instance, in some embodiments, one or more of: the RT domain is heterologous to the DNA-binding domain (DBD); the DBD is heterologous to the endonuclease domain; or the RT domain is heterologous to the endonuclease domain.

[0082] In some embodiments, a template RNA molecule for use in the system comprises, from 5' to 3' (1) a gRNA spacer; (2) a gRNA scaffold; (3) a heterologous object sequence (4) a primer binding site (PBS) sequence. In some embodiments, a gRNA spacer is about 18 to about 22 nucleotides in length, e.g.. is about 20 nucleotides. In some embodiments, a gRNA scaffold comprises one or more hairpin loops, e.g., 1, 2, of 3 loops, for associating the template RNA with a Cas domain, e.g., a nickase Cas9Page 23 of 28713508126v1Attorney Docket No.: 2017469-0062domain. In some embodiments, a heterologous object sequence is about 7 to about 74 nucleotides in length, e.g., about 10 to about 20, about 20 to about 30, about 30 to about 40, about 40 to about 50, about 50 to about 60, about 60 to about 70, about 70 to about 80, or, about 80 to about 90 nucleotides in length. In some embodiments, the first (most 5') base of a heterologous object sequence is not C. In some embodiments, a PBS sequence that binds a target priming sequence after nicking occurs is about 3 to about 20 nucleotides in length, e.g., about 7 to about 15. or about 12 to about 14 nucleotides in length. In some embodiments, a PBS sequence has about 40% to about 60% GC content.

[0083] In some embodiments, a gene modifying system may further comprise a second gRNA (e.g. a second strand targeting gRNA). In some embodiments, a second gRNA may help drive complete integration. In some embodiments, a second gRNA may target a location that is 0 to about 200 nucleotides away from a first-strand nick, e.g., 0 to about 50, about 50 to about 100. about 100 to about 200 nucleotides away from a first-strand nick. In some embodiments, a second gRNA can only bind its target sequence after an edit has been made, e.g., a second gRNA binds a sequence present in the heterologous object sequence, but not in tire initial target sequence.

[0084] In some embodiments, a gene modifying system described herein is used to make an edit in mammalian cells (e.g., humans, non-human primates). In some embodiments, a gene modifying system described herein is used to make an edit in primary cells. In some embodiments, a gene modifying system described herein is used to make an edit in CD34+ cells. In some embodiments, a gene modifying system described herein is used to make an edit in hematopoietic stem and progenitor cells (HSPCs) and / or long-tcmi hematopoietic stem cell (LT-HSCs). In some embodiments, a gene modifying system described herein is used to make an edit in Lin⁻CD34⁺CD38⁻ cells and / or Lin⁻ / CD34⁺ / CD38⁻CD90+cells.

[0085] In some embodiments, a gene modifying polypeptide as described herein comprises a reverse transcriptase or RT domain that comprises a MoMLV RT sequence or variant thereof. In some embodiments, a MoMLV RT sequence comprises one or more mutations selected from D200N, L603W, T330P, T306K, W313F, D524G, E562Q, D583N, P51L, S67R, E67K, T197A, H204R, E302K, F309N, L435G, N454K. H594Q, D653N, R110S, and K103L. In some embodiments, a MoMLV RT sequence comprises a combination of mutations, such as D200N, L603W, and T330P, optionally further including T306K and / or W313F. In some embodiments, an endonuclease domain as described herein comprises a Cas9, e.g., comprising an N863A mutation (e.g., in spCas9) or aH840A mutation.

[0086] In some embodiments, an RT and endonuclease domains are joined by a flexible linker, e.g., comprising the amino acid sequence SGGSSGGSSGSETPGTSESATPESSGGSSGGSS (SEQ ID NO: 289). In some embodiments, an endonuclease domain is N-terminal relative to the RT domain. In some embodiments, an endonuclease domain is C-terminal relative to the RT domain.Page 24 of 28713508126v1Attorney Docket No.: 2017469-0062

[0087] In some embodiments, a gene modifying system of the present disclosure incorporates a heterologous object sequence into a target site by target-primed reverse transcription (TPRT), e.g., as described herein. In some embodiments, a gene modifying polypeptide comprises a DNA binding domain. In some embodiments, a gene modifying polypeptide comprises an RNA binding domain. In some embodiments, an RNA binding domain comprises an RNA binding domain of B-box protein, MS2 coat protein, dCas, or an element of a sequence of a table herein. In some embodiments, the RNA binding domain is capable of binding to a template RNA with greater affinity than a reference RNA binding domain. In some embodiments, a gene modifying system is capable of producing an insertion into a target site of at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90. at least 95, or at least 100 nucleotides (and optionally no more than 500, no more than 400. no more than 300. no more than 200, or no more than 100 nucleotides). In some embodiments, a gene modifying system is capable of producing an insertion into the target site of at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at least 95, or at least 100 nucleotides (and optionally no more than 500, no more than 400, no more than 300, no more than 200, or no more than 100 nucleotides). In some embodiments, a gene modifying system is capable of producing an insertion into the target site of at least 0.2, at least 0.3, at least 0.4, at least 0.5, at least 0.6, at least 0.7, at least 0.8, at least 0.9, at least 1, at least 1.5, at least 2, at least 2.5, at least 3, at least 3.5, at least 4, at least 4.5, at least 5, at least 5.5, at least 6, at least 6.5, at least 7, at least 7.5, at least 8, at least 8.5, at least 9, at least 9.5 or at least 10 kilobases (and optionally no more than 1, no more than 5, no more than 10, or no more than 20 kilobases). In some embodiments, a gene modifying system is capable of producing a deletion of at least 81, at least 85, at least 90. at least 95, at least 100. at least 110, at least 120, at least 130. at least 140, at least 150. at least 160, at least 170, at least 180, at least 190, or at least 200 nucleotides (and optionally no more than 500, no more than 400, no more than 300, or no more than 200 nucleotides). In some embodiments, a gene modifying system is capable of producing a deletion of at least 81, at least 85, at least 90, at least 95, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, at least 170, at least 180, at least 190, or at least 200 nucleotides (and optionally no more than 500, no more than 400, no more than 300, or no more than 200 nucleotides). In some embodiments, a gene modifying system is capable of producing a deletion of at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at least 95, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, at least 170. at least 180, at least 190, or at least 200 nucleotides (and optionally no more than 500, no more thanPage 25 of 28713508126v1Attorney Docket No.: 2017469-0062400, no more than 300, or no more than 200 nucleotides). In some embodiments, a gene modifying system is capable of producing a deletion of at least 0.2, at least 0.3, at least 0.4, at least 0.5, at least 0.6, at least 0.7, at least 0.8, at least 0.9, at least 1, at least 1.5, at least 2, at least 2.5, at least 3, at least 3.5, at least 4, at least 4.5, at least 5, at least 5.5, at least 6, at least 6.5, at least 7, at least 7.5, at least 8, at least 8.5, at least 9, at least 9.5 or at least 10 kilobases (and optionally no more than 1, no more than 5, no more than 10, or no more than 20 kilobases). In some embodiments, a gene modifying system is capable of producing a substitution into the target site of at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, or at least 100 or more nucleotides. In some embodiments, a gene modifying system is capable of producing a substitution in the target site of 1 to 2, 2 to 3. 3 to 4, 4 to 5. 5 to 10, 10 to 15, 15 to 20, 20 to 30, 30 to 40, 40 to 50, 50 to 60, 60 to 70, 70 to 80. 80 to 90, or 90 to 100 nucleotides.

[0088] In some embodiments, a gene modifying system is capable of introducing a single point mutation in a target site.

[0089] In some embodiments, a substitution is a transition mutation. In some embodiments, a substitution is a transversion mutation. In some embodiments, a substitution converts an adenine to a thymine, an adenine to a guanine, an adenine to a cytosine, a guanine to a thymine, a guanine to a cytosine, a guanine to an adenine, a thymine to a cytosine, a thymine to an adenine, a thymine to a guanine, a cytosine to an adenine, a cytosine to a guanine, or a cytosine to a thymine.

[0090] In some embodiments, an insertion, deletion, substitution, or combination thereof, increases or decreases expression (e.g., transcription or translation) of a gene. In some embodiments, an insertion, deletion, substitution, or combination thereof, increases or decreases expression (e.g.. transcription or translation) of a gene by altering, adding, or deleting sequences in a promoter or enhancer, e.g., sequences that bind transcription factors. In some embodiments, an insertion, deletion, substitution, or combination thereof alters translation of a gene (e.g., alters an amino acid sequence), inserts or deletes a start or stop codon, alters or fixes the translation frame of a gene. In some embodiments, an insertion, deletion, substitution, or combination thereof alters splicing of a gene, e.g., by inserting, deleting, or altering a splice acceptor or donor site. In some embodiments, an insertion, deletion, substitution, or combination thereof alters transcript or protein half-life. In some embodiments, an insertion, deletion, substitution, or combination thereof alters protein localization in the cell (e.g., from the cytoplasm to a mitochondria, from the cytoplasm into the extracellular space (e.g. adds a secretion tag)). In some embodiments, an insertion, deletion, substitution, or combination thereof alters (e g., improves) protein folding (e.g., to prevent accumulation of misfolded proteins). In some embodiments, an insertion, deletion, substitution, or combination thereof, alters, increases, decreases the activity of a gene, e.g., a protein encoded by the gene.Page 26 of 28713508126v1Attorney Docket No.: 2017469-0062

[0091] Exemplary gene modifying polypeptides, and systems comprising them and methods of using them are described, e.g., in PCT / US2021 / 020948, which is incorporated herein by reference with respect to retroviral RT domains, including the amino acid and nucleic acid sequences therein.

[0092] Exemplary gene modifying polypeptides and retroviral RT domain sequences are also described, e.g., in International Application No. PCT / US2021 / 020948 filed March 4, 2021, e.g., at Table 30, Table 31, and Table 44 therein: the entire application is incorporated by reference herein with respect to retroviral RTs, e.g., in said sequences and tables. Accordingly, a gene modifying polypeptide described herein may comprise an amino acid sequence according to any of the Tables mentioned in this paragraph, or a domain thereof (e.g., a retroviral RT domain), or a functional fragment or variant of any of the foregoing, or an amino acid sequence having at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, a polypeptide for use in any of the systems described herein can be a molecular reconstruction or ancestral reconstruction based upon the aligned polypeptide sequence of multiple homologous proteins. In some embodiments, a reverse transcriptase domain for use in any of the systems described herein can be a molecular reconstruction or an ancestral reconstruction, or can be modified at particular residues, based upon alignments of reverse transcriptase domains from the same or different sources. A skilled artisan can, based on tire accession numbers provided herein, align polypeptides or nucleic acid sequences, e.g.. by using routine sequence analysis tools as Basic Local Alignment Search Tool (BLAST) or CD-Search for conserved domain analysis. Molecular reconstructions can be created based upon sequence consensus, e.g. using approaches described in Ivies ct al., Cell 1997, 501 - 510; Wagstaff ct al., Molecular Biology and Evolution 2013, 88-99.A. Gene Modifying Polypeptides

[0093] In some embodiments, a gene modifying polypeptide possesses the functions of DNA target site binding, template nucleic acid (e.g., RNA) binding, DNA target site cleavage, and template nucleic acid (e.g., RNA) writing / rewriting, e.g., reverse transcription. In some embodiments, each function is contained within a distinct domain. In some embodiments, a function may be attributed to two or more domains (e.g., two or more domains, together, exhibit the functionality). In some embodiments, two or more domains may have the same or similar function (e.g., two or more domains each independently have DNA-binding functionality, e.g., for two different DNA sequences). In other embodiments, one or more domains may be capable of enabling one or more functions, e.g., a Cas9 domain enabling both DNA binding and target site cleavage. In some embodiments, domains are all located within a single polypeptide. In some embodiments, a first domain is in one polypeptide and a second domain is in a second polypeptide. For example, in some embodiments, sequences may be split between a firstPage 27 of 28713508126v1Attorney Docket No.: 2017469-0062polypeptide and a second polypeptide, e.g., wherein the first polypeptide comprises a reverse transcriptase (RT) domain and wherein the second polypeptide comprises a DNA-binding domain and an endonuclease domain, e.g., a nickase domain. As a further example, in some embodiments, a first polypeptide and a second polypeptide may each comprise a DNA binding domain (e.g., a first DNA binding domain and a second DNA binding domain). In some embodiments, a first and second polypeptide may be brought together post-translationally via a split-intein to form a single gene modifying polypeptide.

[0094] In some embodiments, a gene modifying polypeptide described herein comprises (e.g., a system described herein comprises a gene modifying polypeptide that comprises): 1) a Cas domain (e.g., a Cas nickase domain, e g., a Cas9 nickase domain); 2) a reverse transcriptase (RT) domain of Table D of W02023039440A2 (herein incorporated by reference in its entirety), or a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 97%. 98%. or 99% identity thereto, wherein the RT domain is C-terminal of the Cas domain; and a linker disposed between the RT domain and the Cas domain, wherein the linker (a sequence selected from SEQ ID NOs: 12001 to 15332 of W02023039440A2, herein incorporated by reference in its entirety) has a sequence from the same row of TABLE D of W02023039440A2 as the RT domain, or a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% identity thereto.

[0095] In some embodiments, an RT domain has a sequence with 100% identity to an RT domain of Table D of W02023039440A2 and a linker (e.g., a sequence selected from SEQ ID NOs: 12001 to 15332 of W02023039440A2) has a sequence with 100% identity to a linker sequence from the same row of Tabic D of W02023039440A2 as the RT domain. In some embodiments, a Cas domain comprises a sequence of TABLE 1, or a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%. at least 95%, at least 98%, or at least 99% identity thereto. In some embodiments, a gene modifying polypeptide comprises an amino acid sequence according to any one of SEQ ID NOs: 1-3332 in the sequence listing, or a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto.

[0096] In some embodiments, a gene modifying polypeptide comprises a GG amino acid sequence between a Cas domain and a linker, an AG amino acid sequence between an RT domain and a second NLS, and / or a GG amino acid sequence between a linker and an RT domain. In some embodiments, a gene modifying polypeptide comprises a sequence of SEQ ID NO: 290 which comprises a first NLS and a Cas domain, or a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity thereto. In some embodiments, a gene modifying polypeptide comprises a sequence of SEQ ID NO: 291 which comprises a second NLS, or a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, atPage 28 of 28713508126v1Attorney Docket No.: 2017469-0062least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto.Exemplary N-terminal NLS-Cas9 domainMPAAKRVKLDGGDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSI KKNLIGALLFDSGETAEATRLKRTARRRYTRRKNR1CYLQEIFSNEMAKVDDSFF HRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLI YLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAK AILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQ LSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSAS MIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYK FIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFY PFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKG ASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAF LSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTY HDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQ LKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFK EDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENI VIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLY YLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKARGKSD NVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQL VETRQITKHVAQTLDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVR EINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIG KATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRK VLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTV AYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDL IIKLPKYSLFE (SEQ ID NO: 4000)Exemplary C-terminal sequence comprising an NLS AGKRTADGSEFEKRTADGSEFESPKKKAKVE (SEQ ID NO: 4001)(i) Writing domain (RT Domain)

[0097] In some embodiments, a writing domain of a gene modifying system possesses reverse transcriptase activity and is also referred to as a reverse transcriptase (RT) domain. In some embodiments, an RT domain comprises an RT catalytic portion and an RNA-binding region (e.g., a region that binds a template RNA). In some embodiments, a nucleic acid encoding a reverse transcriptase is altered from its natural sequence to have altered codon usage, e.g. improved for human cells. In some embodiments a reverse transcriptase domain is a heterologous reverse transcriptase from a retrovirus. In some embodiments, an RT domain comprising a gene modifying polypeptide has been mutated from its original amino acid sequence, e.g., has at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, or at least 100 substitutions. In some embodiments, an RT domain is derived from an RT of a retrovirus, e.g., HIV-I RT, Moloney Murine Leukemia Virus (MMLV) RT, avian myeloblastosis virus (AMV) RT, or Rous Sarcoma Virus (RSV) RT.Page 29 of 28713508126v1Attorney Docket No.: 2017469-0062

[0098] In some embodiments, a retroviral reverse transcriptase (RT) domain exhibits enhanced stringency of target-primed reverse transcription (TPRT) initiation, e.g., relative to an endogenous RT domain. In some embodiments, an RT domain initiates TPRT when the 3 nucleotides in a target site immediately upstream of a first strand nick, e.g., the genomic DNA priming an RNA template, have at least 66% or 100% complementarity to the 3 nucleotides of homology in the RNA template. In some embodiments, an RT domain initiates TPRT when there are less than 5 nucleotides mismatched (e.g., less than 1, less than 2, less than 3, less than 4, or less than 5 nucleotides mismatched) between a template RNA homology and a target DNA priming reverse transcription. In some embodiments, an RT domain is modified such that the stringency for mismatches in priming the TPRT reaction is increased, e.g., wherein the RT domain does not tolerate any mismatches or tolerates fewer mismatches in a priming region relative to a wild-type (e.g., unmodified) RT domain. In some embodiments, an RT domain comprises a HIV-1 RT domain. In some embodiments, an HIV-1 RT domain initiates lower levels of synthesis even with three nucleotide mismatches relative to an alternative RT domain (e.g., as described by Jamburuthugoda and Eickbush J Mol Biol 407(5):661-672 (2011); incorporated herein by reference in its entirety). In some embodiments, an RT domain forms a dimer (e.g., a heterodimer or homodimer). In some embodiments, an RT domain is monomeric. In some embodiments, an RT domain, naturally functions as a monomer or as a dimer (e.g., heterodimer or homodimer). In some embodiments, an RT domain naturally functions as a monomer, e.g., is derived from a virus wherein it functions as a monomer. In some embodiments, an RT domain is selected from an RT domain from murine leukemia virus (MLV; sometimes referred to as MoMLV) (e.g., P03355), porcine endogenous retrovirus (PERV) (e.g., UniProt Q4VFZ2), mouse mammary tumor virus (MMTV) (e.g., UniProt P03365), Avian reticuloendotheliosis virus (AVIRE) (e.g., UniProtKB accession: P03360); Feline leukemia virus (FLV or FeLV) (e.g., e.g., UniProtKB accession: P10273): Mason-Pfizer monkey virus (MPMV) (e.g.. UniProt P07572), bovine leukemia virus (BL V) (e.g., UniProt P03361 ), human I-cell leukemia virus-I (HTL V-l) (e.g., UniProt P03362), human foamy virus (HFV) ( e.g., UniProt P14350), simian foamy virus (SFV) (e.g., SFV3L) (e.g., UniProt P23074 or P27401 ), or bovine foamy / syncytial virus (BFV / BSV) (e.g., UniProt 041894), or a functional fragment or variant thereof (e.g., an amino acid sequence having at least 70%, at least 80%, at least 90%, at least 95%, or at least 99% identity thereto). In some embodiments, an RT domain is dimeric in its natural functioning. In some embodiments, an RT domain is derived from a virus wherein it functions as a dimer. In some embodiments, an RT domain is selected from an RT domain from avian sarcoma / leukemia virus (ASLV) (e.g., UniProt A0A142BKH1), Rous sarcoma virus (RSV) (e.g., UniProt P03354), avian myeloblastosis virus (AMV) (e.g., UniProt Q83133), human immunodeficiency virus type I (HIV-1) (e.g., UniProt P03369), human immunodeficiency virus type II (HIV -2) (e.g., UniProt P 15833), simian immunodeficiency virus (SIV) (e.g., UniProt P05896), bovine immunodeficiency virus (BIV)Page 30 of 28713508126v1Attorney Docket No.: 2017469-0062(e.g., UniProt P19560), equine infectious anemia virus (EIAV) (e.g., UniProt P03371), or feline immunodeficiency vims (FIV) (e.g., UniProt P16088) (Herschhom and Hizi Cell Mol Life Sci 67(16):2717-2747 (2010)), or a functional fragment or variant thereof (e.g., an amino acid sequence having at least 70%, 80%, 90%, 95%, or 99% identity thereto). Naturally heterodimeric RT domains may, in some embodiments, also be functional as homodimers. In some embodiments, dimeric RT domains are expressed as fusion proteins, e.g., as homodimeric fusion proteins or heterodimeric fusion proteins.

[0099] In some embodiments, an RT function of the system is fulfilled by multiple RT domains (e.g., as described herein). In some embodiments, multiple RT domains are fused. In some embodiments, multiple RT domains arc separate (e.g., on different polypeptides). In some embodiments, a gene modifying system described herein comprises an integrase domain, e.g., wherein the integrase domain may be part of an RT domain. In some embodiments, an RT domain (e.g.. as described herein) comprises an integrase domain. In some embodiments, an RT domain (e.g., as described herein) lacks an integrase domain, or comprises an integrase domain that has been inactivated by mutation or deleted. In some embodiments, a gene modifying system described herein comprises an RNase H domain, e.g., wherein the RNase H domain may be part of an RT domain. In some embodiments, an RNase H domain is not part of an RT domain and is covalently linked via a flexible linker. In some embodiments, an RT domain (e.g., as described herein) comprises an RNase H domain, e.g.. an endogenous RNAse H domain or a heterologous RNase H domain. In some embodiments, an RT domain (e.g., as described herein) lacks an RNase H domain. In some embodiments, an RT domain (e.g., as described herein) comprises an RNase H domain that has been added, deleted, mutated, or swapped for a heterologous RNase H domain. In some embodiments, a polypeptide comprises an inactivated endogenous RNase H domain. In some embodiments, an endogenous RNase H domain from one of the other domains of a polypeptide is genetically removed such that it is not included in the polypeptide, e.g., the endogenous RNase H domain is partially or completely truncated from the comprising domain. In some embodiments, mutation of an RNase H domain yields a polypeptide exhibiting lower RNase activity, e.g., as determined by the methods described in Kotewicz et al. Nucleic Acids Res 16(1 ):265-277 (1988) (incorporated herein by reference in its entirety), e.g., lower by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% compared to an otherwise similar domain without the mutation. In some embodiments, RNase H activity is abolished.

[0100] In some embodiments, an RT domain is mutated to increase fidelity compared to an otherwise similar domain without the mutation. For instance, in some embodiments, a YADD or YMDD motif in an RT domain (e.g., in a reverse transcriptase) is replaced with YVDD. In some embodiments, replacement of the YADD or YMDD or YVDD results in higher fidelity in retroviral reverse transcriptase activity (e.g., as described in Jamburuthugoda and Eickbush, J Mol Biol 2011: incorporated herein by reference inPage 31 of 28713508126v1Attorney Docket No.: 2017469-0062its entirety). In some embodiments, a gene modifying polypeptide described herein comprises an RT domain having an amino acid sequence according to TABLE 1, or a sequence having at least 70%, at least 75% at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto. In some embodiments, a nucleic acid described herein encodes an RT domain having an amino acid sequence according to TABLE 1, or a sequence having at least 70%, at least 75%, at least 80%. at least 85%. at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto.TABLE 1: Exemplary RT DomainsPage 32 of 28713508126v1Attorney Docket No.: 2017469-0062Page 33 of 28713508126v1Attorney Docket No.: 2017469-0062Page 34 of 28713508126v1Attorney Docket No.: 2017469-0062Page 35 of 28713508126v1Attorney Docket No.: 2017469-0062Page 36 of 28713508126v1Attorney Docket No.: 2017469-0062Page 37 of 28713508126v1Attorney Docket No.: 2017469-0062Page 38 of 28713508126v1Attorney Docket No.: 2017469-0062Page 39 of 28713508126v1Attorney Docket No.: 2017469-0062Page 40 of 28713508126v1Attorney Docket No.: 2017469-0062Page 41 of 28713508126v1Attorney Docket No.: 2017469-0062Page 42 of 28713508126v1Attorney Docket No.: 2017469-0062Page 43 of 28713508126v1Attorney Docket No.: 2017469-0062Page 44 of 28713508126v1Attorney Docket No.: 2017469-0062Page 45 of 28713508126v1Attorney Docket No.: 2017469-0062Page 46 of 28713508126v1Attorney Docket No.: 2017469-0062Page 47 of 28713508126v1Attorney Docket No.: 2017469-0062Page 48 of 28713508126v1Attorney Docket No.: 2017469-0062Page 49 of 28713508126v1Attorney Docket No.: 2017469-0062Page 50 of 28713508126v1Attorney Docket No.: 2017469-0062Page 51 of 28713508126v1Attorney Docket No.: 2017469-0062Page 52 of 28713508126v1Attorney Docket No.: 2017469-0062Page 53 of 28713508126v1Attorney Docket No.: 2017469-0062Page 54 of 28713508126v1Attorney Docket No.: 2017469-0062Page 55 of 28713508126v1Attorney Docket No.: 2017469-0062Page 56 of 28713508126v1Attorney Docket No.: 2017469-0062Page 57 of 28713508126v1Attorney Docket No.: 2017469-0062Page 58 of 28713508126v1Attorney Docket No.: 2017469-0062Page 59 of 28713508126v1Attorney Docket No.: 2017469-0062Page 60 of 28713508126v1Attorney Docket No.: 2017469-0062Page 61 of 28713508126v1Attorney Docket No.: 2017469-0062Page 62 of 28713508126v1Attorney Docket No.: 2017469-0062Page 63 of 28713508126v1Attorney Docket No.: 2017469-0062Page 64 of 28713508126v1Attorney Docket No.: 2017469-0062

[0101] In some embodiments, reverse transcriptase domains are modified, for example by site specific mutation. In some embodiments, reverse transcriptase domains are engineered to have improved properties, e.g. SuperScript IV (SSIV) reverse transcriptase derived from the MMLV RT. In some embodiments, a reverse transcriptase domain may be engineered to have lower error rates, e.g., as described in W02001068895, incorporated herein by reference. In some embodiments, a reverse transcriptase domain may be engineered to be more thermostable. In some embodiments, the reverse transcriptase domain may be engineered to be more processive. In some embodiments, a reverse transcriptase domain may be engineered to have tolerance to inhibitors. In some embodiments, a reverse transcriptase domain may be engineered to be faster. In some embodiments, a reverse transcriptase domain may be engineered to better tolerate modified nucleotides in the RNA template. In some embodiments, a reverse transcriptase domain may be engineered to insert modified DNA nucleotides. In some embodiments, a reverse transcriptase domain is engineered to bind a template RNA. In some embodiments, one or more mutations are chosen from D200N, L603W, T330P, D524G, E562Q, D583N, P51L, S67R, E67K, T197A, H204R. E302K, F309N, W313F, L435G, N454K, H594Q, L671P, E69K. H8Y, T306K, or D653N in the RT domain of murine leukemia virus reverse transcriptase or a corresponding mutation at a corresponding position of another RT domain. In some embodiments, a gene modifying polypeptide comprises an RT domain from a retroviral reverse transcriptase, e.g., a wild-type M-MLV RT, e.g., comprising the following sequence:M-MLV(WT):TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLARQAPLIIPLKATS TPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPV QDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPL FAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFDEALHRDLADFRIQHPDLILLQY VDDLLLAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQKQVKYLGYLLKE GQRWLTEARKETVMGQPTPKTPRQLREFLGTAGFCRLWIPGFAEMAAPLYPLTK TGTLFNWGPDQQKAYQEIKQALLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQ KLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILA PHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEE GLQHNCLDILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTT ETEVIWAKALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIHGE IYRRRGLLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNRMA DQAARKAAITETPDTSTLLI (SEQ ID NO: 5002)Page 65 of 28713508126v1Attorney Docket No.: 2017469-0062

[0102] In some embodiments, a gene modifying polypeptide comprises an RT domain from a retroviral reverse transcriptase, e.g., an M-MLV RT, e.g., comprising the following sequence:TLNIEDEHRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLKAT STPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRP VQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQP LFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFDEALHRDLADFRIQHPDLILLQ YVDDLLLAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQKQVKYLGYLLK EGQRWLTEARKETVMGQPTPKTPRQLREFLGTAGFCRLWIPGFAEMAAPLYPLT KTGTLFNWGPDQQKAYQEIKQALLTAPALGLPDLTKPFELFVDEKQGYAKGVLT QKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVIL APHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPE EGLQHNCLDILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVT TETEVIWAKALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIHG EIYRRRGLLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLL (SEQ ID NO: 5003)

[0103] In some embodiments, a gene modifying polypeptide comprises the RT domain from a retroviral reverse transcriptase comprising the sequence of amino acids 659-1329 of NP 057933. In some embodiments, a gene modifying polypeptide further comprises one additional amino acid at the N-terminus of the sequence of amino acids 659-1329 of NP 057933, e.g., as shown below:TLNIEDEHRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLKAT STPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHP TSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFDEALHRDLADFRIQ HPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGTAGFCRLWIPGF AEMAAPLYPLTKTGTLFNWGPDQQKAYQEIKQALLTAPALGLPDLTKPFELFVD EKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTKDA GKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVV ALNPATLLPLPEEGLOHNCLDILAEAHGTRPDLTDOPLPDADHTWYTDGSSLLQE GQRKAGAAVTTETEVIWAKALPAGTSAORAELIALTQALKMAEGKKLNVYTDS RYAFATAHIHGEIYRRRGLLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKG HSAEARGNRMADQAARKAA (SEQ ID NO; 5004)Core RT (bold), annotated per aboveRNAseH (underlined), annotated per above

[0104] In some embodiments, a gene modifying polypeptide further comprises one additional amino acid at the C -terminus of the sequence of amino acids 659-1329 of NP 057933. In some embodiments, the gene modifying polypeptide comprises an RNaseHl domain (e.g., amino acids 1178-1318 ofNP_057933).

[0105] In some embodiments, a retroviral reverse transcriptase domain, e.g., M-MLV RT, may comprise one or more mutations from a wild-type sequence that may improve features of the RT, e.g., thermostability, processivity, and / or template binding. In some embodiments, an M-MLV RT domainPage 66 of 28713508126v1Attorney Docket No.: 2017469-0062comprises, relative to the M-MLV (WT) sequence above, one or more mutations, e.g., selected from D200N, L603W, T330P, T306K, W313F, D524G, E562Q, D583N, P51L, S67R, E67K, T197A, H204R, E302K, F309N, L435G, N454K, H594Q, D653N, R1 IOS, K103L, e.g., a combination of mutations, such as D200N, L603W, and T330P, optionally further including T306K and W313F. In some embodiments, an M-MLV RT used herein comprises the mutations D200N, L603W, T330P, T306K and W313F. In some embodiments, a mutant M-MLV RT comprises the following amino acid sequence:M-MLV (PE2):TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLKAT STPVS1KQYPMSQEAREG1KPH1QRLEDQG1LVPCQSPWNTPELPVKKPGTNDYRP VQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQP LFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFNEALHRDLADFRIQHPDLILLQ YVDDLLLAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQKQVKYLGYLLK EGQRWLTEARKETVMGQPTPKTPRQLREFLGKAGFCRLFIPGFAEMAAPLYPLT KPGTLFNWGPDQQKAYQEIKQALLTAPALGLPDLTKPFELFVDEKQGYAKGVLT QKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVIL APHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPE EGLQHNCLDILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVT TETEV1WAKALPAGTSAQRAEEIALTQALKMAEGKKLNVYTDSRYAFATAH1HG EIYRRRGWLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNR MADQAARKAAITETPDTSTLLI (SEQ ID NO: 5005)

[0106] In some embodiments, a writing domain (e.g.. RT domain) comprises an RNA-binding domain, e.g., that specifically binds to an RNA sequence. In some embodiments, a template RNA comprises an RNA sequence that is specifically bound by the RNA-binding domain of the writing domain.

[0107] In some embodiments, the reverse transcription domain only recognizes and reverse transcribes a specific template, e.g.. a template RNA of the system. In some embodiments, a template comprises a sequence or structure that enables recognition and reverse transcription by a reverse transcription domain. In some embodiments, a template comprises a sequence or structure that enables association with an RNA-binding domain of a polypeptide component of a genome engineering system described herein. In some embodiments, the genome engineering system reverse preferably transcribes a template comprising an association sequence over a template lacking an association sequence.

[0108] A writing domain may also comprise DNA-dependent DNA polymerase activity, e.g., comprise enzymatic activity capable of writing DNA into the genome from a template DNA sequence. In some embodiments, DNA-dependent DNA polymerization is employed to complete second-strand synthesis of a target site edit. In some embodiments, tire DNA-dependent DNA polymerase activity is provided by a DNA polymerase domain in the polypeptide. In some embodiments, the DNA-dependent DNA polymerase activity is provided by a reverse transcriptase domain that is also capable of DNA-dependent DNA polymerization, e.g., second-strand synthesis. In some embodiments, the DNA-dependent DNA polymerase activity is provided by a second polypeptide of the system. In some embodiments, the DNA- Page 67 of 28713508126v1Attorney Docket No.: 2017469-0062dependent DNA polymerase activity is provided by an endogenous host cell polymerase that is optionally recruited to the target site by a component of the genome engineering system.

[0109] In some embodiments, a reverse transcriptase domain has a lower probability of premature tennination rate Poe) in vitro relative to a reference reverse transcriptase domain. In some embodiments, a reference reverse transcriptase domain is a viral reverse transcriptase domain, e.g.. the RT domain from M-MLV.

[0110] In some embodiments, a reverse transcriptase domain has a lower probability of premature termination rate ( ’off) in vitro of less than about 5 x 10'3 / nt, less than about 5 x 10'4 / nt, or less than about 5 x 10'6 / nt, e.g., as measured on a 1094 nt RNA. In some embodiments, the in vitro premature tennination rate is determined as described in Bibillo and Eickbush (2002) J Biol Chem 277(38):34836-34845 (incorporated by reference herein its entirety).[OHl] In some embodiments, a reverse transcriptase domain is able to complete at least about 30% or about 50% of integrations in cells. The percent of complete integrations can be measured by dividing tire number of substantially full-length integration events (e g., genomic sites that comprise at least 98% of the expected integrated sequence) by the number of total (including substantially lull-length and partial) integration events in a population of cells. In some embodiments, the integrations in cells is detennined (e.g., across the integration site) using long-read amplicon sequencing, e.g., as described in Karst et al. (2020) bioRxiv doi.org / 10.1101 / 645903 (incorporated by reference herein in its entirety).

[0112] In some embodiments, quantifying integrations in cells comprises counting the fraction of integrations that contain at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%. at least about 96%. at least about 97%, at least about 98%, at least about 99%, or 100% of the DNA sequence corresponding to the template RNA (e.g., a template RNA having a length of at least 0.05, at least 0.1, at least 0.5, at least 0.6, at least 0.7, at least 0.8, at least 0.9, at least 1, at least 1.5, at least 2, at least 3, at least 4, or at least 5 kb, e.g., a length between 0.5-0.6, 0.6-0.7, 0.7-0.8, 0.8-0.9, 1.0-1.2, 1.2-1.4, 1.4-1.6, 1.6-1.8, 1.8-2.0, 2-3, 3-4, or 4-5 kb).

[0113] In some embodiments, a reverse transcriptase domain is capable of polymerizing dNTPs in vitro. In some embodiments, a reverse transcriptase domain is capable of polymerizing dNTPs in vitro at a rate between 0.1 - 50 nt / sec (e.g., between 0.1-1, 1-10, or 10-50 nt / sec). In some embodiments, polymerization of dNTPs by a reverse transcriptase domain is measured by a single-molecule assay, e.g., as described in Schwartz and Quake (2009) PNAS 106(48):20294-20299 (incorporated by reference in its entirety).

[0114] In some embodiments, a reverse transcriptase domain has an in vitro error rate (e.g., misincorporation of nucleotides) of between 1 x 10'3- 1 x 10'4or 1 x 10'4- l x 10'3substitutions / nt, e.g., as described in Yasukawa et al. (2017) Biochem Biophys Res Commun 492(2): 147-153 (incorporatedPage 68 of 28713508126v1Attorney Docket No.: 2017469-0062herein by reference in its entirety). In some embodiments, the reverse transcriptase domain has an error rate (e.g., misincorporation of nucleotides) in cells (e.g., HEK293T cells) of between 1 x 10'3- l x 10'4or 1 x 10'4- 1 x 10'5substitutions / nt, e.g., by long-read amplicon sequencing, e.g., as described in Karst et al. (2020) bioRxiv doi.org / 10.1101 / 645903 (incorporated by reference herein in its entirety ).

[0115] In some embodiments, a reverse transcriptase domain is capable of perfonning reverse transcription of a target RNA in vitro. In some embodiments, a reverse transcriptase requires a primer of at least 3 nucleotides to initiate reverse transcription of a template. In some embodiments, reverse transcription of a target RNA is determined by detection of cDNA from the target RNA (e.g., when provided with a ssDNA primer, e.g., which anneals to the target with at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 nt at the 3' end), e g., as described in Bibillo and Eickbush (2002) J Biol Chem 277(38):34836-34845 (incorporated herein by reference in its entirety).

[0116] In some embodiments, a reverse transcriptase domain performs reverse transcription at least 5 or 10 times more efficiently (e.g., by cDNA production), e.g., when converting its RNA template to cDNA, for example, as compared to an RNA template lacking the protein binding motif (e.g., a 3 ' UTR). In some embodiments, efficiency of reverse transcription is measured as described in Yasukawa et al. (2017) Biochem Biophys Res Commun 492(2): 147-153 (incorporated by reference herein in its entirety).

[0117] In some embodiments, a reverse transcriptase domain specifically binds a specific RNA template with higher frequency (e.g., about 5 -fold or about 10-fold higher frequency) than any endogenous cellular RNA, e.g., when expressed in cells (e.g., HEK293T cells). In some embodiments, frequency of specific binding between the reverse transcriptase domain and the template RNA are measured by CLIP-seq, e.g., as described in Lin and Miles (2019) Nucleic Acids Res 47(11):5490-5501 (incorporated herein by reference in its entirety).

[0118] In some embodiments, an RT domain (e.g., as listed in TABLE 1) comprises one or more mutations as listed in TABLE 2 below. In some embodiment, an RT domain as listed in TABLE 1 comprises one, two, three, four, five, or six of the mutations listed in the corresponding row of TABLE 2 below.TABLE 2: Exemplary RT domain mutations (relative to corresponding wild-type sequences as listed in the corresponding row of TABLE 1)Page 69 of 28713508126v1Attorney Docket No.: 2017469-0062Page 70 of 28713508126v1Attorney Docket No.: 2017469-0062Page 71 of 28713508126v1Attorney Docket No.: 2017469-0062Page 72 of 28713508126v1Attorney Docket No.: 2017469-0062(ii) Template nucleic acid binding domain

[0119] A gene modifying polypeptide typically contains regions capable of associating with a template nucleic acid (e.g., template RNA). In some embodiments, a template nucleic acid binding domain is an RNA binding domain. In some embodiments, an RNA binding domain is a modular domain that can associate with RNA molecules containing specific signatures, e.g., structural motifs. In other embodiments, a template nucleic acid binding domain (e.g., RNA binding domain) is contained within the reverse transcription domain, e.g., the reverse transcriptase-derived component has a known signature for RNA preference.

[0120] In other embodiments, a template nucleic acid binding domain (e.g., RNA binding domain) is contained within the target DNA binding domain. For example, in some embodiments, a DNA binding domain is a CRISPR-associated protein that recognizes the structure of a template nucleic acid (e.g., template RNA) comprising a gRNA. In some embodiments, a gene modifying polypeptide comprises a DNA-binding domain comprising a CRISPR-associated protein that associates with a gRNA scaffold that allows the DNA-binding domain to bind a target genomic DNA sequence. In some embodiments, the gRNA scaffold and gRNA spacer is comprised within the template nucleic acid (e.g., template RNA), thus the DNA-binding domain is also the template nucleic acid binding domain. In some embodiments, the polypeptide possesses RNA binding function in multiple domains, e.g., can bind a gRNA structure inPage 73 of 28713508126v1Attorney Docket No.: 2017469-0062a CRISPR-associated DNA binding domain and an additional sequence or structure in a reverse transcriptase domain.

[0121] In some embodiments, an RNA binding domain is capable of binding to a template RNA with greater affinity than a reference RNA binding domain. In some embodiments, a reference RNA binding domain is an RNA binding domain from Cas9 of S. pyogenes. In some embodiments, an RNA binding domain is capable of binding to a template RNA with an affinity between 100 pM - 10 nM (e.g., between 100 pM - 1 nM or 1 nM - 10 nM). In some embodiments, the affinity of an RNA binding domain for its template RNA is measured in vitro, e.g., by thermophoresis, e.g., as described in Asmari et al. Methods 146:107-119 (2018) (incorporated by reference herein in its entirety). In some embodiments, the affinity of an RNA binding domain for its template RNA is measured in cells (e.g., by FRET or CLIP-Seq).

[0122] In some embodiments, an RNA binding domain is associated with a template RNA in vitro at a frequency at least about 5-fold or at least about 10-fold higher than with a scrambled RNA. In some embodiments, the frequency of association between an RNA binding domain and a template RNA or scrambled RNA is measured by CLIP-seq, e.g., as described in Lin and Miles (2019) Nucleic Acids Res 47(11):5490-5501 (incorporated by reference herein in its entirety). In some embodiments, an RNA binding domain is associated with a template RNA in cells at a frequency at least about -fold or at least about 10-fold higher than with a scrambled RNA. In some embodiments, the frequency of association between an RNA binding domain and a template RNA or scrambled RNA is measured by CLIP-seq, e.g., as described in Lin and Miles (2019), supra.(iii) Endonuclease domains and DNA binding domains

[0123] In some embodiments, a gene modifying polypeptide possesses the function of DNA target site cleavage via an endonuclease domain. In some embodiments, a gene modifying polypeptide comprises a DNA binding domain, e.g., for binding to a target nucleic acid. In some embodiments, a domain (e.g., a Cas domain) of a gene modifying polypeptide comprises two or more smaller domains, e.g., a DNA binding domain and an endonuclease domain. It is understood that when a DNA binding domain (e.g., a Cas domain) is said to bind to a target nucleic acid sequence, in some embodiments, the binding is mediated by a gRNA.

[0124] In some embodiments, a domain has two functions. For example, in some embodiments, an endonuclease domain is also a DNA-binding domain. In some embodiments, an endonuclease domain is also a template nucleic acid (e.g., template RNA) binding domain. For example, in some embodiments, a polypeptide comprises a CRISPR-associated endonuclease domain that binds a template RNA comprising a gRNA, binds a target DNA sequence (e.g., with complementarity to a portion of the gRNA), and cuts the target DNA sequence. In some embodiments, an endonuclease domain or endonuclease / DNA-binding Page 74 of 28713508126v1Attorney Docket No.: 2017469-0062domain from a heterologous source can be used or can be modified (e.g., by insertion, deletion, or substitution of one or more residues) in a gene modifying system described herein.

[0125] In some embodiments, a nucleic acid encoding an endonuclease domain or endonuclease / DNA binding domain is altered from its natural sequence to have altered codon usage, e.g., improved for human cells. In some embodiments, an endonuclease element is a heterologous endonuclease element, such as a Cas endonuclease (e.g., Cas9), atype-II restriction endonuclease (e.g., Fokl), a meganuclease (e.g., I-Scel), or other endonuclease domain.

[0126] In some embodiments, a DNA-binding domain of a gene modifying polypeptide described herein is selected, designed, or constructed for binding to a desired host DNA target sequence. In some embodiments, a DNA-binding domain of a gene modifying polypeptide is a heterologous DNA-binding element. In some embodiments a heterologous DNA binding element is a zinc-finger element or a TAL effector element, e.g., a zinc-finger or TAL polypeptide or functional fragment thereof. In some embodiments, a heterologous DNA binding element is a sequence-guided DNA binding element, such as Cas9, Cpfl, or other CRISPR-related protein that has been altered to have no endonuclease activity. In some embodiments a heterologous DNA binding element retains endonuclease activity. In some embodiments, a heterologous DNA binding element retains partial endonuclease activity to cleave ssDNA, e.g., possesses nickase activity. In some embodiments, a heterologous DNA-binding domain can be any one or more of Cas9, TAL domain, ZF domain, Myb domain, combinations thereof, or multiples thereof.

[0127] In some embodiments, DNA-binding domains are modified, for example by site-specific mutation, increasing or decreasing DNA-binding elements (for example, number and / or specificity of zinc fingers), etc., to alter DNA-binding specificity and affinity. In some embodiments a nucleic acid sequence encoding the DNA binding domain is altered from its natural sequence to have altered codon usage, e.g. improved for human cells. In some embodiments, the DNA binding domain comprises one or more modifications relative to a wild-type DNA binding domain, e.g., a modification via directed evolution, e.g., phage-assisted continuous evolution (PACE).

[0128] In some embodiments, the DNA binding domain comprises a meganuclease domain (e.g.. as described herein, e.g., in the endonuclease domain section), or a functional fragment thereof. In some embodiments, a meganuclease domain possesses endonuclease activity, e.g., double-strand cleavage and / or nickase activity. In other embodiments, a meganuclease domain has reduced activity, e.g., lacks endonuclease activity, e.g., the meganuclease is catalytically inactive. In some embodiments, a catalytically inactive meganuclease is used as a DNA binding domain, e.g., as described in Fonfara et al. Nucleic Acids Res 40(2): 847-860 (2012), incorporated herein by reference in its entirety.Page 75 of 28713508126v1Attorney Docket No.: 2017469-0062

[0129] In some embodiments, a gene modifying polypeptide comprises a modification to a DNA-binding domain, e.g., relative to the wild-type polypeptide. In some embodiments, a DNA-binding domain comprises an addition, deletion, replacement, or modification to the amino acid sequence of tire original DNA-binding domain. In some embodiments, a DNA-binding domain is modified to include a heterologous functional domain that binds specifically to a target nucleic acid (e.g., DNA) sequence of interest. In some embodiments, a functional domain replaces at least a portion (e.g., the entirety of) the prior DNA-binding domain of the polypeptide. In some embodiments, a functional domain comprises a zinc finger (e.g., a zinc finger that specifically binds to a target nucleic acid (e.g., DNA) sequence of interest. In some embodiments, a functional domain comprises a Cas domain (e.g., a Cas domain that specifically binds to a target nucleic acid (e.g., DNA) sequence of interest). In some embodiments, a Cas domain comprises a Cas9 or a mutant or variant thereof (e.g., as described herein). In some embodiments, a Cas domain is associated with a guide RNA (gRNA), e.g., as described herein. In some embodiments, a Cas domain is directed to a target nucleic acid (e.g., DNA) sequence of interest by the gRNA. In some embodiments, a Cas domain is encoded in the same nucleic acid (e.g., RNA) molecule as the gRNA. In some embodiments, a Cas domain is encoded in a different nucleic acid (e.g., RNA) molecule from the gRNA.

[0130] In some embodiments, a DNA binding domain is capable of binding to a target sequence (e.g., a dsDNA target sequence) with greater affinity than a reference DNA binding domain. In some embodiments, a reference DNA binding domain is a DNA binding domain from Cas9 of S. pyogenes. In some embodiments, a DNA binding domain is capable of binding to a target sequence (e.g., a dsDNA target sequence) with an affinity between 100 pM - 10 nM (e.g., between 100 pM - 1 nM or between 1 nM - 10 nM).

[0131] In some embodiments, the affinity of a DNA binding domain for its target sequence (e.g., dsDNA target sequence) is measured in vitro, e.g., by thermophoresis, e.g., as described in Asmari et al. Methods 146:107-119 (2018) (incorporated by reference herein in its entirety).

[0132] In embodiments, a DNA binding domain is capable of binding to its target sequence (e.g.. dsDNA target sequence), e.g, with an affinity between 100 pM - 10 nM (e.g., between 100 pM -1 nM or between 1 nM - 10 nM) in the presence of a molar excess of scrambled sequence competitor dsDNA, e.g., of about 100-fold molar excess.

[0133] In some embodiments, a DNA binding domain is found associated with its target sequence (e.g., dsDNA target sequence) more frequently than any other sequence in the genome of a target cell, e.g., human target cell, e.g., as measured by ChlP-seq (e.g., in HEK293T cells), e.g., as described in He and Pu (2010) Curr. Protoc Mol Biol Chapter 21 (incorporated herein by reference in its entirety). In some embodiments, a DNA binding domain is found associated with its target sequence (e.g., dsDNA target Page 76 of 28713508126v1Attorney Docket No.: 2017469-0062sequence) at least about 5 -fold or at least about 10-fold, more frequently than any other sequence in the genome of a target cell, e.g., as measured by ChlP-seq (e.g., in HEK293T cells), e.g., as described in He and Pu (2010), supra.

[0134] In some embodiments, an endonuclease domain has nickase activity and cleaves one strand of a target DNA. In some embodiments, nickase activity reduces the formation of double -stranded breaks at the target site. In some embodiments, an endonuclease domain creates a staggered nick structure in the first and second strands of a target DNA. In some embodiments, a staggered nick structure generates free 3’ overhangs at a target site. In some embodiments, free 3’ overhangs at the target site improve editing efficiency, e.g., by enhancing access and annealing of a 3' homology region of a template nucleic acid. In some embodiments, a staggered nick structure reduces the formation of double-stranded breaks at a target site.

[0135] In some embodiments, an endonuclease domain cleaves both strands of a target DNA, e.g., results in blunt-end cleavage of a target with no ssDNA overhangs on either side of the cut-site. The amino acid sequence of an endonuclease domain of a gene modifying system described herein may be at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%. at least about 96%. at least about 97%, at least about 98%, or at least about 99% identical to the amino acid sequence of an endonuclease domain described herein, e.g., an endonuclease domain from TABLE 4.

[0136] In some embodiments, a heterologous endonuclease is Fokl or a functional fragment thereof. In some embodiments, a heterologous endonuclease is a Holliday junction resolvase or homolog thereof, such as the Holliday junction resolving enzyme from Sulfolobus solfataricus — Ssol Hje (Govindaraju et al., Nucleic Acids Research 44:7, 2016). In some embodiments, a heterologous endonuclease is an endonuclease of the large fragment of a spliceosomal protein, such as Prp8 (Mahbub et al.. Mobile DNA 8: 16, 2017). In some embodiments, a heterologous endonuclease is derived from a CRISPR-associated protein, e.g., Cas9. In some embodiments, a heterologous endonuclease is engineered to have only ssDNA cleavage activity, e.g., only nickase activity, e.g., be a Cas9 nickase, e.g., SpCas9 with D10A, H840A, or N863A mutations. TABLE 3 and TABLE 4 provide exemplary Cas proteins and mutations associated with nickase activity. In some embodiments, homologous endonuclease domains are modified, for example by site-specific mutation, to alter DNA endonuclease activity. In some embodiments, endonuclease domains are modified to reduce DNA-sequence specificity, e.g., by truncation to remove domains that confer DNA-sequence specificity or mutation to inactivate regions conferring DNA-sequence specificity.

[0137] In some embodiments, an endonuclease domain has nickase activity and does not form doublestranded breaks. In some embodiments, an endonuclease domain forms single-stranded breaks at a higher Page 77 of 28713508126v1Attorney Docket No.: 2017469-0062frequency than double-stranded breaks, e.g., at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of the breaks are single-stranded breaks, or less than 10%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1% of the breaks are double -stranded breaks. In some embodiments, an endonuclease forms substantially no double-stranded breaks. In some embodiments, an endonuclease does not form detectable levels of double-stranded breaks.

[0138] In some embodiments, an endonuclease domain has nickase activity that nicks the target site DNA of a first strand; e.g., in some embodiments, an endonuclease domain cuts the genomic DNA of a target site near to the site of alteration on the strand that will be extended by the writing domain. In some embodiments, an endonuclease domain has nickase activity that nicks the target site DNA of a first strand and does not nick the target site DNA of a second strand. For example, when a polypeptide comprises a CRISPR-associated endonuclease domain having nickase activity, in some embodiments, said CRISPR-associated endonuclease domain nicks the target site DNA strand containing the PAM site (e.g., and does not nick the target site DNA strand that does not contain the PAM site). As a further example, when a polypeptide comprises a CRISPR-associated endonuclease domain having nickase activity, in some embodiments, said CRISPR-associated endonuclease domain nicks the target site DNA strand not containing the PAM site (e.g., and does not nick the target site DNA strand that contains the PAM site).

[0139] In some embodiments, an endonuclease domain has nickase activity that nicks the target site DNA of a first strand and a second strand. Without wishing to be bound by theory, after a writing domain (e.g., RT domain) of a polypeptide described herein polymerizes (e.g., reverse transcribes) from the heterologous object sequence of a template nucleic acid (e.g., template RNA), the cellular DNA repair machinery must repair the nick on the first DNA strand. The target site DNA now contains tw o different sequences for the first DNA strand: one corresponding to the original genomic DNA (e.g., having a free 5' end) and a second corresponding to that polymerized from the heterologous object sequence (e.g., having a free 3' end). It is thought that the two different sequences equilibrate with one another, first one hybridizing the second strand, then the other, and which sequence the cellular DNA repair apparatus incorporates into its repaired target site may be a stochastic process. Without wishing to be bound by¬ theory, it is thought that introducing an additional nick to the second strand may bias the cellular DNA repair machinery to adopt the heterologous object sequence -based sequence more frequently than the original genomic sequence (Anzalone et al. Nature 576: 149-157 (2019)). In some embodiments, the additional nick is at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at least 95, at least 100, at least 105, at least 110, at least 115, at least 120, at least 125, at least 130, at least 135, at least 140, at least 145, or at least 150 nucleotides 5' or 3' of the target site modification (e.g., the insertion, deletion, or substitution) or to the nick on the first strand.Page 78 of 28713508126v1Attorney Docket No.: 2017469-0062

[0140] Alternatively or additionally, without wishing to be bound by theory, it is thought that an additional nick to the second strand may promote second-strand synthesis. In some embodiments, where a gene modifying system has inserted or substituted a portion of the first strand, synthesis of a new sequence corresponding to the insertion / substitution in the second strand is necessary.

[0141] In some embodiments, a gene modifying polypeptide comprises a single domain having endonuclease activity (e g, a single endonuclease domain) and said domain nicks both the first strand and the second strand. For example, in some embodiments, an endonuclease domain may be a CRISPR-associated endonuclease domain, and a template nucleic acid (e.g., template RNA) comprises agRNA spacer that directs nicking of the first strand and an additional gRNA spacer that directs nicking of the second strand. In some embodiments, a gene modifying polypeptide comprises a plurality of domains having endonuclease activity, and a first endonuclease domain nicks the first strand and a second endonuclease domain nicks the second strand (optionally, the first endonuclease domain does not (e.g., cannot) nick the second strand and the second endonuclease domain does not (e.g., cannot) nick the first strand).

[0142] In some embodiments, an endonuclease domain is capable of nicking a first strand and a second strand. In some embodiments, the first and second strand nicks occur at the same position in the target site but on opposite strands. In some embodiments, the second strand nick occurs in a staggered location, e.g., upstream or downstream, from the first nick. In some embodiments, an endonuclease domain generates a target site deletion if the second strand nick is upstream of the first strand nick. In some embodiments, an endonuclease domain generates a target site duplication if the second strand nick is downstream of the first strand nick. In some embodiments, an endonuclease domain generates no duplication and / or deletion if the first and second strand nicks occur in the same position of the target site. In some embodiments, an endonuclease domain has altered activity depending on protein conformation or RNA-binding status, e.g., which promotes the nicking of the first or second strand (e.g., as described in Christensen et al. PNAS 2006; incorporated by reference herein in its entirety).

[0143] In some embodiments, an endonuclease domain comprises a meganuclease, or a functional fragment thereof. In some embodiments, an endonuclease domain comprises a homing endonuclease, or a functional fragment thereof. In some embodiments, an endonuclease domain comprises a meganuclease from the LAGLIDADG, GIY-YIG, HNH, His-Cys Box, or PD-(D / E) XK families, or a functional fragment or variant thereof, e.g., which possess conserved amino acid motifs, e.g., as indicated in the family names. In some embodiments, an endonuclease domain comprises a meganuclease, or fragment thereof, chosen from, e.g., I-SmaMI (Uniprot F7WD42), I-Scel (Uniprot P03882), I-Anil (Uniprot P03880), I-Dmol (Uniprot P21505). I-Crel (Uniprot P05725). I-TevI (Uniprot P13299). I-Onul (Uniprot Q4VWW5), or I-Bmol (Uniprot Q9ANR6). In some embodiments, a meganuclease is naturallyPage 79 of 28713508126v1Attorney Docket No.: 2017469-0062monomeric, e.g., I-SceL I-TevL or dimeric, e.g., I-CreL in its functional form. For example, the LAGLID ADG meganucleases with a single copy of the LAGLIDADG motif generally form homodimers, whereas members with two copies of the LAGLIDADG motif are generally found as monomers. In some embodiments, a meganuclease that normally forms as a dimer is expressed as a fusion, e.g., the two subunits are expressed as a single ORF and, optionally, connected by a linker, e g., an I-Crel dimer fusion (Rodriguez-Fomes et al. Gene Therapy 2020; incorporated by reference herein in its entirety). In some embodiments, a meganuclease, or a functional fragment thereof, is altered to favor nickase activity for one strand of a double-stranded DNA molecule, e.g., I-Scel (K122I and / or K223I) (Niu et al. J Mol Biol 2008), I-Anil (K227M) (McConnell Smith et al. PNAS 2009), I-Dmol (Q42A and / or K120M) (Molina et al. J Biol Chem 2015). In some embodiments, a meganuclease or functional fragment thereof possessing this preference for single-strand cleavage is used as an endonuclease domain, e.g.. with nickase activity. In some embodiments, an endonuclease domain comprises a meganuclease, or a functional fragment thereof, which naturally targets or is engineered to target a safe harbor site, e.g., an I-Crel targeting SH6 site (Rodriguez-Fomes et al., supra). In some embodiments, an endonuclease domain comprises a meganuclease, or a functional fragment thereof, with a sequence tolerant catalytic domain, e.g., I-TevI recognizing the minimal motif CNNNG (Kleinstiver et al. PNAS 2012). In some embodiments, a target sequence tolerant catalytic domain is fused to a DNA binding domain, e.g., to direct activity, e.g., by fusing I-TevI to: (i) zinc fingers to create Tev-ZFEs (Kleinstiver et al. PNAS 2012), (ii) other meganucleases to create MegaTevs (Wolfs et al. Nucleic Acids Res 2014), and / or (iii) Cas9 to create TevCas9 (Wolfs et al. PNAS 2016).

[0144] In some embodiments, an endonuclease domain comprises a restriction enzyme, e.g., a Type IIS or Type IIP restriction enzyme. In some embodiments, the endonuclease domain comprises a Type IIS restriction enzyme, e.g.. Fokl. or a fragment or variant thereof. In some embodiments, the endonuclease domain comprises a Type IIP restriction enzyme, e.g., PvuII, or a fragment or variant thereof. In some embodiments, a dimeric restriction enzyme is expressed as a fusion such that it functions as a single chain, e.g., a Fokl dimer fusion (Minczuk et al. Nucleic Acids Res 36(12):3926-3938 (2008)).

[0145] The use of additional endonuclease domains is described, for example, in Guha and Edgell Int J Mol Sci 18(22):2565 (2017), which is incorporated herein by reference in its entirety.

[0146] In some embodiments, a gene modifying polypeptide comprises a modification to an endonuclease domain, e.g., relative to a wild-type Cas protein. In some embodiments, an endonuclease domain comprises an addition, deletion, replacement, or modification to the amino acid sequence of the wild-type Cas protein. In some embodiments, an endonuclease domain is modified to include a heterologous functional domain that binds specifically to and / or induces endonuclease cleavage of a target nucleic acid (e.g., DNA) sequence of interest. In some embodiments, an endonuclease domainPage 80 of 28713508126v1Attorney Docket No.: 2017469-0062comprises a zinc finger. In some embodiments, an endonuclease domain comprising a Cas domain is associated with a guide RNA (gRNA), e.g., as described herein. In some embodiments, an endonuclease domain is modified to include a functional domain that does not target a specific target nucleic acid (e.g., DNA) sequence. In some embodiments, an endonuclease domain comprises a Fokl domain.

[0147] In some embodiments, an endonuclease domain is associated with the target dsDNA in vitro at a frequency at least about 5-fold or 10-fold higher than with a scrambled dsDNA. In some embodiments, an endonuclease domain is associated with the target dsDNA in vitro at a frequency at least about -fold or 10-fold higher than with a scrambled dsDNA, e.g., in a cell (e.g., a HEK293T cell). In some embodiments, the frequency of association between the endonuclease domain and the target DNA or scrambled DNA is measured by ChlP-seq. e.g., as described in He and Pu (2010) Curr. ProtocMol Biol Chapter 21 (incorporated by reference herein in its entirety).

[0148] In some embodiments, an endonuclease domain can catalyze the formation of a nick at a target sequence, e.g., to an increase of at least about 5-fold or 10-fold relative to a non-target sequence (e.g., relative to any other genomic sequence in the genome of the target cell). In some embodiments, the level of nick formation is determined using NickSeq, e.g., as described in Elacqua et al. (2019) bioRxiv doi.org / 10.1101 / 867937 (incorporated herein by reference in its entirety).

[0149] In some embodiments, an endonuclease domain is capable of nicking DNA in vitro. In some embodiments, a nick results in an exposed base. In some embodiments, an exposed base can be detected using a nuclease sensitivity assay, e.g., as described in Chaudhry' and Weinfeld (1995) Nucleic Acids Res 23(19):3805-3809 (incorporated by reference herein in its entirety). In some embodiments, the level of exposed bases (e.g., detected by the nuclease sensitivity assay) is increased by at least 10%, at least 50%, or more relative to a reference endonuclease domain. In some embodiments, a reference endonuclease domain is an endonuclease domain from Cas9 of S. pyogenes.

[0150] In some embodiments, an endonuclease domain is capable of nicking DNA in a cell. In some embodiments, an endonuclease domain is capable of nicking DNA in a HEK293T cell. In some embodiments, an unrepaired nick that undergoes replication in the absence of Rad51 results in increased NHEJ rates at the site of the nick, which can be detected, e.g.. by using a Rad51 inhibition assay, e.g.. as described in Bothmer et al. (2017) Nat Commun 8: 13905 (incorporated by reference herein in its entirety). In some embodiments, NHEJ rates are increased above 0-5%. In some embodiments, NHEJ rates are increased to 20-70% (e.g., between 30%-60% or 40-50%), e.g., upon Rad51 inhibition.

[0151] In some embodiments, an endonuclease domain releases a target after cleavage. In some embodiments, release of a target is indicated indirectly by assessing for multiple turnovers by the enzyme, e.g., as described in Yourik et al. RNA 25(l):35-44 (2019) (incorporated herein by reference in itsPage 81 of 28713508126v1Attorney Docket No.: 2017469-0062entirety). In some embodiments, the kexpof an endonuclease domain is 1 x 10-3- 1 x 10-5min-1as measured by such methods.

[0152] In some embodiments, an endonuclease domain has a catalytic efficiency (kcJKf) greater than about 1 x 10ss’1M-1in vitro. In some embodiments, an endonuclease domain has a catalytic efficiency greater than about 1 x 105. 1 x 106, 1 x 107, or 1 x 108, s-1M-1in vitro. In some embodiments, catalytic efficiency is determined as described in Chen et al. (2018) Science 360(6387):436-439 (incorporated herein by reference in its entirety). In some embodiments, the endonuclease domain has a catalytic efficiency greater than about 1 x 108s-1M-1in cells. In some embodiments, an endonuclease domain has a catalytic efficiency greater than about 1 x 105, 1 x 106, 1 x 107, or 1 x 108s-1M-1in cells.(iv) Gene modifying polypeptides comprising Cas domains

[0153] In some embodiments, a gene modifying polypeptide described herein comprises a Cas domain. In some embodiments, the Cas domain can direct the gene modifying polypeptide to a target site specified by a gRNA spacer, thereby modifying a target nucleic acid sequence in ‘‘cis”. In some embodiments, a gene modifying polypeptide is fused to a Cas domain. In some embodiments, a gene modifying polypeptide comprises a CRISPR / Cas domain (also referred to herein as a CRISPR-associated protein). In some embodiments, a CRISPR / Cas domain comprises a protein involved in the clustered regulatory interspaced short palindromic repeat (CRISPR) system, e.g., a Cas protein, and optionally binds a guide RNA, e.g., single guide RNA (sgRNA).

[0154] CRISPR systems are adaptive defense systems originally discovered in bacteria and archaea. CRISPR systems use RNA-guided nucleases tenned CRISPR-associated or “Cas” endonucleases (e. g., Cas9 or Cpfl) to cleave foreign DNA. For example, in atypical CRISPR-Cas system, an endonuclease is directed to a target nucleotide sequence (e. g., a site in the genome that is to be sequence -edited) by sequence-specific, non-coding “guide RNAs” that target single- or double-stranded DNA sequences. Three classes (I-III) of CRISPR systems have been identified. The class II CRISPR systems use a single Cas endonuclease (rather than multiple Cas proteins). One class II CRISPR system includes a type II Cas endonuclease such as Cas9, a CRISPR RNA (“crRNA”), and a trans-activating crRNA (“tracrRNA”). The crRNA contains a “spacer” sequence, atypically about 20-nucleotide RNA sequence that corresponds to a target DNA sequence (“protospacer”). In a wild-type system, and in some engineered systems, crRNA also contains a region that binds to a tracrRNA to form a partially double-stranded structure that is cleaved by RNase III, resulting in a crRNA / tracrRNA hybrid molecule. A crRNA / tracrRNA hybrid then directs a Cas endonuclease to recognize and cleave a target DNA sequence. A target DNA sequence is generally adjacent to a “protospacer adjacent motif’ (“PAM”) that is specific for a given Cas endonuclease and required for cleavage activity at a target site matching the spacer of thePage 82 of 28713508126v1Attorney Docket No.: 2017469-0062crRNA. CRISPR endonucleases identified from various prokaryotic species have unique PAM sequence requirements, e.g., as listed for exemplary Cas enzymes in TABLE 3 or TABLE 4; examples of PAM sequences include 5 -NGG (Streptococcus pyogenes), 5 -NNAGAA (Streptococcus thermophilus, CRISPR1), 5 -NGGNG (Streptococcus thermophilus, CRISPR3), and 5 -NNNGATT (Neisseria meningiditis). Some endonucleases, e.g., Cas9 endonucleases, are associated with G-rich PAM sites, e. g.. 5 -NGG, and perform blunt-end cleaving of atarget DNA at a location 3 nucleotides upstream from (5 ' from) a PAM site. Another class II CRISPR system includes the type V endonuclease Cpfl, which is smaller than Cas9; examples include AsCpfl (from Acidaminococcus sp.) and LbCpfl (from Lachnospiraceae sp.). Cpfl -associated CRISPR arrays are processed into mature crRNAs without the requirement of a tracrRNA; in other words, a Cpfl system, in some embodiments, comprises only Cpfl nuclease and a crRNA to cleave a target DNA sequence. Cpfl endonucleases, are typically associated with T-rich PAM sites, e. g., 5 -TTN. Cpfl can also recognize a 5 -CTA PAM motif. Cpfl typically cleaves a target DNA by introducing an offset or staggered double-strand break with a 4- or 5-nucleotide 5 ' overhang, for example, cleaving a target DNA with a 5-nucleotide offset or staggered cut located 18 nucleotides downstream from (3 ' from) from a PAM site on tire coding strand and 23 nucleotides downstream from the PAM site on the complimentary strand; the 5-nucleotide overhang that results from such offset cleavage allows more precise genome editing by DNA insertion by homologous recombination than by insertion at blunt-end cleaved DNA. See, e.g., Zetsche et al. (2015) Cell, 163:759 - 771.

[0155] A variety of CRISPR associated (Cas) genes or proteins can be used in embodiments of the present disclosure and the choice of Cas protein will depend upon the particular target and other conditions. Specific examples of Cas proteins include class II systems including Casl, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7. Cas8. Cas9, CaslO. Cpfl. C2C1, or C2C3. In some embodiments, a Cas protein, e.g., a Cas9 protein, may be from any of a variety of prokaryotic species. In some embodiments a particular Cas protein, e.g., a particular Cas9 protein, is selected to recognize a particular protospacer-adjacent motif (PAM) sequence. In some embodiments, a DNA-binding domain or endonuclease domain includes a sequence targeting polypeptide, such as a Cas protein, e g., Cas9. In some embodiments, a Cas protein, e.g., a Cas9 protein, may be obtained from a bacteria or archaea or synthesized using known methods. In some embodiments, a Cas protein may be from a gram-positive bacteria or a gram-negative bacteria. In some embodiments, a Cas protein may be from a Streptococcus (e.g., a S. pyogenes, or a S. thermophilus), a Francisella (e.g., an F. novicida), a Staphylococcus (e.g., an S. aureus), an Acidaminococcus (e.g., an Acidaminococcus sp. BV3L6), a Neisseria (e.g., an N. meningitidis), a Cryptococcus, a Corynebacterium, a Haemophilus, a Eubacterium, a Pasteurella, a Prevotella, a Veillonella, or a Marinobacter.Page 83 of 28713508126v1Attorney Docket No.: 2017469-0062

[0156] In some embodiments, a gene modifying polypeptide may comprise the amino acid sequence of SEQ ID NO: 4000 below, or a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity thereto. In some embodiments, the amino acid sequence of SEQ ID NO: 4000 below, or the sequence having at least 70%, at least 75%, at least 80%. at least 85%, at least 90%, at least 95%, at least 96%, at least 97%. at least 98%, or at least 99% identity thereto, is positioned at the N-terminal end of a gene modifying polypeptide. In some embodiments, the amino acid sequence of SEQ ID NO: 4000 below, or a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto, is positioned within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, or 30 amino acids of the N-terminal end of the gene modifying polypeptide.Exemplary N-terminal NLS-Cas9 domainMPAAKRVKLDGGDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSI KKNLIGALLFDSGETAEATRLKRTARRRYTRRKNR1CYLQEIFSNEMAKVDDSFF HRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLI YLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAK AILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQ LSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSAS MIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYK FIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFY PFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKG ASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAF LSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTY HDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQ LKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFK EDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENI VIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLY YLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKARGKSD NVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQL VETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVR EINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIG KATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRK VLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTV AYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDL IIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSP EDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQ AENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDL SQLGGDGG (SEQ ID NO: 4000)

[0157] In some embodiments, a gene modifying polypeptide may comprise the amino acid sequence of SEQ ID NO: 434 below7, or a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto. In some embodiments, the amino acid sequence of SEQ ID NO: 434 below7, or the sequence having at least 70%, at least 75%, at least 80%. at least 85%, at least 90%, at least 95%, at least 96%, at least 97%. at leastPage 84 of 28713508126v1Attorney Docket No.: 2017469-006298%, or at least 99% identity thereto, is positioned at the C-terminal end of a gene modifying polypeptide.In some embodiments, the amino acid sequence of SEQ ID NO: 434 below, or a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto, is positioned within 1, 2, 3, 4, 5, 6,Exemplary C-terminal sequence comprising an NLSAGKRTADGSEFEKRTADGSEFESPKKKAKVE (SEQ ID NO: 4001)Exemplary SequenceMPAAKRVKLDGGDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSI KKNLIGALLFDSGETAEATRLKRTARRRYTRRKNR1CYLQEIFSNEMAKVDDSFF HRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLI YLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAK AILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQ LSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSAS MIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYK FIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFY PFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKG ASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAF LSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTY HDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQ LKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFK EDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENI VIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLY YLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKARGKSD NVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQL VETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVR EINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIG KATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRK VLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTV AYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDL IIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSP EDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQ AENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDL SQLGGDGGSGGSSGGSSGSETPGTSESATPESSGGSSGGSSGGTLNIEDEYRLHET SKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLKATSTPVSIKQYPMSQ EARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVE DIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPEMG ISGQLTWTRLPQGFKNSPTLFNEALHRDLADFRIQHPDLILLQYVDDLLLAATSEL DCQQGTRALLQTLGNLGYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKET VMGQPTPKTPRQLREFLGKAGFCRLFIPGFAEMAAPLYPLTKPGTLFNWGPDQQ KAYQEIKQALLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYL SKKLDPVAAGWPPCLRMVAA1AVLTKDAGKLTMGQPLV1LAPHAVEALVKQPP DRWLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCLDILAEA HGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTTETEVIWAKALPAG TSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIHGEIYRRRGWLTSEGK EIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNRMADQAARKAAITET PDTSTLLIENSSPSGGSKRTADGSEFEAGKRTADGSEFEKRTADGSEFESPKKKAK VE (SEQ ID NO: 4002)Page 85 of 28713508126v1Attorney Docket No.: 2017469-0062

[0158] In some embodiments, a gene modifying polypeptide may comprise a Cas domain as listed in TABLE 3 or TABLE 4, or a functional fragment thereof, or a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%. 99% identity thereto.TABLE 3: CRISPR / Cas Proteins, Species and MutationsTABLE 4: Amino Acid Sequences of StlCas9 Proteins, Species, and MutationsPage 86 of 28713508126v1Attorney Docket No.: 2017469-0062Page 87 of 28713508126v1Attorney Docket No.: 2017469-0062Page 88 of 28713508126v1Attorney Docket No.: 2017469-0062Page 89 of 28713508126v1Attorney Docket No.: 2017469-0062

[0159] In some embodiments, a Cas protein requires a protospacer adjacent motif (PAM) to be present in or adjacent to a target DNA sequence for the Cas protein to bind and / or function. In some embodiments, the PAM is or comprises, from 5' to 3', NGG, YG, NNGRRT (SEQ ID NO: 451), NNNRRT (SEQ ID NO: 452), NGA, TYCV, TATV, NTTN, or NNNGATT (SEQ ID NO: 453), where N stands for any nucleotide, Y stands for C or T, R stands for A or G, and V stands for A or C or G. In some embodiments, a Cas protein is a protein listed in TABLE 3 or TABLE 4. In some embodiments, a Cas protein comprises one or more mutations altering its PAM. In some embodiments, a Cas protein comprises E1369R, E1449H, and R1556A mutations or analogous substitutions to the amino acids corresponding to said positions. In some embodiments, a Cas protein comprises E782K, N968K, and R1015H mutations or analogous substitutions to the amino acids corresponding to said positions. In some embodiments, a Cas protein comprises DI 135V, R1335Q, and T1337R mutations or analogous substitutions to the amino acids corresponding to said positions. In some embodiments, a Cas protein comprises S542R and K607R mutations or analogous substitutions to the amino acids corresponding to said positions. In some embodiments, a Cas protein comprises S542R, K548V, and N552R mutations or analogous substitutions to the amino acids corresponding to said positions. Exemplary advances in the engineering of Cas enzymes to recognize altered PAM sequences are reviewed in Collias et al Nature Communications 12:555 (2021), incorporated herein by reference in its entirety.

[0160] In some embodiments, a Cas protein is catalytically active and cuts one or both strands of the target DNA site. In some embodiments, cutting the target DNA site is followed by formation of an alteration, e.g., an insertion or deletion, e.g., by the cellular repair machinery.Page 90 of 28713508126v1Attorney Docket No.: 2017469-0062

[0161] In some embodiments, a Cas protein is modified to deactivate or partially deactivate the nuclease, e.g., nuclease-deficient Cas9. Whereas wild-type Cas9 generates double-strand breaks (DSBs) at specific DNA sequences targeted by a gRNA, a number of CRISPR endonucleases having modified functionalities are available, for example: a “nickase’’ version of Cas9 that has been partially deactivated generates only a single-strand break; a catalytically inactive Cas9 (“dCas9”) does not cut target DNA. In some embodiments, dCas9 binding to a DNA sequence may interfere with transcription at that site by steric hindrance. In some embodiments, dCas9 binding to an anchor sequence may interfere with (e.g., decrease or prevent) genomic complex (e.g., ASMC) formation and / or maintenance. In some embodiments, a DNA-binding domain comprises a catalytically inactive Cas9, e.g., dCas9. Many catalytically inactive Cas9 proteins are known in the art. In some embodiments, dCas9 comprises mutations in each endonuclease domain of tire Cas protein, e.g., D10A and H840A or N863A mutations. In some embodiments, a catalytically inactive or partially inactive CRISPR / Cas domain comprises a Cas protein comprising one or more mutations, e.g., one or more of the mutations listed in TABLE 3. In some embodiments, a Cas protein described on a given row of TABLE 3 comprises one, two, three, or all of the mutations listed in the same row of TABLE 3. In some embodiments, a Cas protein, e.g., not described in TABLE 3, comprises one, two. three, or all of the mutations listed in a row of TABLE 3 or a corresponding mutation at a corresponding site in that Cas protein.

[0162] In some embodiments, a catalytically inactive, e.g., dCas9, or partially deactivated Cas9 protein comprises a DI 1 mutation (e.g., DI 1A mutation) or an analogous substitution to the amino acid corresponding to said position. In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, or partially deactivated Cas9 protein comprises a H969 mutation (e.g., H969A mutation) or an analogous substitution to the amino acid corresponding to said position. In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, or partially deactivated Cas9 protein comprises a N995 mutation (e.g., N995A mutation) or an analogous substitution to the amino acid corresponding to said position. In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, comprises mutations at one, two, or three of positions Dll, H969, and N995 (e.g., DI 1A, H969A, and N995A mutations) or analogous substitutions to the amino acids corresponding to said positions.

[0163] In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, or partially deactivated Cas9 protein comprises a DIO mutation (e.g., a D10A mutation) or an analogous substitution to the amino acid corresponding to said position. In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, or partially deactivated Cas9 protein comprises a H557 mutation (e.g., a H557A mutation) or an analogous substitution to the amino acid corresponding to said position. In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, comprises a DIO mutation (e.g., a D10A mutation) and aPage 91 of 28713508126v1Attorney Docket No.: 2017469-0062H557 mutation (e.g., a H557A mutation) or analogous substitutions to the amino acids corresponding to said positions.

[0164] In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, or partially deactivated Cas9 protein comprises a D839 mutation (e.g., a D839A mutation) or an analogous substitution to the amino acid corresponding to said position. In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, or partially deactivated Cas9 protein comprises aH840 mutation (e.g., aH840A mutation) or an analogous substitution to the amino acid corresponding to said position. In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, or partially deactivated Cas9 protein comprises aN863 mutation (e.g., aN863A mutation) or an analogous substitution to the amino acid corresponding to said position. In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, comprises a DIO mutation (e.g.. D10A), a D839 mutation (e.g., D839A), a H840 mutation (e.g., H840A). and a N863 mutation (e.g., N863A) or analogous substitutions to the amino acids corresponding to said positions.

[0165] In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, or partially deactivated Cas9 protein comprises a E993 mutation (e.g., a E993A mutation) or an analogous substitution to the amino acid corresponding to said position.

[0166] In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, or partially deactivated Cas9 protein comprises a D917 mutation (e.g., a D917A mutation) or an analogous substitution to the amino acid corresponding to said position. In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, or partially deactivated Cas9 protein comprises an E1006 mutation (e.g., a E1006A mutation) or an analogous substitution to the amino acid corresponding to said position. In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, or partially deactivated Cas9 protein comprises a D 1255 mutation (e.g.. a D1255A mutation) or an analogous substitution to the amino acid corresponding to said position. In some embodiments, a catalytically inactive Cas9 protein, e g., dCas9, comprises a D917 mutation (e.g., D917A), a E1006 mutation (e.g., E1006A), and a D1255 mutation (e.g., D1255A) or analogous substitutions to the amino acids corresponding to said positions.

[0167] In some embodiments, a catalytically inactive Cas9 protein, e g., dCas9, or partially deactivated Cas9 protein comprises a D16 mutation (e.g., a D16A mutation) or an analogous substitution to the amino acid corresponding to said position. In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, or partially deactivated Cas9 protein comprises a D587 mutation (e.g., a D587A mutation) or an analogous substitution to the amino acid corresponding to said position. In some embodiments, a partially deactivated Cas domain has nickase activity. In some embodiments, a partially deactivated Cas9 domain is a Cas9 nickase domain. In some embodiments, a catalytically inactive Cas domain or dead Cas domain produces no detectable double strand break formation. In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, or partially deactivated Cas9 protein comprises a H588 mutation (e.g., a H588APage 92 of 28713508126v1Attorney Docket No.: 2017469-0062mutation) or an analogous substitution to the amino acid corresponding to said position. In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, or partially deactivated Cas9 protein comprises a N611 mutation (e.g., a N611A mutation) or an analogous substitution to the amino acid corresponding to said position. In some embodiments, a catalytically inactive Cas9 protein, e.g., dCas9, comprises a D16 mutation (e.g., D16A), a D587 mutation (e.g., D587A), a H588 mutation (e.g., H588A), and a N611 mutation (e.g., N611A) or analogous substitutions to the amino acids corresponding to said positions.

[0168] In some embodiments, a DNA-binding domain or endonuclease domain may comprise a Cas molecule comprising or linked (e.g., covalently) to a gRNA (e.g., a template nucleic acid, e.g., template RNA, comprising a gRNA).

[0169] In some embodiments, an endonuclease domain or DNA binding domain comprises a Streptococcus pyogenes Cas9 (SpCas9) or a functional fragment or variant thereof. In some embodiments, the endonuclease domain or DNA binding domain comprises a modified SpCas9. In some embodiments, a modified SpCas9 comprises a modification that alters protospacer-adjacent motif (PAM) specificity. In some embodiments, the PAM has specificity for the nucleic acid sequence 5'-NGT-3'. In some embodiments, a modified SpCas9 comprises one or more amino acid substitutions, e.g., at one or more of positions LI 111, DI 135, G1218, E1219, A1322, ofR1335, e.g.. selected from LI I HR, DI 135V.G1218R, E1219F, A1322R, R1335V. In some embodiments, a modified SpCas9 comprises the amino acid substitution T1337R and one or more additional amino acid substitutions, e.g., selected from Lilli, DI 135L, SI 136R, G1218S, E1219V, D1332A, D1332S, D1332T, D1332V, D1332L, D1332K, D1332R, R1335Q, T1337, T1337L, T1337Q, T1337I. T1337V, T1337F, T1337S, T1337N, T1337K, T1337H, T1337Q, and T1337M, or corresponding amino acid substitutions thereto. In some embodiments, a modified SpCas9 comprises: (i) one ormore amino acid substitutions selected from D1135L, S1136R, G1218S, E1219V, A1322R, R1335Q, and T1337; and (ii) one ormore amino acid substitutions selected from Lil 11R, G1218R, E1219F, D1332A, D1332S, D1332T, D1332V, D1332L, D1332K, D1332R, T1337L, T1337I, T1337V, T1337F, T1337S, T1337N, T1337K, T1337R, T1337H, T1337Q, and T1337M, or corresponding amino acid substitutions thereto.

[0170] In some embodiments, an endonuclease domain or DNA binding domain comprises a Cas domain, e.g., a Cas9 domain. In some embodiments, an endonuclease domain or DNA binding domain comprises a nuclease-active Cas domain, a Cas nickase (nCas) domain, or a nuclease -inactive Cas (dCas) domain. In some embodiments, an endonuclease domain or DNA binding domain comprises a nucleaseactive Cas9 domain, a Cas9 nickase (nCas9) domain, or a nuclease-inactive Cas9 (dCas9) domain. In some embodiments, an endonuclease domain or DNA binding domain comprises a Cas9 domain of Cas9 (e.g., dCas9 and nCas9), Casl2a / Cpfl, Casl2b / C2cl, Casl2c / C2c3, Casl2d / CasY, Casl2e / CasX, Casl2g,Page 93 of 28713508126v1Attorney Docket No.: 2017469-0062Casl2h, or Casl2i. In some embodiments, an endonuclease domain or DNA binding domain comprises a Cas9 (e.g., dCas9 and nCas9), Casl2a / Cpfl, Casl2b / C2cl, Casl2c / C2c3, Casl2d / CasY, Casl2e / CasX, Casl2g, Casl2h, or Casl2i. In some embodiments, an endonuclease domain or DNA binding domain comprises an S. pyogenes or an S. thermophilus Cas9, or a functional fragment thereof. In some embodiments, an endonuclease domain or DNA binding domain comprises a Cas9 sequence, e.g., as described in Chylinski, Rhun, and Charpentier (2013) RNA Biology 10:5. 726-737; incorporated herein by reference. In some embodiments, an endonuclease domain or DNA binding domain comprises the HNH nuclease subdomain and / or the RuvCl subdomain of a Cas, e.g., Cas9, e.g., as described herein, or a variant thereof. In some embodiments, an endonuclease domain or DNA binding domain comprises Casl2a / Cpfl, Casl2b / C2cl, Casl2c / C2c3, Casl2d / CasY, Casl2e / CasX, Casl2g, Casl2h, or Casl2i. In some embodiments, an endonuclease domain or DNA binding domain comprises a Cas polypeptide (e.g., enzyme), or a functional fragment thereof. In some embodiments, a Cas polypeptide (e.g., enzyme) is selected from Casl, Cas IB, Cas2, Cas3, Cas4, Cas5, Cas5d, Cas5t, Cas5h, Cas5a, Cas6, Cas7, Cas8, Cas8a, Cas8b, Cas8c, Cas9 (e.g., Csnl or Csxl2), CaslO, CaslOd, Casl2a / Cpfl, Casl2b / C2cl, Casl2c / C2c3, Casl2d / CasY, Casl2e / CasX, Casl2g, Casl2h, Casl2i, Csyl, Csy2, Csy3, Csy4, Csel, Cse2, Cse3, Cse4, Cse5e, Cscl, Csc2, Csa5, Csnl, Csn2, Csml, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Csbl, Csb2, Csb3, Csxl7, Csxl4, CsxlO. Csxl6, CsaX, Csx3, Csxl, CsxlS, Csxll, Csfl, Csf2, CsO, Csf4, Csdl, Csd2, Cstl, Cst2, Cshl, Csh2, Csal, Csa2. Csa3, Csa4, Csa5, Type II Cas effector proteins, Type V Cas effector proteins, Type VI Cas effector proteins, CARF, DinG, Cpfl, Casl2b / C2cl, Casl2c / C2c3, Casl2b / C2cl, Casl2c / C2c3, SpCas9(K855A), eSpCas9(l. I), SpCas9-HFl, hyper accurate Cas9 variant (HypaCas9), homologues thereof, modified or engineered versions thereof, and / or functional fragments thereof. In some embodiments, a Cas9 comprises one or more substitutions, e.g., selected from H840A, D10A, P475A. W476A, N477A. DI 125A. W1126A, and DI 127A. In some embodiments, a Cas9 comprises one or more mutations at positions selected from: DIO, G12, G17, E762, H840, N854, N863, H982, H983, A984, D986, and / or A987, e.g., one or more substitutions selected from D10A, G12A, G17A, E762A, H840A, N854A, N863A, H982A, H983A, A984A, and / or D986A. In some embodiments, an endonuclease domain or DNA binding domain comprises a Cas (e.g., Cas9) sequence from Corynebacterium ulcerans, Corynebacterium diphtheria, Spiroplasma syrphidicola, Prevotella intennedia, Spiroplasma taiwanense. Streptococcus iniae, Belliella baltica, Psychroflexus torquis. Streptococcus thermophilus, Listeria innocua, Campylobacter jejuni. Neisseria meningitidis. Streptococcus pyogenes, or Staphylococcus aureus, or a fragment or variant thereof.

[0171] In some embodiments, an endonuclease domain or DNA binding domain comprises a Cpfl domain, e.g., comprising one or more substitutions, e.g.. at position D917. E1006A, D1255 or anyPage 94 of 28713508126v1Attorney Docket No.: 2017469-0062combination thereof, e.g., selected from D917A, E1006A, D1255A, D917A / E1006A, D917A / D1255A,E1006A / D1255A, and D917A / E1006A / D1255A.

[0172] In some embodiments, an endonuclease domain or DNA binding domain comprises spCas9, spCas9-VRQR (SEQ ID NO: 5019). spCas9- VRER (SEQ ID NO: 5020), xCas9 (sp), saCas9, saCas9-KKH, spCas9-MQKSER (SEQ ID NO: 5021), spCas9-LRKIQK (SEQ ID NO: 5022). or spCas9-LRVSQL (SEQ ID NO: 5023).

[0173] In some embodiments, a gene modifying polypeptide has an endonuclease domain comprising a Cas9 nickase, e.g., Cas9 H840A. In some embodiments, the Cas9 H840A has the following amino acid sequence:Cas9 nickase (H840A):DKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSG ETAEATRLKRTARRRYTRRKNR1CYLQEIFSNEMAKVDDSFFHRLEESFLVEEDK KHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRG HFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRL ENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDN LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLT LLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEE LLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILT FRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDK NLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFK TNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDN EENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSR KLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDS LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKG QKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQE LDINRLSDYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKN YWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILD SRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLN AVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMN FFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEV QTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKS KKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRK RMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKH YLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAP AAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD (SEQ ID NO: 11001)

[0174] In some embodiments, a gene modifying polypeptide comprises a dCas9 sequence comprising aD10A and / or H840A mutation, e.g., the following sequence:SMDKKYSIGLAIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHSIKKNLIGALLFD SGETAEATRLKRTARRRYTRRKNR1CYLQEIFSNEMAKVDDSFFHRLEESFLVEE DKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKF RGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSR RLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDL DNLEAQIGDQYADLFLAAKNLSDAILESD1LRVNTEITKAPLSASMIKRYDEHHQPage 95 of 28713508126v1Attorney Docket No.: 2017469-0062DLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDG TEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIE KILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMT NFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVD LLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDF LDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWG RLSRKLINGIRDKQSGKHLDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQ GDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQ KGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVD QELDINRLSDYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKM KNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQ ILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDA YLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSN IMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKK TEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEK GKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELEN GRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQ HKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNL GAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD (SEQ ID NO: 5007)(v) TAL Effectors and Zinc Finger Nucleases

[0175] In some embodiments, an endonuclease domain or DNA-binding domain comprises a TAL effector molecule. A TAL effector molecule, e.g., a TAL effector molecule that specifically binds a DNA sequence, typically comprises a plurality of TAL effector domains or fragments thereof, and optionally one or more additional portions of naturally occurring TAL effectors (e.g., N- and / or C-terminal of the plurality of TAL effector domains). Many TAL effectors are known to those of skill in the art and are commercially available, e.g., from Thermo Fisher Scientific.

[0176] Naturally occurring TALEs are natural effector proteins secreted by numerous species of bacterial pathogens including the plant pathogen Xanthomonas which modulates gene expression in host plants and facilitates bacterial colonization and survival. The specific binding of TAL effectors is based on a central repeat domain of tandemly arranged nearly identical repeats of typically 33 or 34 amino acids (the repeatvariable di-rcsiducs, RVD domain).

[0177] Members of the TAL effectors family differ mainly in the number and order of their repeats. The number of repeats typically ranges from 1.5 to 33.5 repeats and the C-terminal repeat is usually shorter in length (e.g., about 20 amino acids) and is generally referred to as a ‘’half-repeat.” Each repeat of the TAL effector generally features a one-repeat-to-one-base-pair correlation with different repeat types exhibiting different base-pair specificity (one repeat recognizes one base-pair on the target gene sequence).Generally, the smaller the number of repeats, the weaker the protein-DNA interactions. A number of 6.5 repeats has been shown to be sufficient to activate transcription of a reporter gene (Scholze et al., 2010).Page 96 of 28713508126v1Attorney Docket No.: 2017469-0062

[0178] Repeat to repeat variations occur predominantly at amino acid positions 12 and 13, which have therefore been termed “hypervariable” and which are responsible for the specificity of the interaction with the target DNA promoter sequence, as shown in TABLE 5 listing exemplary repeat variable dircsiducs (RVD) and their correspondence to nucleic acid base targets.TABLE 5: RVDs and Nucleic Acid Base Specificity

[0179] Accordingly, it is possible to modify the repeats of a TAL effector to target specific DNA sequences. Further studies have shown that the RVD NK can target G. Target sites of TAL effectors also tend to include a T flanking the 5' base targeted by the first repeat, but the exact mechanism of this recognition is not known. More than 113 TAL effector sequences are known to date. Non-limiting examples of TAL effectors from Xanthomonas include, Hax2, Hax3, Hax4, AvrXa7, AvrXalO and AvrBs3.

[0180] Accordingly, the TAL effector domain of a TAL effector molecule described herein may be derived from a TAL effector from any bacterial species (e.g., Xanthomonas species such as the African strain of Xanthomonas oryzae pv. Oryzae (Yu et al. 2011), Xanthomonas campestris pv. raphani strain 756C and Xanthomonas oryzae pv. Oryzicola strain BLS256 (Bogdanove et al. 2011). In some embodiments, the TAL effector domain comprises an RVD domain as well as flanking sequence(s) (sequences on the N -terminal and / or C-terminal side of the RVD domain) also from the naturally occurring TAL effector. It may comprise more or fewer repeats than the RVD of the naturally occurring TAL effector. The TAL effector molecule can be designed to target a given DNA sequence based on the above code and others known in the art. The number of TAL effector domains (e.g., repeats (monomers or modules)) and their specific sequence can be selected based on the desired DNA target sequence. For example, TAL effector domains, e.g., repeats, may be removed or added in order to suit a specific target sequence. In an embodiment, the TAL effector molecule of the present disclosure comprises between 6.5 and 33.5 TAL effector domains, e.g., repeats. In an embodiment, TAL effector molecule of the present disclosure comprises between 8 and 33.5 TAL effector domains, e.g., repeats, e.g., between 10 and 25 TAL effector domains, e.g., repeats, e.g., between 10 and 14 TAL effector domains, e.g., repeats.Page 97 of 28713508126v1Attorney Docket No.: 2017469-0062

[0181] In some embodiments, a TAL effector molecule comprises TAL effector domains that correspond to a perfect match to the DNA target sequence. In some embodiments, a mismatch between a repeat and a target base-pair on the DNA target sequence is permitted as along as it allows for the function of the polypeptide comprising the TAL effector molecule. In general, TALE binding is inversely correlated with the number of mismatches. In some embodiments, a TAL effector molecule of a polypeptide of the present disclosure comprises no more than 7 mismatches, no more than 6 mismatches, no more than 5 mismatches, no more than 4 mismatches, no more than 3 mismatches, no more than 2 mismatches, or no more than 1 mismatch, and optionally no mismatch, with a target DNA sequence. Without wishing to be bound by theory, in general the smaller the number of TAL effector domains in a TAL effector molecule, the smaller the number of mismatches w ill be tolerated and still allow for the function of the polypeptide comprising the TAL effector molecule. Tire binding affinity is thought to depend on the sum of matching repeat-DNA combinations. For example, TAL effector molecules having 25 TAL effector domains or more may be able to tolerate up to 7 mismatches.

[0182] In addition to TAL effector domains, a TAL effector molecule of the present disclosure may comprise additional sequences derived from a naturally occurring TAL effector. The length of the C-terminal and / or N-terminal sequence(s) included on each side of a TAL effector domain portion of a TAL effector molecule can van- and be selected by one skilled in the art, for example based on the studies of Zhang et al. (2011). Zhang et al., have characterized a number of C-terminal and N-terminal truncation mutants in Hax3 derived TAL-effector based proteins and have identified key elements, which contribute to optimal binding to the target sequence and thus activation of transcription. Generally, it was found that transcriptional activity is inversely correlated with the length of N-terminus. Regarding the C-temiinus, an important element for DNA binding residues within the first 68 amino acids of the Hax 3 sequence was identified. Accordingly, in some embodiments, the first 68 amino acids on the C-terminal side of a TAL effector domains of the naturally occurring TAL effector is included in a TAL effector molecule. In some embodiments, a TAL effector molecule comprises 1) one or more TAL effector domains derived from a naturally occurring TAL effector; 2) at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, at least 170, at least 180. at least 190, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260, at least 270. at least 280 or more amino acids from a naturally occurring TAL effector on the N-terminal side of tire TAL effector domains: and / or 3) at least 68, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260 or more amino acids from a naturally occurring TAL effector on the C-terminal side of the TAL effector domains. In some embodiments, an endonuclease domain or DNA-binding domain is or comprises a Zn finger molecule. A Zn finger molecule comprises aPage 98 of 28713508126v1Attorney Docket No.: 2017469-0062Zn finger protein, e.g., a naturally occurring Zn finger protein or engineered Zn finger protein, or fragment thereof. Many Zn finger proteins are known to those of skill in the art and are commercially available, e.g., from Sigma-Aldrich.

[0183] In some embodiments, a Zn finger molecule comprises a non-naturally occurring Zn finger protein that is engineered to bind to a target DNA sequence of choice. See, for example, Beerli. et al. (2002) Nature Biotechnol. 20: 135-141; Pabo, et al. (2001) Ann. Rev. Biochem. 70:313-340; Isalan, et al. (2001) Nature Biotechnol. 19:656-660; Segal, et al. (2001) Curr. Opin. Biotechnol. 12:632-637; Choo, et al. (2000) Curr. Opin. Struct. Biol. 10:411-416; U. S. Pat. Nos. 6,453,242; 6,534,261; 6,599,692;6,503,717; 6,689,558; 7,030,215; 6,794,136; 7,067,317; 7,262,054; 7,070,934; 7,361,635; 7,253,273; and U. S. Patent Publication Nos. 2005 / 0064474; 2007 / 0218528; 2005 / 0267061, all incorporated herein by reference in their entireties.

[0184] An engineered Zn finger protein may have a novel binding specificity, compared to a naturally-occurring Zn finger protein. Engineering methods include, but are not limited to, rational design and various types of selection. Rational design includes, for example, using databases comprising triplet (or quadruplet) nucleotide sequences and individual Zn finger amino acid sequences, in which each triplet or quadruplet nucleotide sequence is associated with one or more amino acid sequences of zinc fingers which bind the particular triplet or quadruplet sequence. See, for example, U. S. Pat. Nos. 6.453,242 and 6,534,261, incorporated by reference herein in their entireties.

[0185] Exemplary selection methods, including phage display and two-hybrid systems, are disclosed in U. S. Pat. Nos. 5,789,538; 5,925,523; 6,007,988; 6,013,453; 6,410,248; 6,140,466; 6,200,759; and 6,242,568; as well as International Patent Publication Nos. WO 98 / 37186; WO 98 / 53057; WO 00 / 27878; and WO 01 / 88197 and GB 2,338,237. In addition, enhancement of binding specificity for zinc finger proteins has been described, for example, in International Patent Publication No. WO 02 / 077227.

[0186] In addition, as disclosed in these and other references, zinc finger domains and / or multi-fingered zinc finger proteins may be linked together using any suitable linker sequences, including for example, linkers of 5 or more amino acids in length. See, also, U. S. Pat. Nos. 6,479,626; 6,903,185: and 7,153,949 for exemplary linker sequences 6 or more amino acids in length. The proteins described herein may include any combination of suitable linkers between the individual zinc fingers of the protein. In addition, enhancement of binding specificity for zinc finger binding domains has been described, for example, in co-owned International Patent Publication No. WO 02 / 077227.

[0187] Zn finger proteins and methods for design and construction of fusion proteins (and polynucleotides encoding same) are known to those of skill in the art and described in detail in U. S. Pat. Nos. 6,140,0815; 789,538; 6,453,242; 6,534,261; 5,925,523; 6,007,988; 6,013,453; and 6,200,759;International Patent Publication Nos. WO 95 / 19431; WO 96 / 06166; WO 98 / 53057; WO 98 / 54311; WO Page 99 of 28713508126v1Attorney Docket No.: 2017469-006200 / 27878; WO 01 / 60970; WO 01 / 88197; WO 02 / 099084; WO 98 / 53058; WO 98 / 53059; WO 98 / 53060; WO 02 / 016536; and WO 03 / 016496.

[0188] In addition, as disclosed in these and other references, Zn finger proteins and / or multi-fingered Zn finger proteins may be linked together, e.g., as a fusion protein, using any suitable linker sequences, including for example, linkers of 5 or more amino acids in length. See, also, U. S. Pat. Nos. 6.479,626; 6,903,185; and 7,153,949 for exemplary linker sequences 6 or more amino acids in length. The Zn finger molecules described herein may include any combination of suitable linkers between the individual zinc finger proteins and / or multi-fingered Zn finger proteins of the Zn finger molecule.

[0189] In some embodiments, a DNA-binding domain or endonuclease domain comprises a Zn finger molecule comprising an engineered zinc finger protein that binds (in a sequence-specific manner) to a target DNA sequence. In some embodiments, a Zn finger molecule comprises one Zn finger protein or fragment thereof. In other embodiments, a Zn finger molecule comprises a plurality of Zn finger proteins (or fragments thereof), e.g., 2, 3, 4, 5, 6 or more Zn finger proteins (and optionally no more than 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2 Zn finger proteins). In some embodiments, a Zn finger molecule comprises at least three Zn finger proteins. In some embodiments, a Zn finger molecule comprises four, five or six fingers. In some embodiments, aZn finger molecule comprises 8. 9, 10, 11 or 12 fingers. In some embodiments, a Zn finger molecule comprising three Zn finger proteins recognizes a target DNA sequence comprising 9 or 10 nucleotides. In some embodiments, a Zn finger molecule comprising four Zn finger proteins recognizes a target DNA sequence comprising 12 to 14 nucleotides. In some embodiments, a Zn finger molecule comprising six Zn finger proteins recognizes a target DNA sequence comprising 18 to 21 nucleotides.

[0190] In some embodiments, a Zn finger molecule comprises a two-handed Zn finger protein. Two handed zinc finger proteins are those proteins in which two clusters of zinc finger proteins are separated by intervening amino acids so that the two zinc finger domains bind to two discontinuous target DNA sequences. An example of a two handed type of zinc finger binding protein is SIP1, where a cluster of four zinc finger proteins is located at the amino terminus of the protein and a cluster of three Zn finger proteins is located at the carboxyl terminus (see Remade, et al. (1999) EMBO Journal 18( 18): 5073-5084). Each cluster of zinc fingers in these proteins is able to bind to a unique target sequence and the spacing between the two target sequences can comprise many nucleotides.(vi) Linkers

[0191] In some embodiments, a gene modifying polypeptide may comprise a linker, e.g., a peptide linker, e.g., a linker as described in TABLE 6. In some embodiments, a gene modifying polypeptide comprises, in an N-terminal to C-terminal direction, a Cas domain (e.g., a Cas domain of TABLE 3 or Page 100 of 28713508126v1Attorney Docket No.: 2017469-0062TABLE 4), a linker of TABLE 6 (or a sequence having at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto), and an RT domain (e.g., an RT domain of TABLE 1). In some embodiments, a gene modifying polypeptide comprises a flexible linker between the endonuclease and the RT domain, e.g., a linker comprising the amino acid sequence SGGSSGGSSGSETPGTSESATPESSGGSSGGSS (SEQ ID NO: 456). In some embodiments, an RT domain of a gene modifying polypeptide may be located C-terminal to an endonuclease domain. In some embodiments, an RT domain of a gene modifying polypeptide may be located N-terminal to an endonuclease domain.TABLE 6: Exemplary linker sequencesPage 101 of 28713508126v1Attorney Docket No.: 2017469-0062Page 102 of 28713508126v1Attorney Docket No.: 2017469-0062Page 103 of 28713508126v1Attorney Docket No.: 2017469-0062

[0192] In some embodiments, a linker of a gene modifying polypeptide comprises a motif chosen from:(SGGS)n, (GGGS)n, (GGGGS)n, (G)n(EAAAK)n, (GGS)„, or (XP)n(vii) Gene modifying polypeptide selection by pooled screening

[0193] Candidate gene modifying polypeptides may be screened to evaluate a candidate’s gene editing ability. For example, an RNA gene modifying system designed for the targeted editing of a coding sequence in the human genome may be used. In some embodiments, such a gene modifying system may be used in conjunction with a pooled screening approach.

[0194] For example, a library of gene modifying polypeptide candidates and a template guide RNA (tgRNA) may be introduced into mammalian cells to test a candidate's gene editing abilities by a pooled screening approach. In some embodiments, a library of gene modifying polypeptide candidates is introduced into mammalian cells followed by introduction of a tgRNA into the cells.

[0195] Representative, non-limiting examples of mammalian cells that may be used in screening include HEK293T cells, U2OS cells, HeLa cells, HepG2 cells, Huh7 cells, K562 cells, or iPS cells.Page 104 of 28713508126v1Attorney Docket No.: 2017469-0062

[0196] A gene modifying polypeptide candidate may comprise 1) a Cas-nuclease, for example a wildtype Cas nuclease, e.g., a wild-type Cas9 nuclease, a mutant Cas nuclease, e.g., a Cas nickase, for example, a Cas9 nickase such as a Cas9 N863A nickase, or a Cas nuclease selected from TABLE 3 or TABLE 4, 2) a peptide linker, e.g., a sequence from TABLE 6, that may exhibit varying degrees of length, flexibility, hydrophobicity, and / or secondary structure: and 3) a reverse transcriptase (RT), e.g. an RT domain from Table D ofW02023 / 039440 (herein incorporated by reference in its entirety) or TABLE 1. A gene modifying polypeptide candidate library comprises: a plurality of different gene modifying polypeptide candidates that differ from each other with respect to one, two or all three of the Cas nuclease, peptide linker or RT domain components, or a plurality of nucleic acid expression vectors that encode such gene modifying polypeptide candidates.

[0197] For screening of gene modifying polypeptide candidates, a two-component system may be used that comprises a gene modifying polypeptide component and a tgRNA component. A gene modifying component may comprise, for example, an expression vector, e.g., an expression plasmid or lentiviral vector, that encodes a gene modifying polypeptide candidate, for example, comprises a human codon-optimized nucleic acid that encodes a gene modifying polypeptide candidate, e.g., a Cas-linker-RT fusion as described above. In some embodiments, a lentiviral cassette is utilized that comprises: (i) a promoter for expression in mammalian cells, e.g., a CMV promoter; (ii) a gene modifying library candidate, e.g. a Cas-linker-RT fusion comprising a Cas nuclease of TABLE 3 or TABLE 4, a peptide linker of TABLE 6, and an RT of TABLE 1, for example a Cas-linker-RT fusion as in Table D of W02023 / 039440 (herein incorporated by reference in its entirety); (iii) a self-cleaving polypeptide, e.g., a T2A peptide; (iv) a marker enabling selection in mammalian cells, e.g., a puromycin resistance gene; and (v) a termination signal, e.g., a poly A tail.

[0198] A tgRNA component may comprise atgRNA or expression vector, e.g., an expression plasmid, that produces a tgRNA, for example, utilizes a U6 promoter to drive expression of a tgRNA, wherein the tgRNA is a non-coding RNA sequence that is recognized by Cas and localizes it to a genomic locus of interest, and that also templates reverse transcription of tire desired edit into the genome by an RT domain.

[0199] To prepare a pool of cells expressing gene modifying polypeptide library candidates, mammalian cells, e.g., HEK293T or U2OS cells, may be transduced with pooled gene modifying polypeptide candidate expression vector preparations, e.g., lentiviral preparations, of the gene modifying candidate polypeptide library’. In some embodiments, lentiviral plasmids are utilized, and HEK293 Lenti-X cells are seeded in 15 cm plates (~12 x 106cells) prior to lentiviral plasmid transfection. In some embodiments, lentiviral plasmid transfection may be performed using the Lentiviral Packaging Mix (Biosettia) and transfection of a plasmid DNA for a gene modifying candidate library is performed the following dayPage 105 of 28713508126v1Attorney Docket No.: 2017469-0062using Lipofectamine 2000 and Opti-MEM media according to the manufacturer’s protocol. In some embodiments, extracellular DNA may be removed by a full media change the next day and viruscontaining media may be harvested 48 hours after. Lentiviral media may be concentrated using Lenti-X Concentrator (TaKaRa Biosciences) and 5 mL lentiviral aliquots may be made and stored at -80°C. Lentiviral titering is performed by enumerating colony fonning units post-selection, e.g., post Puromycin selection.

[0200] For monitoring gene editing of a target DNA, mammalian cells, e.g., HEK293T or U2OS cells, carrying a target DNA may be utilized. In some embodiments, for monitoring gene editing of a target DNA, mammalian cells, e.g., HEK293T or U2OS cells, carry ing a target DNA genomic landing pad may be utilized. In some embodiments, a target DNA genomic landing pad may comprise a gene to be edited for treatment of a disease or disorder of interest. In some embodiments, a target DNA is a gene sequence that expresses a protein that exhibits detectable characteristics that may be monitored to determine whether gene editing has occurred. For example, in some embodiments, a blue fluorescence protein (BFP)- or green fluorescence protein (GFP)-expressing genomic landing pad is utilized. In some embodiments, mammalian cells, e.g., HEK293T or U2OS cells, comprising a target DNA, e.g., a target DNA genomic landing pad, are seeded in culture plates at 500x-3000x cells per gene modifying library candidate and transduced at a 0.2 - 0.3 multiplicity of infection (MOI) to minimize multiple infections per cell. Puromycin (2.5 ug / mL) may be added 48 hours post infection to allow for selection of infected cells. In som embodiments, cells may be kept under puromycin selection for at least 7 days and then scaled up fortgRNA introduction, e.g., tgRNA electroporation.

[0201] To ascertain whether gene editing occurs, mammalian cells containing a target DNA to be edited may be infected with gene modifying polypeptide library candidates then transfected with tgRNA designed for use in editing of the target DNA. Subsequently, cells may be analyzed to determine whether editing of the target locus has occurred according to the designed outcome, or w hether no editing or imperfect editing has occurred, e.g., by using cell sorting and sequence analysis.

[0202] In someembodiments, to ascertain whether genome editing occurs, BFP- or GFP -expressing mammalian cells, e.g.. HEK293T or U2OS cells, may be infected with gene modifying library candidates and then transfected or electroporated with tgRNA plasmid or RNA, e.g., by electroporation of 250,000 cells / well with 200 ng of a tgRNA plasmid designed to convert BFP-to-GFP or GFP-to-BFP, at a cell count ensuring >250x - lOOOx coverage per library candidate. In some embodiments, the genome -editing capacity of the various constructs in this assay may be assessed by sorting cells by Fluorescence-Activated Cell Sorting (FACS) for expression of the color-converted fluorescent protein (FP) at 4-10 days post-electroporation. Cells are sorted and harvested as distinct populations of unedited cells (exhibiting original florescence protein signal), edited cells (exhibiting converted fluorescence protein signal), andPage 106 of 28713508126v1Attorney Docket No.: 2017469-0062imperfect edit (exhibiting no florescence protein signal) cells. A sample of unsorted cells may also be harvested as the input population to determine candidate enrichment during analysis.

[0203] To determine which gene modifying library candidates exhibit genome-editing capacity in an assay, genomic DNA (gDNA) is harvested from the sorted cell populations, and analyzed by sequencing the gene modifying library candidates in each population. Briefly, gene modifying candidates may be amplified from the genome using primers specific to the gene modifying polypeptide expression vector, e.g., the lentiviral cassette, amplified in a second round of PCR to dilute genomic DNA, and then sequenced, for example, sequenced by a next-generation sequencing platform. After quality control of sequencing reads, reads of at least about 1500 nucleotides and generally no more than about 3200 nucleotides are mapped to a gene modifying polypeptide library sequences and those containing a minimum of about an 80% match to a library sequence are considered to be successfully aligned to a given candidate for purposes of this pooled screen. In order to identify candidates capable of performing gene editing in the assay, e.g., the BFP-to-GFP or GFP-to-BFP edit, a read count of each library candidate in an edited population is compared to its read count in an initial, unsorted population.

[0204] For purposes of pooled screening, gene modifying candidates with genome-editing capacity are identified based on enrichment in the edited (converted FP) population relative to unsorted (input) cells. In some embodiments, an enrichment of at least 1.0, at least 1.5. at least 2.0, at least 2.5, at least 3.0, at least 4.0, at least 5.0, at least 6.0, at least 7.0, at least 8.0, at least 9.0, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, or at least 100-fold over the input indicates potentially useful gene editing activity, e.g., at least 2-fold enrichment. In some embodiments, enrichment is converted to a log-value by taking the log base 2 of the enrichment ratio. In some embodiments, a log2 enrichment score of at least 0, at least 1, at least 2, at least 3, at least 4, at least 5, at least 5.5, at least 6.0, at least 6.2, at least 6.3, at least 6.4, at least 6.5, or at least 6.6 indicates potentially useful gene editing activity, e.g., a log2 enrichment score of at least 1.0. In particular embodiments, enrichment values observed for gene modifying candidates may be compared to enrichment values observed under similar conditions utilizing a reference, e g., Element ID No: 17380.

[0205] In some embodiments, multiple tgRNAs may be used to screen a gene modifying candidate library. In some embodiments, a plurality of tgRNAs may be utilized to optimize template / Cas-linker-RT fusion pairs, e g., for gene editing of particular target genes, for example, gene targets for the treatment of disease. In specific embodiments, a pooled approach to screening gene modifying candidates may be performed using a multiplicity of different tgRNAs in an arrayed fomrat.

[0206] In some embodiments, multiple types of edits, e.g., insertions, substitutions, and / or deletions of different lengths, may be used to screen the gene modifying candidate library.Page 107 of 28713508126v1Attorney Docket No.: 2017469-0062

[0207] In some embodiments, multiple target sequences, e.g., different fluorescent proteins, may be used to screen the gene modifying candidate library. In some embodiments, multiple target sequences, e.g., different fluorescent proteins, may be used to screen the gene modifying candidate library. In some embodiments, multiple cell types, e.g., HEK293T or U2OS, may be used to screen the gene modifying candidate library. A person of ordinary skill in tire art will appreciate that a given candidate may exhibit altered editing capacity or even the gain or loss of any observable or useful activity across different conditions, including tgRNA sequence (e.g., nucleotide modifications, PBS length, RT template length), target sequence, target location, type of edit, location of mutation relative to the first-strand nick of the gene modifying polypeptide, or cell type. Thus, in some embodiments, gene modifying library candidates are screened across multiple parameters, e.g., with at least two distinct tgRNAs in at least two cell types, and gene editing activity is identified by enrichment in any single condition. In some embodiments, a candidate with more robust activity across different tgRNA and cell types is identified by enrichment in at least two conditions, e.g., in all conditions screened. For clarity, candidates found to exhibit little to no enrichment under any given condition are not assumed to be inactive across all conditions and may be screened with different parameters or reconfigured at the polypeptide level, e.g., by swapping, shuffling, or evolving domains (e.g., RT domain), linkers, or other signals (e.g., NLS).(viii) Sequences of exemplary Cas9-linker-RT fusions

[0208] In some embodiments, a gene modifying polypeptide comprises a linker sequence and an RT sequence. In some embodiments, a gene modifying polypeptide comprises a linker sequence (a sequence selected from SEQ ID NOs: 12001 to 15332 of W02023039440A2, herein incorporated by reference in its entirety) as listed in Table D of W02023039440A2, or an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto. In some embodiments, a gene modifying polypeptide comprises the amino acid sequence of an RT domain as listed in Table D of W02023039440A2 (herein incorporated by reference in its entirety), or an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto. In some embodiments, a gene modifying polypeptide comprises a linker sequence as listed in Table D (SEQ ID NOs: 12001 to 15332 of W02023039440A2, herein incorporated by reference in its entirety), or an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto; and the amino acid sequence of an RT domain as listed in Table D of W02023039440A2 (herein incorporated by reference in its entirety), or an amino acid sequence having at least 75%, at least 80%. at least 85%, at least 90%, at least 95%, at least 96%, at least 97%. at least 98%, or at least 99% identity thereto. In some embodiments, a gene modifyingPage 108 of 28713508126v1Attorney Docket No.: 2017469-0062polypeptide comprises: (i) a linker sequence (SEQ ID NOs: 12001 to 15332 ofW02023039440A2, herein incorporated by reference in its entirety) as listed in a row of Table D of W02023039440A2, or an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto; and (ii) the amino acid sequence of an RT domain as listed in the same row of Table D ofW02023039440A2, or an amino acid sequence having at least 75%, at least 80%. at least 85%, at least 90%, at least 95%, at least 96%, at least 97%. at least 98%, or at least 99% identity thereto.(ix) Exemplary gene modifying polypeptides

[0209] In some embodiments, a gene modifying polypeptide (e.g., a gene modifying polypeptide that is part of a system described herein) comprises an amino acid sequence of any one of SEQ ID NOs: 1-7743. or an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, a gene modifying polypeptide comprises an amino acid sequence of any one of SEQ ID NOs: 1-7743, or an amino acid sequence having at least 80% identity thereto. In some embodiments, a gene modifying polypeptide comprises an amino acid sequence of any¬ one of SEQ ID NOs: 1-7743, or an amino acid sequence having at least 90% identity thereto. In some embodiments, a gene modifying polypeptide comprises an amino acid sequence of any one of SEQ ID NOs: 1-7743, or an amino acid sequence having at least 95% identity thereto. In some embodiments, a gene modifying polypeptide comprises an amino acid sequence of any one of SEQ ID NOs: 1-7743, or an amino acid sequence having at least 99% identity thereto. In some embodiments, a gene modifying polypeptide comprises an amino acid sequence of any one of SEQ ID NOs: 1-7743. In some embodiments, a gene modifying polypeptide comprises an amino acid sequence of any one of SEQ ID NOs: 6001-7743, or an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%. at least 95%, or at least 99% identity thereto. In some embodiments, a gene modifying polypeptide comprises an amino acid sequence of any one of SEQ ID NOs: 4501-4541, or an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, a gene modifying polypeptide described herein comprises an RT and linker sequence from any of SEQ ID NOs: 1-7743. or an amino acid sequence having at least 75%, at least 80%. at least 85%, at least 90%. at least 95%, or at least 99% identity theretoand a StlCas9 domain described herein. In some embodiments, a gene modifying polypeptide described herein comprises an RT and linker sequence from any one of SEQ ID NOs: 1-7743, and a StlCas9 domain described herein.

[0210] In some embodiments, a gene modifying polypeptide comprises an amino acid sequence as listed in TABLE Al of W02023039440A2 (herein incorporated by reference in its entirety), or an amino acidPage 109 of 28713508126v1Attorney Docket No.: 2017469-0062sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto.

[0211] In some embodiments, a gene modifying polypeptide comprises an amino acid sequence as listed in TABLE 7 or TABLE 8, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%. at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, a gene modifying polypeptide comprises a linker comprising a linker sequence as listed in TABLE 6 or TABLE 7, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, a gene modifying polypeptide comprises an RT domain comprising an RT domain sequence as listed in TABLE 1, TABLE 7, or TABLE 8, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%. at least 95%, or at least 99% identity thereto. In some embodiments, a gene modifying polypeptide comprises: (i) a linker comprising a linker sequence as listed in a row of TABLE 7, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto; and (ii) an RT domain comprising an RT domain sequence as listed in the same row of TABLE 7, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto.TABLE 7: Selection of exemplary gene modifying polypeptides

[0212] In some embodiments, a gene modifying polypeptide comprises an amino acid sequence as listed in TABLE 8, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, a gene modifying polypeptide comprises a linker comprising a linker sequence as listed in TABLE 8 or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, a gene modifying polypeptide comprises an RT domain comprising an RT domain sequence as listed in TABLE 8, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identityPage 110 of 28713508126v1Attorney Docket No.: 2017469-0062thereto. In some embodiments, a gene modifying polypeptide comprises: (i) a linker comprising a linker sequence as listed in a row of TABLE 8, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto; and (ii) an RT domain comprising an RT domain sequence as listed in the same row of TABLE 8, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%. at least 95%, or at least 99% identity thereto.TABLE 8: Selection of exemplary gene modifying polypeptidesPage 111 of 28713508126v1Attorney Docket No.: 2017469-0062Page 112 of 28713508126v1Attorney Docket No.: 2017469-0062(x) Subsequences of exemplary gene modifying polypeptides

[0213] In some embodiments, a gene modifying polypeptide comprises, in N-terminal to C-terminal order, one or more (e.g.. 1, 2, 3, 4. 5, or all 6) of an N-terminal methionine residue, a first nuclear localization signal (NLS), a DNA binding domain, a linker, an RT domain, and / or a second NLS. In some embodiments, a gene modifying polypeptide comprises, in N-terminal to C-terminal order, a NLS (e.g., a first NLS), a DNA binding domain, a linker, and an RT domain, wherein the linker and RT domain are the linker and RT domain of a gene modifying polypeptide of any one of SEQ ID NOs: 1-7743, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%. at least 90%, at least 95%, or at least 99% identity to said linker and RT domain. In some embodiments, a gene modifying polypeptide comprises, in N-terminal to C-terminal order, a DNA binding domain, a linker, an RT domain, and an NLS (e.g., a second NLS) wherein the linker and RT domain are the linker and RT domain of a gene modifying polypeptide of any one of SEQ ID NOs: 1-7743, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to said linker and RT domain. In some embodiments, a gene modifying polypeptide comprises, in N-terminal to C-terminal order, a first NLS, a DNA binding domain, a linker, an RT domain, and a second NLS, wherein the linker and RT domain are the linker and RT domain of a gene modifying polypeptide of any one of SEQ ID NOs: 1-7743, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identify to said linker and RT domain. In some embodiments, the gene modify ing poly peptide further comprises an N-terminal methionine residue.

[0214] In some embodiments, a gene modifying polypeptide comprises, in N-terminal to C-terminal order, one or more (e g., 1, 2, 3, 4, 5, or all 6) of an N-terminal methionine residue, a first nuclear localization signal (NLS) (e.g., of a gene modifying polypeptide of any one of SEQ ID NOs: 1-7743 and / or as listed in any of TABLE 12, TABLE 13, or TABLE 14, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%. at least 95%, or at least 99% identity thereto), a DNA binding domain (e.g.. a Cas domain, e.g.. a SpyCas9 domain, e.g., as listed in TABLE 3, TABLE 4, and TABLE 8, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto; or a DNA binding domain of a gene modifying polypeptide of any one of SEQ ID NOs: 1-7743 and / or as listed in any of Tables Al, Tl, or T2 of W02023039440A2 (herein incorporated by reference in its entirety), or an amino acid sequence havingPage 113 of 28713508126v1Attorney Docket No.: 2017469-0062at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto), a linker (e.g., of a gene modifying polypeptide of any one of SEQ ID NOs: 1-7743 and / or as listed in any of Tables Al, Tl, or T2 of W02023039440A2 (herein incorporated by reference in its entirety), or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto), an RT domain (e.g.. of a gene modifying polypeptide of any one of SEQ ID NOs: 1-7743 and / or as listed in any of Tables Al, Tl, or T2 of W02023039440A2 (herein incorporated by reference in its entirety), or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto), and a second NLS (e.g., of a gene modifying polypeptide of any one of SEQ ID NOs: 1-7743 and / or as listed in any of Tables Al, Tl, or T2 of W02023039440A2 (herein incorporated by reference in its entirety), or an amino acid sequence having at least 70%, at least 75%. at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto). In some embodiments, the gene modifying polypeptide further comprises (e.g., C-terminal to the second NLS) a T2A sequence and / or a puromycin sequence (e.g., of a gene modifying polypeptide of any one of SEQ ID NOs: 1-7743 and / or as listed in any of Tables Al, Tl, or T2 of W02023039440A2 (herein incorporated by reference in its entirety), or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto). In some embodiments, a nucleic acid encoding a gene modifying polypeptide (e.g., as described herein) encodes a T2A sequence, e.g., wherein the T2A sequence is situated between a region encoding the gene modifying polypeptide and a second region, wherein the second region optionally encodes a selectable marker, e.g., puromycin.

[0215] In some embodiments, the first NLS comprises a first NLS sequence of a gene modifying polypeptide having an amino acid sequence of any one of SEQ ID NOs: 1-7743, or an amino acid sequence having at least 70%. at least 75%, at least 80%, at least 85%, at least 90%. at least 95%, or at least 99% identity thereto. In some embodiments, a first NLS comprises a first NLS sequence of a gene modifying polypeptide as listed in any of Tables Al, Tl, or T2 ofW02023039440A2 (herein incorporated by reference in its entirety), or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, a first NLS sequence comprises a C-myc NLS. In some embodiments, a first NLS comprises the amino acid sequence PAAKRVKLD (SEQ ID NO: 11095). or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto.

[0216] In some embodiments, a gene modifying poly peptide further comprises a spacer sequence between the first NLS and the DNA binding domain. In some embodiments, a spacer sequence between the first NLS and the DNA binding domain comprises 1, 2, 3, 4. 5, 6, 7, 8. 9, or 10 amino acids. In somePage 114 of 28713508126v1Attorney Docket No.: 2017469-0062embodiments, a spacer sequence between the first NLS and the DNA binding domain comprises the amino acid sequence GG.

[0217] In some embodiments, a DNA binding domain comprises a DNA binding domain of a gene modifying polypeptide of any one of SEQ ID NOs: 1-7743, or an amino acid sequence having at least 70%, at least 75%, at least 80%. at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, a DNA binding domain comprises a DNA binding domain of a gene modifying polypeptide as listed in any of Tables Al, Tl, or T2 of W02023039440A2 (herein incorporated by reference in its entirety or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, a DNA binding domain comprises a Cas domain (e.g., as listed in TABLE 3 or TABLE 4). In some embodiments, aDNA binding domain comprises the amino acid sequence of a SpyCas9 polypeptide (e.g.. as listed in TABLE 4, e.g., a Cas9 N863A polypeptide), or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, a DNA binding domain comprises the amino acid sequence:DKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSG ETAEATRLKRTARRRYTRRKNR1CYLQEIFSNEMAKVDDSFFHRLEESFLVEEDK KHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRG HFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRL ENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDN LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLT LLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEE LLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILT FRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDK NLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFK TNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDN EENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSR KLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDS LHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKG QKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQE LDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKARGKSDNVPSEEVVKKMKN YWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILD SRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLN AVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMN FFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEV QTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKS KKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRK RMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKH YLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAP AAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD (SEQ ID NO:11096)or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto.Page 115 of 28713508126v1Attorney Docket No.: 2017469-0062

[0218] In some embodiments, a gene modifying polypeptide further comprises a spacer sequence between a DNA binding domain and a linker. In some embodiments, a spacer sequence between a DNA binding domain and a linker comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids. In some embodiments, a spacer sequence between the DNA binding domain and a linker comprises the amino acid sequence GG.

[0219] In some embodiments, a linker comprises a linker sequence of a gene modifying polypeptide of any one of SEQ ID NOs: 1-7743, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, a linker comprises a linker sequence of a gene modifying polypeptide as listed in any of Tables Al, Tl, or T2 of W02023039440A2 (herein incorporated by reference in its entirety), or an amino acid sequence having at least 70%. at least 75%, at least 80%, at least 85%, at least 90%. at least 95%, or at least 99% identity thereto. In some embodiments, a linker comprises an amino acid sequence as listed in Table D of W02023039440A2 (herein incorporated by reference in its entirety) or TABLE 6, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto.

[0220] In some embodiments, a gene modifying polypeptide further comprises a spacer sequence between a linker and an RT domain. In some embodiments, a spacer sequence between a linker and an RT domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids. In some embodiments, a spacer sequence between a linker and an RT domain comprises the amino acid sequence GG.

[0221] In some embodiments, an RT domain comprises a RT domain sequence of a gene modifying polypeptide of any one of SEQ ID NOs: 1-7743, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%. at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, an RT domain comprises a RT domain sequence of a gene modifying polypeptide as listed in any of Tables Al, Tl, or T2 of W02023039440A2 (herein incorporated by reference in its entirety), or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identify’ thereto. In some embodiments, an RT domain comprises an amino acid sequence as listed in Table D of W02023039440A2 (herein incorporated by reference in its entirety) or TABLE 1, or an amino acid sequence having at least 70%, at least 75%, at least 80%. at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, an RT domain has a length of about 400-500, 500-600, 600-700, 700-800, 800-900, or 900-1000 amino acids.

[0222] In some embodiments, a gene modifying polypeptide further comprises a spacer sequence between an RT domain and a second NLS. In some embodiments, a spacer sequence between an RT domain and a second NLS comprises 1, 2. 3, 4, 5, 6. 7, 8, 9, or 10 amino acids. In some embodiments, a spacer sequence between an RT domain and a second NLS comprises the amino acid sequence AG.Page 116 of 28713508126v1Attorney Docket No.: 2017469-0062

[0223] In some embodiments, a second NLS comprises a second NLS sequence of a gene modifying polypeptide of any one of SEQ ID NOs: 1-7743. In some embodiments, a second NLS comprises a second NLS sequence of a gene modifying polypeptide of any one of SEQ ID NOs: 1-7743. In some embodiments, a second NLS comprises a second NLS sequence of a gene modifying polypeptide as listed in any of Tables AL TL or T2 of W02023039440A2 (herein incorporated by reference in its entirety). In some embodiments, a second NLS sequence comprises a plurality of partial NLS sequences. In some embodiments, a NLS sequence, e.g., the second NLS sequence, comprises a first partial NLS sequence, e.g., comprising the amino acid sequence KRTADGSEEE (SEQ ID NO: 11,097), or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, a NLS sequence, e.g., a second NLS sequence, comprises a second partial NLS sequence. In some embodiments, a NLS sequence, e.g., a second NLS sequence, comprises an SV40A5 NLS, e.g., a bipartite SV40A5 NLS, e.g., comprising the amino acid sequence KRTADGSEFESPKKKAKVE (SEQ ID NO: 11,098), or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identify thereto. In some embodiments, a NLS sequence, e.g., a second NLS sequence, comprises the amino acid sequence KRTADGSEFEKRTADGSEFESPKKKAKVE (SEQ ID NO: 11,099), or an amino acid sequence having at least 70%. at least 75%, at least 80%, at least 85%, at least 90%. at least 95%, or at least 99% identity thereto.

[0224] In some embodiments, a gene modifying polypeptide further comprises a spacer sequence between a second NLS and a T2A sequence and / or puromycin sequence. In some embodiments, a spacer sequence between a second NLS and a T2A sequence and / or puromycin sequence comprises 1, 2, 3, 4, 5, 6, 7. 8, 9, or 10 amino acids. In some embodiments, a spacer sequence between a second NLS and a T2A sequence and / or puromycin sequence comprises the amino acid sequence GSG.(xi) Linkers andRT domains

[0225] In some embodiments, a gene modifying polypeptide comprises a linker (e.g., as described herein) and an RT domain (e.g., as described herein). In some embodiments, a gene modifying polypeptide comprises, in N-terminal to C-terminal order, a linker (e.g., as described herein) and an RT domain (e.g, as described herein).

[0226] In some embodiments, a linker comprises a linker sequence as listed in TABLE 6, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, a linker comprises a linker sequence of any one of SEQ ID NOs: 1-7743. or an amino acid sequence having at least 70%. at least 75%. at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, a linkerPage 117 of 28713508126v1Attorney Docket No.: 2017469-0062comprises a linker sequence of any one of SEQ ID NOs: 6001-7743, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, a linker comprises a linker sequence of any one of SEQ ID NOs: 4501-4541, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, a linker comprises a linker sequence of an exemplary gene modifying polypeptide listed in any of Tables Al. Tl. or T2 of W02023039440A2 (herein incorporated by reference in its entirety), or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, an RT domain comprises an RT domain sequence as listed in TABLE 1, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, an RT domain comprises an RT domain sequence of an exemplary gene modifying polypeptide listed in any of Tables Al. Tl. or T2 of W02023039440A2 (herein incorporated by reference in its entirety), or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto.

[0227] In some embodiments, a gene modifying polypeptide comprises a portion of a gene modifying polypeptide of any one of SEQ ID NOs: 1-7743, wherein the portion comprises a linker and RT domain, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to said portion.

[0228] In some embodiments, a gene modifying polypeptide comprises a linker of a gene modifying polypeptide of any one of SEQ ID NOs: 1-7743, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%. at least 90%, at least 95%, or at least 99% identity to said linker. In some embodiments, a gene modifying polypeptide comprises a linker of a gene modifying polypeptide of any one of SEQ ID NOs: 6001-7743, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to said linker. In some embodiments, a gene modifying polypeptide comprises a linker of a gene modifying polypeptide of any¬ one of SEQ ID NOs: 4501-4541, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%. at least 95%, or at least 99% identity to said linker. In some embodiments, a gene modifying polypeptide comprises a linker of a gene modifying polypeptide as listed in any of Tables Al, Tl, or T2 of W02023039440A2 (herein incorporated by reference in its entirety), or a linker comprising an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, or 99% identity thereto.

[0229] In some embodiments, a gene modifying polypeptide comprises an RT domain of a gene modifying polypeptide of any one of SEQ ID NOs: 1-7743, or an amino acid sequence having at leastPage 118 of 28713508126v1Attorney Docket No.: 2017469-006270%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to said RT domain. In some embodiments, a gene modifying polypeptide comprises an RT domain of a gene modifying polypeptide of any one of SEQ ID NOs: 6001-7743, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to said RT domain. In some embodiments, a gene modifying polypeptide comprises an RT domain of a gene modifying polypeptide of any one of SEQ ID NOs: 4501-4541, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity said RT domain. In some embodiments, a gene modifying polypeptide comprises an RT domain of a gene modifying polypeptide as listed in any of Tables Al, Tl, or T2 of W02023039440A2 (herein incorporated by reference in its entirety), or an RT domain comprising an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%. at least 95%, or at least 99% identity thereto.

[0230] In some embodiments, a linker and an RT domain of a gene modifying polypeptide comprise the amino acid sequences of a linker and RT domain (or amino acid sequences having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto) of a gene modifying polypeptide having the amino acid sequence of any one of SEQ ID NOs: 1-7743. In some embodiments, a linker and an RT domain of a gene modifying polypeptide comprise amino acid sequences of a linker and RT domain having at least 80% identity to the linker and RT domains of any one of SEQ ID NOs: 1-7743. In some embodiments, a linker and an RT domain of a gene modifying polypeptide comprise amino acid sequences of a linker and RT domain having at least 90% identity to the linker and RT domains of any one of SEQ ID NOs: 1-7743. In some embodiments, a linker and an RT domain of a gene modifying polypeptide comprise amino acid sequences of a linker and RT domain having at least 95% identity to the linker and RT domains of any one of SEQ ID NOs: 1-7743. In some embodiments, a linker and an RT domain of a gene modifying polypeptide comprise amino acid sequences of a linker and RT domain having at least 99% identity to tire linker and RT domains of any one of SEQ ID NOs: 1-7743. In some embodiments, a linker and an RT domain of a gene modifying polypeptide comprise the amino acid sequences of a linker and RT domain (or amino acid sequences having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%. at least 95%, or at least 99% identity thereto) of a gene modifying polypeptide having the amino acid sequence of any one of SEQ ID NOs: 6001-7743. In some embodiments, a linker and an RT domain of a gene modifying polypeptide comprise the amino acid sequences of a linker and RT domain (or amino acid sequences having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto) of a gene modifying polypeptide having the amino acid sequence of any one of SEQ ID NOs: 4501-4541. In some embodiments, a linker and an RT domain of a gene modifying polypeptide comprise the aminoPage 119 of 28713508126v1Attorney Docket No.: 2017469-0062acid sequences of a linker and RT domain (or amino acid sequences having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto) from a single row of any of Tables Al, Tl, or T2 of W02023039440A2 (herein incorporated by reference in its entirety) (e.g., from a single exemplary gene modifying polypeptide as listed in any of Tables Al, Tl, or T2 of W02023039440A2 (herein incorporated by reference in its entirety)).

[0231] In some embodiments, a linker and an RT domain of a gene modifying polypeptide comprise the amino acid sequences of a linker and RT domain (or amino acid sequences having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto) from two different amino acid sequences selected from SEQ ID NOs: 1-7743. In some embodiments, a linker and an RT domain of a gene modifying polypeptide comprise the amino acid sequences of a linker and RT domain (or amino acid sequences having at least 70%. at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto) from different rows of any of Tables Al, Tl, or T2 of W02023039440A2 (herein incorporated by reference in its entirety).

[0232] In some embodiments, a gene modifying polypeptide further comprises a first NLS (e.g., a 5’ NLS), e.g., as described herein. In some embodiments, a gene modifying polypeptide further comprises a second NLS (e.g., a 3’ NLS), e.g., as described herein. In some embodiments, a gene modifying polypeptide further comprises an N-terminal methionine residue.(xii) RT Families and Mutants

[0233] In some embodiments, a gene modifying polypeptide comprises the amino acid sequence of an RT domain sequence from a family selected from: AVIRE, BAEVM, FFV, FLV, FOAMV, GALV. KORV, MLVAV. MLVBM, MLVCB, MLVFF, ML VMS, PERV, SFVL SFV3L, WMSV, XMRV6, BLVAU, BLVJ, HTL1A, HTL1C, HTL1L, HTL32, HTL3P, HTLV2, JSRV, MLVF5, MLVRD, MMTVB, MPMV, SFVCP, SMRVH, SRV1, SRV2, and WDSV. In some embodiments, a gene modifying polypeptide comprises the amino acid sequence of an RT domain sequence from a family selected from: AVIRE, BAEVM, FFV, FLV, FOAMV, GALV, KORV, MLVAV, MLVBM, MLVCB, MLVFF, MLVMS, PERV, SFV1, SFV3L, WMSV, and XMRV6.

[0234] In some embodiments, a gene modifying polypeptide comprises the amino acid sequence of an RT domain sequence from an MLVMS RT domain. In some embodiments, the amino acid sequence of an RT domain sequence comprises one or more point mutations as listed in column 1 of TABLE 9, or a point mutation corresponding thereto. In some embodiments, the amino acid sequence of an RT domain sequence comprises one or more point mutations as listed in column 3 of TABLE 9 (Genl MLVMS). or a point mutation corresponding thereto. In some embodiments, the amino acid sequence of an RT domainPage 120 of 28713508126v1Attorney Docket No.: 2017469-0062sequence comprises one or more point mutations at an amino acid position of the RT domain as listed in columns 1 and 2 of TABLE 9, or an amino acid position corresponding thereto.

[0235] In some embodiments, a gene modifying polypeptide comprises the amino acid sequence of an RT domain sequence from an AVIRE RT domain. In some embodiments, the amino acid sequence of an RT domain sequence comprises one or more point mutations as listed in column 2 of TABLE 9, or a point mutation corresponding thereto. In some embodiments, the amino acid sequence of an RT domain sequence comprises one or more point mutations as listed in column 4 of TABLE 9 (Gen2 AVIRE), or a point mutation corresponding thereto. In some embodiments, the amino acid sequence of an RT domain sequence comprises one or more point mutations at an amino acid position of the RT domain as listed in columns 3 and 4 of TABLE 10, or an amino acid position corresponding thereto. In some embodiments, an RT domain comprises an IENSSP (e.g., at the C-terminus).TABLE 9: Exemplary point mutations in ML VMS and AVIRE RT domainsPage 121 of 28713508126v1Attorney Docket No.: 2017469-0062TABLE 10: Positions that can be mutated in exemplary ML VMS and AVIRE RT domains

[0236] In some embodiments, a gene modifying polypeptide comprises a gamma retrovirus derived RT domain. In some embodiments, a gamma retrovirus-derived RT domain of a gene modifying polypeptide comprises the amino acid sequence of an RT domain sequence from a family selected from: AVIRE, BAEVM, FFV, FLV, FOAMV, GALV, KORV. MLVAV, MLVBM, MLVCB, MLVFF, MLVMS, PERV, SFVL SFV3L, WMSV, and XMRV6. In some embodiments, the gamma retrovirus-derived RT domain of a gene modifying polypeptide is not derived from PERV. In some embodiments, said RT includes one, two, three, four, five, six or more mutations shown in Table 2A and corresponding to mutations D200N, L603W, T330P, D524G, E562Q, D583N, P51L, S67R, E67K, T197A, H204R,Page 122 of 28713508126v1Attorney Docket No.: 2017469-0062E302K, F309N, W313F, L435G, N454K, H594Q, L671P, E69K, or D653N in the RT domain of murine leukemia virus reverse transcriptase. In some embodiments, a gene modifying polypeptide further comprises a linker having at least 99% identity to a linker domains of any one of SEQ ID NOs: 1-7743. In some embodiments, a gene modifying polypeptide further comprises a linker having at least 99% or 100% identity to SEQ ID NO: 5217 or SEQ ID NO:11,041.

[0237] In some embodiments, an RT domain comprises the amino acid sequence of an RT domain of an AVIRE RT (e.g., an AVIRE P03360 sequence, e.g., SEQ ID NO: 8001), or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, an RT domain comprises the amino acid sequence of an AVIRE RT further comprising one, two, three, four, or five mutations selected from the group consisting of D200N, G330P, L605W, T306K, and W313F. or a corresponding position in a homologous RT domain. In some embodiments, an RT domain comprises the amino acid sequence of an AVIRE RT further comprising one, two, or three mutations selected from the group consisting of D200N, G330P, and L605W, or a corresponding position in a homologous RT domain.

[0238] In some embodiments, an RT domain comprises the amino acid sequence of an RT domain of a BAEVM RT (e.g.. an BAEVM P10272 sequence, e.g., SEQ ID NO: 8004). or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, an RT domain comprises the amino acid sequence of a BAEVM RT further comprising one, two, three, four, or five mutations selected from the group consisting of D198N, E328P, L602W, T304K, and W31 IF, or a corresponding position in a homologous RT domain. In some embodiments, an RT domain comprises the amino acid sequence of a BAEVM RT further comprising one, two, or three mutations selected from the group consisting of D198N, E328P, and L602W, or a corresponding position in a homologous RT domain.

[0239] In some embodiments, an RT domain comprises the amino acid sequence of an RT domain of an FFV RT (e.g., an FFV O93209 sequence, e.g., SEQ ID NO: 8012), or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%. at least 95%, or at least 99% identity thereto. In some embodiments, an RT domain comprises the amino acid sequence of an FFV RT further comprising one, two, three, or four mutations selected from the group consisting of D21N, T293N, T419P, and L393K, or a corresponding position in a homologous RT domain. In some embodiments, an RT domain comprises the amino acid sequence of an FFV RT further comprising one, two, or three mutations selected from the group consisting of D21N, T293N, and T419P, or a corresponding position in a homologous RT domain. In some embodiments, an RT domain comprises the amino acid sequence of an FFV RT further comprising the mutation D21N. In some embodiments, an RT domain comprises the amino acid sequence of an FFV RT further comprising one, two, or three mutations selected from thePage 123 of 28713508126v1Attorney Docket No.: 2017469-0062group consisting of T207N, T333P, and L307K, or a corresponding position in a homologous RT domain. In some embodiments, an RT domain comprises the amino acid sequence of an FFV RT further comprising one or two mutations selected from the group consisting of T207N and T333P, or a corresponding position in a homologous RT domain.

[0240] In some embodiments, an RT domain comprises the amino acid sequence of an RT domain of an FLV RT (e.g., an FLV P10273 sequence, e.g., SEQ ID NO: 8019), or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, an RT domain comprises the amino acid sequence of an FLV RT further comprising one, two, three, or four mutations selected from the group consisting of D199N, L602W, T305K, and W312F, or a corresponding position in a homologous RT domain. In some embodiments, an RT domain comprises the amino acid sequence of an FLV RT further comprising one or two mutations selected from the group consisting of D199N and L602W, or a corresponding position in a homologous RT domain.

[0241] In some embodiments, an RT domain comprises the amino acid sequence of an RT domain of a FOAMV RT (e.g.. an FOAMV P14350 sequence, e.g., SEQ ID NO: 8021), or an amino acid sequence having at least 70%. at least 75%, at least 80%, at least 85%, at least 90%. at least 95%, or at least 99% identity thereto. In some embodiments, an RT domain comprises the amino acid sequence of an FOAMV RT further comprising one, two, three, or four mutations selected from the group consisting of D24N, T296N, S420P, and L396K, or a corresponding position in a homologous RT domain. In some embodiments, an RT domain comprises the amino acid sequence of an FOAMV RT further comprising one, two, or three mutations selected from the group consisting of D24N, T296N, and S420P, or a corresponding position in a homologous RT domain. In some embodiments, an RT domain comprises tire amino acid sequence of an FOAMV RT further comprising the mutation D24N, or a corresponding position in a homologous RT domain. In some embodiments, an RT domain comprises the amino acid sequence of an FOAMV RT further comprising one, two, or three mutations selected from the group consisting of T207N, S33 IP, and L307K, or a corresponding position in a homologous RT domain. In some embodiments, an RT domain comprises the amino acid sequence of an FOAMV RT further comprising one or two mutations selected from the group consisting of T207N and S33 IP, or a corresponding position in a homologous RT domain.

[0242] In some embodiments, an RT domain comprises the amino acid sequence of an RT domain of a GALV RT (e.g., an GALV P21414 sequence, e.g., SEQ ID NO: 8027), or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%. or at least 99% identity thereto. In some embodiments, an RT domain comprises the amino acid sequence of a GALV RT further comprising one, two, three, four, or five mutations selected from the group consisting of D198N, E328P,Page 124 of 28713508126v1Attorney Docket No.: 2017469-0062L600W, T304K, and W31 IF, or a corresponding position in a homologous RT domain. In some embodiments, an RT domain comprises the amino acid sequence of a GALV RT further comprising one, two, or three mutations selected from the group consisting of D198N, E328P, and L600W, or a corresponding position in a homologous RT domain.

[0243] In some embodiments, an RT domain comprises the amino acid sequence of an RT domain of a KORV RT (e.g., an KORV Q9TTC 1 sequence, e.g., SEQ ID NO: 8047), or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, an RT domain comprises the amino acid sequence of a GALV RT further comprising one, two, three, four, five, or six mutations selected from tire group consisting of D32N, D322N, E452P, L274W, T428K, and W435F, or a corresponding position in a homologous RT domain. In some embodiments, an RT domain comprises the amino acid sequence of a GALV RT further comprising one, two, three, or four mutations selected from the group consisting of D32N, D322N, E452P, and L274W, or a corresponding position in a homologous RT domain. In some embodiments, an RT domain comprises the amino acid sequence of a GALV RT further comprising the mutation D32N. In some embodiments, an RT domain comprises the amino acid sequence of a KORV RT further comprising one, two, three, four, or five mutations selected from the group consisting of D23 IN, E361P, L633W, T337K, and W344F, or a corresponding position in a homologous RT domain. In some embodiments, an RT domain comprises the amino acid sequence of a KORV RT further comprising one, two, or three mutations selected from the group consisting of D231N, E361P, and L633W, or a corresponding position in a homologous RT domain.

[0244] In some embodiments, an RT domain comprises the amino acid sequence of an RT domain of a MLVAV RT (e.g., an MLVAV P03356 sequence, e.g., SEQ ID NO: 8053). or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, an RT domain comprises the amino acid sequence of a MLVAV RT further comprising one, two, three, four, or five mutations selected from the group consisting of D200N, T330P, L603W, T306K, and W313F, or a corresponding position in a homologous RT domain. In some embodiments, an RT domain comprises the amino acid sequence of a MLVAV RT further comprising one, two, or three mutations selected from the group consisting of D200N, T330P, and L603W, or a corresponding position in a homologous RT domain.

[0245] In some embodiments, an RT domain comprises the amino acid sequence of an RT domain of a MLVBM RT (e.g., an MLVBM Q7SVK7 sequence, e.g., SEQ ID NO: 8056), or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, an RT domain comprises the amino acid sequence of a MLVBM RT further comprising one, two, three, four, or five mutations selected from the group consisting ofPage 125 of 28713508126v1Attorney Docket No.: 2017469-0062D199N, T329P, L602W, T305K, and W312F, or a corresponding position in a homologous RT domain. In some embodiments, an RT domain comprises the amino acid sequence of a MLVBM RT further comprising one, two, and three mutations selected from the group consisting of D200N, T330P, and L603W, or a corresponding position in a homologous RT domain.

[0246] In some embodiments, an RT domain comprises the amino acid sequence of an RT domain of a MLVCB RT (e.g., an MLVCB P08361 sequence, e.g., SEQ ID NO: 8062), or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, an RT domain comprises the amino acid sequence of a MLVCB RT further comprising one, two, three, four, or five mutations selected from the group consisting of D200N, T330P, L603W, T306K, and W313F, or a corresponding position in a homologous RT domain. In some embodiments, the RT domain comprises the amino acid sequence of a MLVCB RT further comprising one, two, and three mutations selected from the group consisting of D200N, T330P, and L603W, or a corresponding position in a homologous RT domain.

[0247] In some embodiments, an RT domain comprises the amino acid sequence of an RT domain of a MLVFF RT, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%. at least 95%, or at least 99% identity thereto. In some embodiments, an RT domain comprises the amino acid sequence of a MLVFF RT further comprising one, two, three, four, or five mutations selected from the group consisting of D200N, T330P, L603W, T306K, and W313F, or a corresponding position in a homologous RT domain. In some embodiments, an RT domain comprises the amino acid sequence of a MLVFF RT further comprising one, two, and three mutations selected from tire group consisting of D200N, T330P, and L603W, or a corresponding position in a homologous RT domain.

[0248] In some embodiments, an RT domain comprises the amino acid sequence of an RT domain of a MLVMS RT (e.g., an MLVMS reference sequence, e.g., SEQ ID NO: 8137: or an MLVMS P03355 sequence, e.g., SEQ ID NO: 8070), or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, an RT domain comprises the amino acid sequence of a MLVMS RT further comprising one, two, three, four, five, or six mutations selected from the group consisting of D200N, T330P, L603W, T306K, W313F, and H8Y, or a corresponding position in a homologous RT domain. In some embodiments, an RT domain comprises the amino acid sequence of a MLVMS RT further comprising one, two, three, four, or five mutations selected from the group consisting of D200N, T330P, L603W, T306K, and W313F, or a corresponding position in a homologous RT domain. In some embodiments, an RT domain comprises the amino acid sequence of a MLVMS RT further comprising one, two, or three mutations selected from the group consisting of D200N, T330P, and L603W, or a corresponding position in a homologous RT domain.Page 126 of 28713508126v1Attorney Docket No.: 2017469-0062

[0249] In some embodiments, an RT domain comprises the amino acid sequence of an RT domain of a PERV RT (e.g., an PERV Q4VFZ2 sequence, e.g., SEQ ID NO: 8099), or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, an RT domain comprises the amino acid sequence of a PERV RT further comprising one, two, three, four, or five mutations selected from the group consisting of D196N, E326P, L599W, T302K, and W309F, or a corresponding position in a homologous RT domain. In some embodiments, an RT domain comprises the amino acid sequence of a PERV RT further comprising one, two, or three mutations selected from the group consisting of D196N, E326P, and L599W, or a corresponding position in a homologous RT domain.

[0250] In some embodiments, an RT domain comprises the amino acid sequence of an RT domain of a SFV1 RT (e.g., an SFV1 P23074 sequence, e.g., SEQ ID NO: 8105), or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, an RT domain comprises the amino acid sequence of a SFV1 RT further comprising one, two, three, or four mutations selected from the group consisting of D24N, T296N, N420P, and L396K, or a corresponding position in a homologous RT domain. In some embodiments, an RT domain comprises the amino acid sequence of a SFV1 RT further comprising one. two, or three mutations selected from the group consisting of D24N, T296N, and N420P, or a corresponding position in a homologous RT domain. In some embodiments, an RT domain comprises the amino acid sequence of a SFV 1 RT further comprising the D24N, or a corresponding position in a homologous RT domain.

[0251] In some embodiments, an RT domain comprises the amino acid sequence of an RT domain of a SFV3L RT (e.g., an SFV3L P27401 sequence, e.g., SEQ ID NO: 8111), or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, an RT domain comprises the amino acid sequence of a SFV3L RT further comprising one, two, three, or four mutations selected from the group consisting of D24N, T296N, N422P, and L396K, or a corresponding position in a homologous RT domain. In some embodiments, an RT domain comprises the amino acid sequence of a SFV3L RT further comprising one, two. or three mutations selected from the group consisting of D24N, T296N, and N422P, or a corresponding position in a homologous RT domain. In some embodiments, an RT domain comprises the amino acid sequence of a SFV3L RT further comprising the mutation D24N, or a corresponding position in a homologous RT domain. In some embodiments, an RT domain comprises the amino acid sequence of a SFV3L RT further comprising one, two, or three mutations selected from the group consisting of T307N, N333P, and L307K, or a corresponding position in a homologous RT domain. In some embodiments, an RT domain comprises the amino acid sequence of a SFV3L RT further comprising onePage 127 of 28713508126v1Attorney Docket No.: 2017469-0062or two mutations selected from the group consisting of T307N and N333P, or a corresponding position in a homologous RT domain.

[0252] In some embodiments, an RT domain comprises the amino acid sequence of an RT domain of a WMSV RT (e.g., an WMSV P03359 sequence, e.g., SEQ ID NO: 8131), or an amino acid sequence having at least 70%. at least 75%, at least 80%, at least 85%, at least 90%. at least 95%, or at least 99% identity thereto. In some embodiments, an RT domain comprises the amino acid sequence of a WMSV RT further comprising one, two, three, four, or five mutations selected from the group consisting of D198N, E328P, L600W, T304K, and W31 IF, or a corresponding position in a homologous RT domain. In some embodiments, an RT domain comprises the amino acid sequence of a WMSV RT further comprising one, two, or three mutations selected from the group consisting of D198N, E328P, and L600W. or a corresponding position in a homologous RT domain.

[0253] In some embodiments, an RT domain comprises the amino acid sequence of an RT domain of a XMRV6 RT (e.g., an XMRV6_A1Z651 sequence, e.g., SEQ ID NO: 8134), or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, an RT domain comprises the amino acid sequence of a XMRV6 RT further comprising one, two. three, four, or five mutations selected from the group consisting of D200N, T330P, L603W, T306K, and W313F, or a corresponding position in a homologous RT domain. In some embodiments, an RT domain comprises the amino acid sequence of a XMRV6 RT further comprising one, two, or three mutations selected from the group consisting of D200N, T330P, and L603W, or a corresponding position in a homologous RT domain.

[0254] In some embodiments, an RT domain of a gene modifying polypeptide comprises the amino acid sequence of an RT domain of an AVIRE RT, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, an RT domain comprises the amino acid sequence of an RT domain comprised in a sequence listed in column 1 of TABLE 11, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, the gene modifying polypeptide further comprises a linker having at least 99% or 100% identity to SEQ ID NO: 5217 or SEQ ID NO: 11,041.

[0255] In some embodiments, an RT domain of a gene modifying polypeptide comprises the amino acid sequence of an RT domain of an ML VMS RT, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, an RT domain comprises the amino acid sequence of an RT domain comprised in a sequence listed in any of columns 2-6 of TABLE 11, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In somePage 128 of 28713508126v1Attorney Docket No.: 2017469-0062embodiments, a gene modifying polypeptide further comprises a linker having at least 99% or 100% identity to SEQ ID NO: 5217 or SEQ ID NO: 11041.TABLE 11: Exemplary gene modifying polypeptides comprising an AVIRE RT domain or an ML VMS RT domain.Page 129 of 28713508126v1Attorney Docket No.: 2017469-0062Page 130 of 28713508126v1Attorney Docket No.: 2017469-0062Page 131 of 28713508126v1Attorney Docket No.: 2017469-0062Page 132 of 28713508126v1Attorney Docket No.: 2017469-0062Page 133 of 28713508126v1Attorney Docket No.: 2017469-0062Page 134 of 28713508126v1Attorney Docket No.: 2017469-0062(xiii) Systems

[0256] In some embodiments, the present disclosure provides systems comprising a nucleic acid molecule encoding a gene modifying polypeptide (e.g., as described herein) and a template nucleic acid (e.g., a template RNA, e.g., as described herein). In some embodiments, a nucleic acid molecule encoding a gene modifying polypeptide comprises one or more silent mutations in the coding region (e.g., in the sequence encoding the RT domain) relative to a nucleic acid molecule as described herein. In some embodiments, a system further comprises a gRNA (e.g.. a gRNA that binds to a polypeptide that induces a nick, e.g., in the opposite strand of the target DNA bound by a gene modifying polypeptide).Page 135 of 28713508126v1Attorney Docket No.: 2017469-0062

[0257] In some embodiments, a nucleic acid molecule encoding a gene modifying polypeptide encodes a polypeptide having an amino acid sequence selected from SEQ ID NOs: 1-7743, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, a nucleic acid molecule encoding a gene modifying polypeptide encodes a polypeptide having an amino acid sequence selected from SEQ ID NOs: 6001-7743, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, a nucleic acid molecule encoding a gene modifying polypeptide encodes a polypeptide having an amino acid sequence selected from SEQ ID NOs: 4501-4541, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, a nucleic acid molecule encoding a gene modifying polypeptide encodes a polypeptide as listed in any of Tables Al, Tl, or T2 of W02023039440A2 (herein incorporated by reference in its entirety), or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto.

[0258] In some embodiments, a nucleic acid molecule encoding a gene modifying polypeptide comprises a sequence encoding a portion of an amino acid sequence selected from SEQ ID NOs: 1-7743, wherein the portion comprises a linker and RT domain, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to said portion. In some embodiments, a nucleic acid molecule encoding a gene modifying polypeptide comprises a sequence encoding a portion of an amino acid sequence selected from SEQ ID NOs: 6001-7743, wherein the portion comprises a linker and RT domain, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%. at least 90%, at least 95%, or at least 99% identity to said portion. In some embodiments, a nucleic acid molecule encoding a gene modifying polypeptide comprises a sequence encoding a portion of an amino acid sequence selected from SEQ ID NOs: 4501-4541, wherein the portion comprises a linker and RT domain, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identify to said portion. In some embodiments, a nucleic acid molecule encoding a gene modifying polypeptide comprises a sequence encoding a portion of a polypeptide listed in any of Tables Al, Tl, or T2 of W02023039440A2 (herein incorporated by reference in its entirety), wherein the portion comprises a linker and RT domain, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to said portion.

[0259] In some embodiments, a nucleic acid molecule encoding a gene modifying polypeptide comprises a sequence encoding the linker of an amino acid sequence selected from SEQ ID NOs: 1-7743, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least Page 136 of 28713508126v1Attorney Docket No.: 2017469-006295%, or at least 99% identity thereto. In some embodiments, a nucleic acid molecule encoding a gene modifying polypeptide comprises a sequence encoding the linker of a polypeptide having an amino acid sequence selected from SEQ ID NOs: 6001-7743, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, a nucleic acid molecule encoding a gene modifying polypeptide comprises a sequence encoding the linker of a polypeptide having an amino acid sequence selected from SEQ ID NOs: 4501-4541, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, a nucleic acid molecule encoding a gene modifying polypeptide comprises a sequence encoding the linker of a polypeptide as listed in any of Tables Al, Tl, or T2 of W02023039440A2 (herein incorporated by reference in its entirety), or an amino acid sequence having at least 70%, at least 75%, at least 80%. at least 85%, at least 90%, at least 95%, or at least 99% identity thereto.

[0260] In some embodiments, a nucleic acid molecule encoding a gene modifying polypeptide comprises a sequence encoding the RT domain of an amino acid sequence selected from SEQ ID NOs: 1-7743, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, a nucleic acid molecule encoding a gene modifying polypeptide comprises a sequence encoding the RT domain of a polypeptide having an amino acid sequence selected from SEQ ID NOs: 6001-7743, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, a nucleic acid molecule encoding a gene modifying polypeptide comprises a sequence encoding the RT domain of a polypeptide having an amino acid sequence selected from SEQ ID NOs: 4501-4541, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%. at least 90%. at least 95%, or at least 99% identity thereto. In some embodiments, a nucleic acid molecule encoding a gene modifying polypeptide comprises a sequence encoding the RT domain of a polypeptide as listed in any of Tables Al, Tl, or T2 of W02023039440A2 (herein incorporated by reference in its entirety), or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto.

[0261] In some embodiments, the present disclosure provides systems comprising a gene modifying polypeptide (e.g., as described herein) and a template nucleic acid (e.g., a template RNA, e.g., as described herein).

[0262] In some embodiments, a gene modifying polypeptide comprises a polypeptide having an amino acid sequence selected from SEQ ID NOs: 1-7743, or an amino acid sequence having at least 70%, at least 75%. at least 80%, at least 85%, at least 90%, at least 95%. or at least 99% identity thereto. In some embodiments, a gene modifying polypeptide comprises a polypeptide having an amino acid sequencePage 137 of 28713508126v1Attorney Docket No.: 2017469-0062selected from SEQ ID NOs: 6001-7743, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, a gene modifying polypeptide comprises a polypeptide having an amino acid sequence selected from SEQ ID NOs: 4501-4541, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, a gene modifying polypeptide comprises a polypeptide as listed in any of Tables Al, Tl, or T2 of W02023039440A2 (herein incorporated by reference in its entirety), or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto.

[0263] In some embodiments, a gene modifying polypeptide comprises a portion of an amino acid sequence selected from SEQ ID NOs: 1-7743. wherein the portion comprises a linker and RT domain, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to said portion. In some embodiments, a gene modifying polypeptide comprises a portion of an amino acid sequence selected from SEQ ID NOs: 6001-7743, wherein the portion comprises a linker and RT domain, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to said portion. In some embodiments, a gene modifying polypeptide comprises a portion of an amino acid sequence selected from SEQ ID NOs: 4501-4541, wherein the portion comprises a linker and RT domain, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to said portion. In some embodiments, a gene modifying polypeptide comprises a portion of a polypeptide listed in any of Tables Al, Tl, or T2 of W02023039440A2 (herein incorporated by reference in its entirety), wherein the portion comprises a linker and RT domain, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%. at least 95%, or at least 99% identity to said portion.

[0264] In some embodiments, a gene modifying polypeptide comprises the linker of an amino acid sequence selected from SEQ ID NOs: 1-7743, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, a gene modifying polypeptide comprises a sequence encoding the linker of a polypeptide having an amino acid sequence selected from SEQ ID NOs: 6001-7743, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, a gene modifying polypeptide comprises a sequence encoding the linker of a polypeptide having an amino acid sequence selected from SEQ ID NOs: 4501-4541, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%. at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, a gene modifying polypeptide comprises the Page 138 of 28713508126v1Attorney Docket No.: 2017469-0062linker of a polypeptide as listed in any of Tables Al, Tl, or T2 of W02023039440A2 (herein incorporated by reference in its entirety), or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto.

[0265] In some embodiments, a gene modifying polypeptide comprises the RT domain of an amino acid sequence selected from SEQ ID NOs: 1-7743. or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, a gene modifying polypeptide comprises a sequence encoding the RT domain of a polypeptide having an amino acid sequence selected from SEQ ID NOs: 6001-7743, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, a gene modifying polypeptide comprises a sequence encoding the RT domain of a polypeptide having an amino acid sequence selected from SEQ ID NOs: 4501-4541, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. In some embodiments, a gene modifying polypeptide comprises the RT domain of a polypeptide as listed in any of Tables Al, Tl, or T2 of W02023039440A2 (herein incorporated by reference in its entirety), or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%. at least 95%, or at least 99% identity thereto.TABLE 12: Exemplary amino acid sequences for gene modifying polypeptidesPage 139 of 28713508126v1Attorney Docket No.: 2017469-0062Page 140 of 28713508126v1Attorney Docket No.: 2017469-0062Page 141 of 28713508126v1Attorney Docket No.: 2017469-0062Page 142 of 28713508126v1Attorney Docket No.: 2017469-0062Page 143 of 28713508126v1Attorney Docket No.: 2017469-0062Page 144 of 28713508126v1Attorney Docket No.: 2017469-0062(xiv) Localization sequences for gene modifying systems

[0266] In some embodiments, a gene editor system RNA further comprises an intracellular localization sequence, e.g., a nuclear localization sequence (NLS). In some embodiments, a gene modifying polypeptide comprises an NLS as comprised in SEQ ID NO: 4000 and / or SEQ ID NO: 4001, or an NLS having an amino acid sequences having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity thereto.

[0267] A nuclear localization sequence may be an RNA sequence that promotes the import of the RNA into the nucleus. In some embodiments, a nuclear localization signal is located on the template RNA. In some embodiments, a gene modifying polypeptide is encoded on a first RNA, and a template RNA is a second, separate, RNA, and a nuclear localization signal is located on the template RNA and not on an RNA encoding the gene modifying polypeptide. While not wishing to be bound by theory, in some embodiments, an RNA encoding a gene modifying polypeptide is targeted primarily to the cytoplasm to promote its translation, while the template RNA is targeted primarily to the nucleus to promote insertion into the genome. In some embodiments, a nuclear localization signal is at the 3' end, 5' end, or in an internal region of a template RNA. In some embodiments a nuclear localization signal is 3' of a heterologous sequence (e.g., is directly 3' of a heterologous sequence) or is 5' of a heterologous sequence (e.g., is directly 5' of a heterologous sequence). In some embodiments, a nuclear localization signal is placed outside of the 5' UTR or outside of the 3' UTR of a template RNA. In some embodiments, a nuclear localization signal is placed between a 5' UTR and a 3' UTR, wherein optionally the nuclear localization signal is not transcribed with a transgene (e.g., the nuclear localization signal is an anti-sense orientation or is downstream of a transcriptional termination signal or polyadenylation signal). In some embodiments, a nuclear localization sequence is situated inside of an intron. In some embodiments, a plurality of the same or different nuclear localization signals are in the RNA, e.g., in a template RNA. In some embodiments, a nuclear localization signal is less than 5, less than 10, less than 25, less than 50. less than 75, less than 100, less than 150, less than 200, less than 250, less than 300, less than 350, less thanPage 145 of 28713508126v1Attorney Docket No.: 2017469-0062400, less than 450, less than 500, less than 600, less than 700, less than 800, less than 900 or less than 1000 bp in length. Various RNA nuclear localization sequences can be used. For example, Lubelsky and Ulitsky, Nature 555 (107-111), 2018 describe RNA sequences which drive RNA localization into the nucleus. In some embodiments, a nuclear localization signal is a SINE-derived nuclear RNA localization (SIRLOIN) signal. In some embodiments, a nuclear localization signal binds a nuclear-enriched protein. In some embodiments the nuclear localization signal binds the HNRNPK protein. In some embodiments, a nuclear localization signal is rich in pyrimidines, e.g., is a C / T rich, C / U rich, C rich, T rich, or U rich region. In some embodiments, a nuclear localization signal is derived from a long non-coding RNA. In some embodiments, a nuclear localization signal is derived from MALAT1 long non-coding RNA or is the 600 nucleotide M region of MALAT1 (described in Miyagawa et al., RNA 18, (738-751), 2012). In some embodiments, nuclear localization signal is derived from BORG long non-coding RNA or is a AGCCC motif (described in Zhang etal., Molecular and Cellular Biology 34. 2318-2329 (2014). In some embodiments, a nuclear localization sequence is described in Shukla et al., The EMBO Journal e98452 (2018). In some embodiments, a nuclear localization signal is derived from a retrovirus.

[0268] In some embodiments, a polypeptide described herein comprises one or more (e.g., 2, 3, 4, 5) nuclear targeting sequences, for example a nuclear localization sequence (NLS). In some embodiments, a NLS is a bipartite NLS. In some embodiments, a NLS facilitates the import of a protein comprising an NLS into the cell nucleus. In some embodiments, a NLS is fused to the N-terminus of a gene modifying polypeptide as described herein. In some embodiments, a NLS is fused to the C-terminus of a gene modifying polypeptide. In some embodiments, a NLS is fused to the N-terminus or the C-terminus of a Cas domain. In some embodiments, a linker sequence is disposed between a NLS and a neighboring domain of a gene modifying polypeptide.

[0269] In some embodiments, an NLS comprises the amino acid sequence MDSLLMNRRKFLYQFKNVRWAKGRRETYLC (SEQ ID NO: 5009), PKKRKVEGADKRTADGSEFESPKKKRKV(SEQ ID NO: 5010), RKSGKIAAIWKRPRKPKKKRKV (SEQ ID NO: 5011) KRTADGSEFESPKKKRKV(SEQ ID NO: 5012), KKTELQTTNAENKTKKL (SEQ ID NO: 5013), or KRGINDRNFWRGENGRKTR (SEQ ID NO: 5014), KRPAATKKAGQAKKKK (SEQ ID NO: 5015), PAAKRVKLD (SEQ ID NO:4644), KRTADGSEFEKRTADGSEFESPKKKAKVE (SEQ ID NO: 4649), KRTADGSEFE (SEQ ID NO: 4650), KRTADGSEFESPKKKAKVE (SEQ ID NO: 4651), AGKRTADGSEFEKRTADGSEFESPKKKAKVE (SEQ ID NO: 4001), or a functional fragment or variant thereof. Exemplary’ NLS sequences are also described in PCT / EP2000 / 011690, the contents of which are incorporated herein by reference for their disclosure of exemplary nuclear localization sequences. In some embodiments, an NLS comprises an amino acid sequence as disclosed in TABLE 13.Page 146 of 28713508126vlAttorney Docket No.: 2017469-0062An NLS of this table may be utilized with one or more copies in a polypeptide in one or more locations in a polypeptide, e.g., 1, 2, 3 or more copies of an NLS in an N-terminal domain, between peptide domains, in a C-terminal domain, or in a combination of locations, in order to improve subcellular localization to the nucleus. Multiple unique sequences may be used within a single polypeptide. Sequences may be naturally monopartite or bipartite, e.g., having one or two stretches of basic amino acids, or may be used as chimeric bipartite sequences. Sequence references correspond to UniProt accession numbers, except where indicated as SeqNLS for sequences mined using a subcellular localization prediction algorithm (Lin et al BMC Bioinformat 13:157 (2012), incorporated herein by reference in its entirety).TABLE 13: Exemplary nuclear localization signals for use in gene modifying systemsPage 147 of 28713508126v1Attorney Docket No.: 2017469-0062Page 148 of 28713508126v1Attorney Docket No.: 2017469-0062Page 149 of 28713508126v1Attorney Docket No.: 2017469-0062Page 150 of 28713508126v1Attorney Docket No.: 2017469-0062

[0270] In some embodiments, a NLS is a bipartite NLS. A bipartite NLS typically comprises two basic amino acid clusters separated by a spacer sequence (which may be, e.g., about 10 amino acids in length). A monopartite NLS typically lacks a spacer. An example of a bipartite NLS is the nucleoplasmin NLS. having the sequence KR[PAATKKAGQA]KKKK (SEQ ID NO: 5015), wherein the spacer is bracketed. Another exemplary bipartite NLS has the sequence PKKKRKVEGADKRTADGSEFESPKKKRKV (SEQ ID NO: 5016). Exemplary NLSs are described in International Application W02020051561, which is herein incorporated by reference in its entirety, including for its disclosures regarding nuclear localization sequences.

[0271] In some embodiments, a gene editor system polypeptide (e.g., a gene modifying polypeptide as described herein) further comprises an intracellular localization sequence, e.g., a nuclear localization sequence and / or a nucleolar localization sequence. A nuclear localization sequence and / or nucleolar localization sequence may be amino acid sequences that promote the import of the protein into the nucleus and / or nucleolus, where it can promote integration of heterologous sequence into the genome. In some embodiments, a gene editor system polypeptide (e.g., a gene modifying polypeptide as described herein) further comprises a nucleolar localization sequence. In some embodiments, a gene modifying polypeptide is encoded on a first RNA, and a template RNA is a second, separate, RNA, and the nucleolar localization signal is encoded on the RNA encoding the gene modifying polypeptide and not on the template RNA. In some embodiments, a nucleolar localization signal is located at the N-tenninus, C-tenninus, or in an internal region of the polypeptide. In some embodiments, a plurality of the same or different nucleolar localization signals are used. In some embodiments, a nuclear localization signal is less than 5, less than 10, less than 25, less than 50, less than 75, or less than 100 amino acids in length. Various polypeptide nucleolar localization signals can be used. For example, Yang et al., Journal of Biomedical Science 22, 33 (2015), describe a nuclear localization signal that also functions as a nucleolar localization signal. In some embodiments, a nucleolar localization signal may also be a nuclearPage 151 of 28713508126v1Attorney Docket No.: 2017469-0062localization signal. In some embodiments, a nucleolar localization signal may overlap with a nuclear localization signal. In some embodiments, a nucleolar localization signal may comprise a stretch of basic residues. In some embodiments, a nucleolar localization signal may be rich in arginine and lysine residues. In some embodiments, a nucleolar localization signal may be derived from a protein that is enriched in the nucleolus. In some embodiments, a nucleolar localization signal may be derived from a protein enriched at ribosomal RNA loci. In some embodiments, a nucleolar localization signal may be derived from a protein that binds rRNA. In some embodiments, a nucleolar localization signal may be derived from MSP58. In some embodiments, a nucleolar localization signal may be a monopartite motif. In some embodiments, the nucleolar localization signal may be a bipartite motif. In some embodiments, a nucleolar localization signal may consist of a multiple monopartite or bipartite motifs. In some embodiments, a nucleolar localization signal may consist of a mix of monopartite and bipartite motifs. In some embodiments, a nucleolar localization signal may be a dual bipartite motif. In some embodiments, a nucleolar localization motif may be a KRASSQALGTIPKRRSSSRFIKRKK (SEQ ID NO: 5017). In some embodiments, a nucleolar localization signal may be derived from nuclear factor-KB -inducing kinase. In some embodiments, a nucleolar localization signal may be an RKKRKKK motif (SEQ ID NO: 5018) (described in Birbach et aL, Journal of Cell Science, 117 (3615-3624), 2004).(xv) Evolved Variants of Gene Modifying Polypeptides and Systems

[0272] In some embodiments, the present disclosure provides evolved variants of gene modifying polypeptides as described herein. Evolved variants can, in some embodiments, be produced by mutagenizing a reference gene modifying polypeptide, or one of the fragments or domains comprised therein. In some embodiments, one or more of the domains (e.g., the reverse transcriptase domain) is evolved. One or more of such evolved variant domains can. in some embodiments, be evolved alone or together with other domains. An evolved variant domain or domains may, in some embodiments, be combined with unevolved cognate component(s) or evolved variants of the cognate component(s), e.g., which may have been evolved in either a parallel or serial manner.

[0273] In some embodiments, aprocess of mutagenizing a reference gene modifying polypeptide, or fragment or domain thereof, comprises mutagenizing the reference gene modifying polypeptide or fragment or domain thereof. In some embodiments, mutagenesis comprises a continuous evolution method (e.g., PACE) or non-continuous evolution method (e g., PANCE), e.g., as described herein. In some embodiments, an evolved gene modifying polypeptide, or a fragment or domain thereof, comprises one or more amino acid variations introduced into its amino acid sequence relative to the amino acid sequence of the reference gene modifying polypeptide, or fragment or domain thereof. In some embodiments, amino acid sequence variations may include one or more mutated residues (e.g.,Page 152 of 28713508126v1Attorney Docket No.: 2017469-0062conservative substitutions, non-conservative substitutions, or a combination thereof) within the amino acid sequence of a reference gene modifying polypeptide, e.g., as a result of a change in the nucleotide sequence encoding the gene modifying polypeptide that results in, e.g., a change in the codon at any particular position in the coding sequence, the deletion of one or more amino acids (e.g., a truncated protein), the insertion of one or more amino acids, or any combination of the foregoing. An evolved variant gene modifying polypeptide may include variants in one or more components or domains of the gene modifying polypeptide (e.g., variants introduced into a reverse transcriptase domain).

[0274] In some embodiments, the present disclosure provides gene modifying polypeptides, systems, kits, and methods using or comprising an evolved variant of a gene modifying polypeptide, e.g., employs an evolved variant of a gene modifying polypeptide or a gene modifying polypeptide produced or producible by PACE or PANCE. In some embodiments, an unevolved reference gene modifying polypeptide is a gene modifying polypeptide as disclosed herein.

[0275] The term “phage-assisted continuous evolution (PACE),”as used herein, generally refers to continuous evolution that employs phage as viral vectors. Examples of PACE technology have been described, for example, in International PCT Application No. PCT / US 2009 / 056194, fded September 8, 2009, published as WO 2010 / 028347 on March 11, 2010; International PCT Application, PCT / US2011 / 066747. filed December 22. 2011. published as WO 2012 / 088381 on June 28. 2012; U. S. Patent No. 9,023,594, issued May 5, 2015; U. S. Patent No. 9,771,574, issued September 26, 2017: U. S. Patent No. 9,394,537, issued July 19, 2016; International PCT Application, PCT / US2015 / 012022, filed January 20, 2015, published as WO 2015 / 134121 on September 11, 2015; U. S. Patent No. 10,179,911, issued January 15, 2019; and International PCT Application, PCT / US2016 / 027795, filed April 15, 2016, published as WO 2016 / 168631 on October 20, 2016, the entire contents of each of which are incorporated herein by reference.

[0276] The term “phage-assisted non-continuous evolution (PANCE),” as used herein, generally refers to non-continuous evolution that employs phage as viral vectors. Examples of PANCE technology have been described, for example, in Suzuki T. et al, Crystal structures reveal an elusive functional domain of pyrrolysyl-tRNA synthetase, Nat Chem Biol. 13(12): 1261-1266 (2017), incorporated herein by reference in its entirety. Briefly, PANCE is a technique for rapid in vivo directed evolution using serial flask transfers of evolving selection phage (SP), which contain a gene of interest to be evolved, across fresh host cells (e.g., E. coli cells). Genes inside the host cell may be held constant while genes contained in the SP continuously evolve. Following phage growth, an aliquot of infected cells may be used to transfect a subsequent flask containing host E. coli. This process can be repeated and / or continued until the desired phenotype is evolved, e.g.. for as many transfers as desired.Page 153 of 28713508126v1Attorney Docket No.: 2017469-0062

[0277] Methods of applying PACE and PANCE to gene modifying polypeptides may be readily appreciated by the skilled artisan by reference to, inter alia, the foregoing references. Additional exemplary methods for directing continuous evolution of genome-modifying proteins or systems, c.g., in a population of host cells, e.g., using phage particles, can be applied to generate evolved variants of gene modifying polypeptides, or fragments or subdomains thereof. Non-limiting examples of such methods are described in International PCT Application, PCT / US2009 / 056194, fded September 8, 2009, published as WO 2010 / 028347 on March 11, 2010: International PCT Application, PCT / US2011 / 066747, filed December 22, 2011, published as WO 2012 / 088381 on June 28, 2012; U. S. Patent No. 9,023,594, issued May 5, 2015; U. S. Patent No. 9,771,574, issued September 26, 2017; U. S. Patent No. 9,394,537, issued July 19, 2016; International PCT Application, PCT / US2015 / 012022, filed January 20, 2015, published as WO 2015 / 134121 on September 11. 2015: U. S. Patent No. 10,179,911, issued January 15, 2019;International Application No. PCT / US2019 / 37216, filed June 14, 2019, International Patent Publication WO 2019 / 023680, published January 31, 2019, International PCT Application, PCT / US2016 / 027795, filed April 15, 2016, published as WO 2016 / 168631 on October 20, 2016, and International Patent Publication No. PCT / US2019 / 47996, filed August 23, 2019, each of which is incorporated herein by reference in its entirety.

[0278] In some non-limiting illustrative embodiments, a method of evolution of a evolved variant gene modifying polypeptide, of a fragment or domain thereof, comprises: (a) contacting a population of host cells with a population of viral vectors comprising the gene of interest (the starting gene modifying polypeptide or fragment or domain thereof), wherein: (1) the host cell is amenable to infection by the viral vector; (2) the host cell expresses viral genes required for the generation of viral particles; (3) the expression of at least one viral gene required for the production of an infectious viral particle is dependent on a function of the gene of interest; and / or (4) the viral vector allows for expression of the protein in the host cell, and can be replicated and packaged into a viral particle by the host cell. In some embodiments, the method comprises (b) contacting the host cells with a mutagen, using host cells with mutations that elevate mutation rate (c.g., either by carrying a mutation plasmid or some genome modification — c.g., proofing-impaired DNA polymerase, SOS genes, such as UmuC, UmuD', and / or RecA, which mutations, if plasmid-bound, may be under control of an inducible promoter), or a combination thereof. In some embodiments, the method comprises (c) incubating the population of host cells under conditions allowing for viral replication and the production of viral particles, wherein host cells are removed from the host cell population, and fresh, uninfected host cells are introduced into the population of host cells, thus replenishing the population of host cells and creating a flow of host cells. In some embodiments, the cells are incubated under conditions allowing for the gene of interest to acquire a mutation. In some embodiments, the method further comprises (d) isolating a mutated version of the viral vector, encodingPage 154 of 28713508126v1Attorney Docket No.: 2017469-0062an evolved gene product (e.g., an evolved variant gene modifying polypeptide, or fragment or domain thereof), from the population of host cells.

[0279] A skilled artisan will appreciate a variety of features employable within the above-described framework. For example, in some embodiments, the viral vector or the phage is a filamentous phage, for example, an M13 phage, e.g., an M13 selection phage. In some embodiments, a gene required for the production of infectious viral particles is the M13 gene III (gill). In some embodiments, the phage may lack a functional gill, but otherwise comprise gl, gll, gIV, gV, gVI, gVII, gVIII, glX, and agX. In some embodiments, the generation of infectious VSV particles involves the envelope protein VSV-G. Various embodiments can use different retroviral vectors, for example, Murine Leukemia Virus vectors, or Lenti viral vectors. In some embodiments, the retroviral vectors can efficiently be packaged with VSV-G envelope protein, e.g.. as a substitute for the native envelope protein of the virus.

[0280] In some embodiments, host cells are incubated according to a suitable number of viral life cycles, e.g., at least 10, at least 20, at least 30, at least 40, at least 50, at least 100, at least 200, at least 300, at least 400, at least, 500, at least 600, at least 700, at least 800, at least 900, at least 1000, at least 1250, at least 1500, at least 1750, at least 2000, at least 2500, at least 3000. at least 4000. at least 5000, at least 7500, at least 10000, or more consecutive viral life cycles, which in on illustrative and non-limiting examples of Ml 3 phage is 10-20 minutes per virus life cycle. Similarly, conditions can be modulated to adjust the time a host cell remains in a population of host cells, e.g., about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 70, about 80, about 90, about 100, about 120, about 150, or about 180 minutes. Host cell populations can be controlled in part by density of the host cells, or, in some embodiments, the host cell density in an inflow, e.g., 103cells / ml, about I04cells / ml, about 10’ cells / ml, about 5- 10’ cells / ml, about 106cells / ml, about 5-I0ftcells / ml, about 107cells / ml, about 5- 107cells / ml, about IO8cells / ml, about 5- 108cells / ml, about I09cells / ml, about 5- 109cells / ml, about IO10cells / ml, or about 5- IO10cells / ml.(xvi) Inteins

[0281] In some embodiments, as described in more detail below, an intein-N (intN) domain may be fused to the N-terminal portion of a first domain of a gene modifying polypeptide described herein, and an intein-C (intC) domain may be fused to the C-terminal portion of a second domain of a gene modifying polypeptide described herein for the joining of the N-tenninal portion to the C-terminal portion, thereby joining the first and second domains. In some embodiments, the first and second domains are each independently chosen from a DNA binding domain, an RNA binding domain, an RT domain, and an endonuclease domain.Page 155 of 28713508126v1Attorney Docket No.: 2017469-0062

[0282] Inteins can occur as self-splicing protein intron (e.g., peptide), e.g., which ligates flanking N-terminal and C-terminal exteins (e.g., fragments to be joined). An intein may, in some instances, comprise a fragment of a protein that is able to excise itself and join tire remaining fragments (tire exteins) with a peptide bond in a process known as protein splicing. Inteins are also referred to as “protein introns." Tire process of an intein excising itself and joining the remaining portions of the protein is herein termed “protein splicing” or “intein-mediated protein splicing.”

[0283] In some embodiments, an intein of a precursor protein (an intein containing protein prior to intein-mediated protein splicing) comes from two genes. Such intein is referred to herein as a split intein (e.g., split intein-N and split intein-C). Accordingly, an intein-based approach may be used to join a first polypeptide sequence and a second polypeptide sequence together. For example, in cyanobacteria, DnaE, the catalytic subunit a of DNA polymerase III, is encoded by two separate genes, dnaE-n and dnaE-c. An intein-N domain, such as that encoded by the dnaE-n gene, when situated as part of a first polypeptide sequence, may join the first polypeptide sequence with a second polypeptide sequence, wherein the second polypeptide sequence comprises an intein-C domain, such as that encoded by the dnaE-c gene. Accordingly, in some embodiments, a protein can be made by providing nucleic acid encoding the first and second polypeptide sequences (e.g.. wherein a first nucleic acid molecule encodes the first polypeptide sequence and a second nucleic acid molecule encodes the second polypeptide sequence), and the nucleic acid is introduced into the cell under conditions that allow for production of the first and second polypeptide sequences, and for joining of the first to the second polypeptide sequence via an intein-based mechanism.

[0284] Use of inteins for joining heterologous protein fragments is described, for example, in Wood et al., J. Biol. Chem.289(21); 14512-9 (2014) (incorporated herein by reference in its entirety). For example, when fused to separate protein fragments, the inteins IntN and IntC may recognize each other, splice themselves out, and / or simultaneously ligate the flanking N- and C-terminal exteins of the protein fragments to which they were fused, thereby reconstituting a full-length protein from the two protein fragments.

[0285] In some embodiments, a synthetic intein based on the dnaE intein, the Cfa-N (e.g., split intein-N) and Cfa-C (e.g., split intein-C) intein pair, is used. Examples of such inteins have been described, e.g., in Stevens et al., J Am Chem Soc. 2016 Feb. 24; 138(7):2162-5 (incorporated herein by reference in its entirety). Non-limiting examples of intein pairs that may be used in accordance with the present disclosure include: Cfa DnaE intein, Ssp GyrB intein, Ssp DnaX intein, Ter DnaE3 intein, Ter ThyX intein, Rma DnaB intein and Cne Prp8 intein (e.g., as described in U. S. Pat. No. 8,394,604, incorporated herein by reference.Page 156 of 28713508126v1Attorney Docket No.: 2017469-0062

[0286] In some embodiments involving a split Cas9, an intein-N domain and an intein-C domain may be fused to the N-terminal portion of the split Cas9 and the C-terminal portion of a split Cas9, respectively, for the joining of the N-tcrminal portion of the split Cas9 and the C -terminal portion of the split Cas9. For example, in some embodiments, an intein-N is fused to the C-terminus of the N-terminal portion of the split Cas9. i.e., to form a structure of N — [N-terminal portion of the split Cas9]-[intein-N]~ C. In some embodiments, an intein-C is fused to the N-terminus of the C-terminal portion of the split Cas9, i.e., to form a structure of N- [intein-C] ~ [C-terminal portion of the split Cas9]-C. The mechanism of intein-mediated protein splicing for joining the proteins the inteins are fused to (e.g., split Cas9) is described in Shah ct al., Chcm Sci. 2014; 5(1):446-461, incorporated herein by reference. Methods for designing and using inteins are known in the art and described, for example by W02020051561, W02014004336, WO2017132580, US20150344549, and US20180127780, each of which is incorporated herein by reference in their entirety.

[0287] In some embodiments, a split refers to a division into two or more fragments. In some embodiments, a split Cas9 protein or split Cas9 comprises a Cas9 protein that is provided as an N-terminal fragment and a C-terminal fragment encoded by two separate nucleotide sequences. The polypeptides corresponding to the N-terminal portion and the C-terminal portion of the Cas9 protein may be spliced to form a reconstituted Cas9 protein. In some embodiments, the Cas9 protein is divided i...

Claims

Attorney Docket No.: 2017469-0062LISTING OF THE CLAIMSWHAT IS CLAIMED IS:

1. A template RNA comprising from 5 ’ to 3 ':(i) a gRNA spacer,(ii) a gRNA scaffold comprising a nucleotide sequence at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any one gRNA scaffold sequence listed in TABLE 16,(iii) a heterologous object sequence, and(iv) a primer binding site (PBS) sequence.

2. The template RNA of claim 1, wherein the gRNA spacer is at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% complementary to a first portion of an HBB gene.

3. The template RNA of claim 1 or 2, wherein the gRNA spacer comprises a polynucleotide sequence at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to a polynucleotide sequence according to SEQ ID NO: 22010 or SEQ ID NO: 22012.

4. The template RNA of any one of claims 1 to 3, wherein the heterologous object sequence is 10 to 25 nucleotides in length.

5. The template RNA of any one of claims 1 to 4, wherein the heterologous object sequence comprises a polynucleotide sequence at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any one heterologous object sequence listed in TABLE 17.

6. The template RNA of any one of claims 1 to 5, wherein the PBS sequence is 8 to 14 nucleotides in length.

7. Tire template RNA of any one of claims 1 to 6, wherein the PBS sequence comprises a polynucleotide sequence at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%,Page 283 of 28713508126v1Attorney Docket No.: 2017469-0062at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to a polynucleotide sequence according to any one PBS sequence listed in TABLE 18.

8. Tire template RNA of any one of claims 1 to 7, wherein the PBS sequence comprises one or more phosphorothioate linkages.

9. The template RNA of any one of claims 1 to 8, wherein the template RNA comprises a polynucleotide sequence at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to a polynucleotide sequence according to any one of the template RNA sequences listed inTABLE 19, TABLE 27, TABLE 28 or TABLE 2910. A template RNA comprising a polynucleotide sequence at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any template RNA sequence in TABLE 19, TABLE 27, TABLE 28, or TABLE 2911. A gene modifying system comprising:(i) a template RNA of any one of claims 1 to 10: and(ii) an mRNA encoding a gene modifying polypeptide.

12. The gene modifying system of claim 11, further comprising (iii) a second strand-targeting gRNA.

13. The gene modifying system of claim 12, wherein the second strand-targeting gRNA comprises a gRNA spacer and a gRNA scaffold.

14. Tire gene modifying system of claim 13, wherein the gRNA spacer of tire second strand-targeting gRNA comprises a polynucleotide sequence at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%. at least 98%, at least 99%, or 100% identical to a polynucleotide sequence according to SEQ ID NO: 22014.

15. The gene modifying system of claim 13 or 14, wherein the gRNA spacer of the second strandtargeting gRNA comprises one or more phosphorothioate linkages.Page 284 of 28713508126v1Attorney Docket No.: 2017469-006216. The gene modifying system of any one of claims 11 to 15, wherein the gene modifying polypeptide comprises:(i) an endonuclease and / or DNA-binding domain;(ii) a peptide linker; and(iii) a reverse transcriptase (RT) domain.

17. The gene modifying system of any one of claims 11 to 16, wherein the gene modifying polypeptide comprises an amino acid sequence at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to an amino acid sequence according to any one of SEQ ID NO: 22006 to SEQ ID NO: 22009.

18. A gene modifying system comprising:(i) a template RNA comprising a poly nucleotide sequence at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any template RNA sequence in TABLE 19, TABLE 27, TABLE 28, or TABLE 29: and(ii) an mRNA encoding a gene modifying polypeptide.

19. A lipid nanoparticle (LNP) formulation comprising the gene modifying system of any one of claims 11 to 18.

20. The LNP formulation of claim 19, comprising:(i) one or more ionic lipids:(ii) one or more conjugated lipids; and(iii) one or more sterols.

21. A method of modifying a target HBB locus in a cell, the method comprising contacting the cell with the gene modifying system of any one of claims 11 to 18, thereby modify ing the target HBB locus.

22. The method of claim 21, wherein modifying the target HBB locus comprises substituting an adenine in the sixth codon of an HBB gene for a guanine.Page 285 of 28713508126v1Attorney Docket No.: 2017469-006223. The method of claim 21, wherein modifying tire target HBB locus comprises substituting a nucleotide in a codon encoding a valine residue in HbS to a different nucleotide resulting in a codon encoding a glutamic acid residue.

24. The method of claim 22 or 23, wherein the cell is a human or non-human primate cell.

25. The method of any one of claims 22 to 24, wherein the cell is a hematopoietic stem and progenitor cell (HSPC) or long-term hematopoietic stem cell (LT-HSC).

26. A method for treating or preventing sickle cell disease in a subject, the method comprising administering to the subject a system of any one of claims 11 to 18, or an LNP fonnulation of claim 19 or 20.Page 286 of 28713508126v1